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Abstract 
 
Networks of protein-protein interactions (PPIs) are essential in all aspects of cellular 
biology. At the nodes of these networks are multi-protein complexes that are often 
composed of dynamic, exchangeable modules assembled around a central enzyme. In this 
thesis, I have used the molecular chaperone heat shock protein 70 (Hsp70) as a model to 
develop ways of creating inhibitors of PPIs that tune the assembly and function of multi-
protein complexes. Hsp70 is an ATPase and master regulator of protein homeostasis that 
interacts with co-chaperones, including nucleotide exchange factors (NEFs) and J-
proteins. There is interest in creating chemical inhibitors that selectively interrupt PPIs 
between Hsp70 and its co-chaperones, as these molecules would be powerful chemical 
probes for validating Hsp70 as a target in cancer and other diseases. In this dissertation, I 
first review how advances in chemical screening methodologies, structural and 
computational biology, and proteomics have paved the way for the discovery of potent 
PPI inhibitors, even for difficult targets such as Hsp70 complexes. In Chapter 2, I 
develop a new high throughput screening (HTS) method in which Hsp70 is combined 
with co-chaperones and the ATPase activity of the combination is measured. I use this 
method to identify new inhibitors of Hsp70, characterizing their binding sites and 
molecular mechanism by NMR, mutagenesis and biochemical approaches. Importantly, I 
found that this HTS method reveals inhibitors of multiple PPIs within the Hsp70 system, 
including the interactions with NEFs and J proteins. This approach allowed me to find 
that Hsp70-NEF complexes control the stability of inhibitor of apoptosis (IAP) protein 
family members. In Chapter 3, I characterize IAPs as new “clients” of the Hsp70 system 
and explore the physical interaction between these proteins. That work establishes IAPs 
as the first sensitive, selective biomarkers suitable for use in pre-clinical studies of Hsp70 
inhibitors. Finally, I show how inhibiting the Hsp70-NEF interaction has effects 
throughout the broader PPI network in Chapter 4. Together, these findings not only have 
important implications for Hsp70 drug discovery, but they also illustrate, more broadly, 
 xvi 
how small molecules can be used to re-shape multi-protein complexes and propagate 
changes throughout PPI networks.  
 
 
 1 
Chapter 1 
Direct and Propagated Effects of Small Molecules on Protein-Protein Interaction 
Networks 
 
1.1 Abstract 
Networks of protein–protein interactions (PPIs) link all aspects of cellular biology. 
Dysfunction in the assembly or dynamics of PPI networks is a hallmark of human 
disease, and as such, there is growing interest in the discovery of small molecules that 
either promote or inhibit PPIs. PPIs were once considered undruggable because the 
surfaces buried in these interactions are often large and shallow. Despite these challenges, 
recent advances in chemical screening methodologies, combined with improvements in 
structural and computational biology have made some of these targets more tractable. In 
this chapter, I highlight developments that have opened the door to potent chemical 
modulators. I focus on how allostery is being used to produce surprisingly robust changes 
in PPIs, even for the most challenging targets. I also discuss how interfering with one PPI 
can propagate changes through the broader web of interactions. Through this analysis, it 
is becoming clear that a combination of direct and propagated effects on PPI networks is 
ultimately how small molecules re-shape biology. 
 
1.2  Introduction 
Multi-protein complexes are often assembled around a central enzyme, such as a kinase, 
phosphatase, protease, or nuclease. Interactions of the “core” enzyme with adaptor and 
scaffolding proteins often direct it to specific subcellular locations and/or regulating its 
enzymatic activity.1–3 For instance, protein A might trap a given conformer of the enzyme 
to favor a specific outcome, while interactions between the enzyme and a different 
partner, protein B, might change the activity (Figure 1.1). Many non-enzymes also 
control access of substrates to the core enzyme, shaping its selectivity. For example, 
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protein A might bind a specific substrate for the enzyme and thereby accelerate turnover 
by increasing its local availability. 
 
The assembly of multi-protein complexes is often mediated by a combination of strong 
and weak interactions between the individual protein components. Weak interactions are 
used to provide facile exchange of components.4 Expanding beyond these immediate 
binding partners, multi-protein complexes often serve as “hubs” in a larger protein–
protein interaction (PPI) network.5 These ancillary interactions link the core and its 
partners to the broader cellular systems through a physical web of PPIs. It is becoming 
clear that chemical perturbations of a single node within the PPI network can have 
implications far beyond the immediate neighborhood.6  
  
 
Figure 1.1 Common themes in multi-protein complex assembly. Multi-protein complexes are typically 
assembled around a core enzyme, while interactions with adaptor, scaffolding, and other partner proteins 
affect the overall function of the complex. Binding to ligands or macromolecules can trap one conformer of 
the complex. For example, binding to Protein A might alter the conformation of the enzyme to impact 
turnover or selectivity. Likewise, binding to Protein B (rather than Protein A) might be favored by a small 
molecule, changing the function and composition of the complex. 
 
1.2.1 Protein-protein interactions as drug targets 
Multi-protein complexes play critical roles in nearly all normal cellular functions, 
including gene expression, cell division, protein homeostasis, and signaling.7,8 
Conversely, dysfunction in the assembly, localization, or dynamics of multi-protein 
complexes is associated with many diseases, including cancer, autoimmune disorders, 
and neurodegeneration. In some diseases, a complex may be aberrantly active; for 
example, in acute leukemia the MLL gene is translocated, resulting in fusion proteins 
between an N-terminal fragment of MLL and over 50 different target proteins.9 In other 
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diseases, the function of a multi-protein complex may be disrupted, such as occurs in 
some p53 mutations.10 While targeting the enzymatic components of multi-protein 
complexes has traditionally been the norm in drug discovery and in chemical biology, it 
is increasingly appreciated that PPIs could offer several advantages as targets.11–13 For 
instance, this approach might allow disruption of some aspects of signaling cascades 
without completely shutting them down.14 Also, PPI interfaces tend to be more unique 
and varied than enzyme active sites, thus offering the possibility of greater selectivity.15 
As such, there is significant biological and therapeutic interest in developing chemical 
modulators of PPIs.14 Here, modulator is a term used to include both compounds that 
promote PPIs and those that inhibit PPIs. Such tools, provided they meet established 
criteria for chemical probes,16 are highly useful in revealing how specific PPIs are 
involved in normal function and pathobiology, as well as serving as starting points for 
therapies.17 
 
PPIs have typically been challenging to disrupt with small molecules and, until relatively 
recently, these contacts have been classified as undruggable. It has become better 
appreciated that some PPIs may be more amenable to inhibition than others. For example, 
PPIs with relatively weak affinity and large surface areas (SAs) tend to be more 
challenging, while PPIs that rely on a few, closely spaced amino acids to bind with high 
affinity are relatively easier to inhibit.12,18–20 This point is demonstrated by the fact that of 
all known PPI modulators, the majority (> 60%) target PPIs with affinity better than 1 
μM and total buried SA less than 1800 Å2 (Figure 1.2). Another key observation is that, 
across many systems, orthosteric competitors are ideal for inhibiting the types of PPIs 
that are characterized by low SAs and tight affinity. For other types of PPIs, allosteric 
inhibitors tend to be more successful because they can exploit distal pockets that might 
have more favorable binding properties. Indeed, it is often the lack of defined binding 
pockets that makes it challenging to target small molecules to the PPIs that involve large, 
complex surfaces. In such cases, the free energy of binding is typically a summation of 
many low-affinity contacts, making it hard to design an effective competitor with low 
molecular weight.21  
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Figure 1.2 Some protein-protein interactions may be more amenable to inhibition than others. (A) 
PPIs categorized according to the apparent affinity of the interaction and the surface area (SA) buried by 
assembly. Application of arbitrary criteria for affinity (greater or less than 1 μM) and buried SA (greater or 
less than 1800 Å2) generates four quadrants. Examples of each class are shown. High affinity, small SA: 
p53−MDM2 (3DAC), RGS4−Gαo (1AGR); high affinity, large SA: IL-2−IL-2Rα (1Z92), CBFβ−Runx1 
(1E50); low affinity, small SA: GACKIX−pKID−MLL (2LXT), 14-3-3−RAF (3IQJ); low affinity, large 
SA: Hsp70−BAG1 (1HX1). (B) Known inhibitors of PPIs were collected from 2P2IDB and TIMBAL 
databases and plotted according to the affinity (reported in PDBbind22) and buried SA (calculated by 
InterProSurf23) of the target PPI. Inhibitors published since a similar analysis in 201224 are represented by 
hatched bars to highlight the most recent development and trends. Small molecules targeting PPIs with high 
affinity and small buried SA represent 66% of all known inhibitors, although 56% of newly identified 
inhibitors target more difficult classes of PPIs.  
 
1.2.2 Allosteric inhibitors can offer greater control over downstream response 
Two (or more) chemical inhibitors that act on the same target can produce different 
cellular responses because of the way that they alter local PPI networks. Extensive work 
on allosteric modulation of G-protein coupled receptors (GPCRs) and kinases has 
provided a blueprint for how this might be accomplished in other systems.25 
 
1.2.2.1 Allosteric modulation of GPCRs 
GPCRs signal through a series of well-characterized downstream PPIs.26 Allosteric and 
biased compounds offer an opportunity to have greater control over signaling by “fine-
tuning” the response, illustrating the nuanced ways in which small molecules modulate 
the output of these systems.27 A key observation from these examples is that binding of 
distinct ligands, even to the same site, can produce dramatically different effects on 
downstream signaling.28 For example, propranolol binds the β2 adrenergic receptor, 
although it is an inverse agonist for adenylyl cyclase signaling and an agonist for 
extracellular signal-regulated kinase activity.  
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1.2.2.2 Allosteric inhibition of kinases 
The field of kinase inhibitors may also provide another illustrative example. Kinase 
inhibitors fall into four general categories, the two most important of which are: type I 
and type II. Type I compounds bind directly to the ATP binding site in the kinase 
domain. Type II inhibitors, on the other hand, interact preferentially with the inactive 
conformation via binding to an allosteric site.29 While both type I and type II inhibitors 
block enzymatic activity, they appear to have distinct effects on downstream PPIs 
between the kinases and their effectors. Why is this categorization important? For the 
sake of this analysis, type I and type II inhibitors might be expected to have different 
effects on the interactions between the kinase and its downstream effectors, such as 14-3-
3 proteins, which link it to broader PPI networks. Thus, the effects of the inhibitors on 
cells might reflect both the inhibition of the kinase itself, but also the changes in PPIs. 
 
1.2.3 Strategies for targeting PPIs with small molecules 
In this chapter, I discuss how small molecules might be discovered and developed to take 
advantage of allosteric networks within multi-protein complexes. In the first section, I 
describe lessons learned from natural PPI modulators. I also review examples of synthetic 
molecules that have been discovered by serendipity to control PPIs through interesting 
mechanisms. In the second section, I survey a number of promising high-throughput 
screening (HTS) approaches that are geared toward the purposeful discovery of PPI 
modulators with similar mechanisms. Finally, in the third section, I speculate on which 
new methods and ideas might be needed to take full advantage of future opportunities. 
The over-arching theme is that small molecules have both proximal (or direct) effects on 
PPIs (e.g., they block or favor specific PPIs), while also having less well-appreciated 
effects on downstream interactions within PPI networks.  
 
1.3 Lessons learned: Natural and synthetic examples of allosteric regulation of 
protein complexes 
Allostery, in which binding of a ligand at one site affects protein conformation at a 
distant site, enables small molecules to produce dramatic effects on protein structure and 
function, even at a distance.30,31 Classic work in this area was performed on the 
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hemoglobin system, revealing that action at one binding site can propagate 
conformational changes that impact other sites more than 25 Å away.32 This theme has 
been observed countless times in biology, with allosteric control observed for both small 
molecule- and protein-mediated interactions. To name just one example, the activity of 
the histone deacetylase enzyme HDAC3 requires recruitment to a co-repressor SMRT 
complex.33,34 However, when expressed in bacteria, recombinant HDAC3 and SMRT do 
not interact, leading to speculation that an assembly factor was missing.35 It was 
subsequently found that the deacetylase activation domain (DAD) of SMRT undergoes 
substantial structural rearrangement upon binding to HDAC3 and that an inositol 
tetraphosphate molecule was essential for this transition.36 The inositol molecule 
stabilizes the HDAC3–SMRT complex through conformational transitions involving both 
protein–protein and protein–small molecule contacts. What can be learned from these 
natural examples? In the HDAC3–SMRT case, a cascade of conformational changes 
occurs following the small molecule interaction. Thus, the small molecule needs to not 
only bind its target protein, but also alter the conformer of the target in the right way to 
enable subsequent binding to the downstream partner(s). In a broader sense, it seems 
possible that whenever a protein is bound by a small molecule, a specific subset of 
conformers is captured and those conformers might have important implications for what 
happens next. 
1.3.1 Small molecules trap specific protein conformers 
One illustrative example of these concepts is the case of the retinoic acid receptor (RAR). 
In this system, gene expression is repressed when RAR is bound to a co-repressor, while 
gene expression is activated when RAR recruits a co-activator.37 The key structural 
feature is a switch between an extended β-strand and α-helix in RAR, which occurs in a 
region that is important for binding to both co-repressors and co-activators.38 Chemical 
agonists of RAR promote co-activator binding by stabilizing the correct, permissive 
conformation,39 while inverse agonists convert the α-helix to an extended β-strand, 
promoting binding to co-repressors. Finally, neutral antagonists stabilize a conformer in 
which neither co-activators nor co-repressors are bound.40 Thus, depending on the 
chemical cue that is encountered (e.g., agonist, neutral antagonist, etc.), there are 
dramatic and important changes in PPIs that dictate downstream signals.38 Such systems 
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can be considered pharmacological “switches,” in which the local PPI network is re-
wired by the small molecule. 
 
Another useful example is the scaffolding protein family 14-3-3. These versatile adaptor 
proteins bind to hundreds of individual partners through a conserved amphipathic binding 
groove.41,42 14-3-3 proteins are able to adopt many distinct conformations that allow them 
to interact with different binding partners.43 Inhibitors exploit this property. For example, 
the natural product fusicoccin A promotes 14-3-3 complex assembly with some 
partners,44,45 while the pyridoxal-phosphate derivative FOBISIN101 inhibits interactions 
with other partners.46 In these cases, the compound produces a specific cellular effect 
because it traps a conformation of the 14-3-3 protein and alters its PPI interfaces.47 
 
Another example includes the case in which small molecules have been found to tune the 
activity of the molecular chaperone, Hsp70. Dihydropyrimidines were identified that bind 
at the interface between Hsp70 and its PPI partner, Hsp40. Members of the 
dihydropyrimidine scaffold remodel the PPI surface, such that some analogs strengthen 
the Hsp70–Hsp40 complex, while others inhibit it.48 Similar concepts have been proposed 
for the transcriptional co-activator proteins, including the master co-activator CBP and 
components of the Mediator complex, in which allosterically coupled binding interfaces 
mediate interactions with transcriptional activators.49–51 The theme in these systems is that 
the small molecule does not just alter enzyme activity – it impacts the way in which the 
protein partners recognize the target. Thus, I suggest that one of the most important 
features of a small molecule is how it traps a specific ensemble of protein conformers. 
The ultimate biological output of a small molecule will be a product of the changes in 
both enzyme activity and its effects on PPIs networks. 
1.3.2 Inhibition of protein-protein interactions 
 
1.3.2.1 Orthosteric inhibitors of PPIs 
Significant progress has been made toward identifying orthosteric inhibitors of PPIs over 
the past 15–20 years.12,17,19,20 Classic success stories include inhibitors of p53–MDM252 
and inhibitors of BCL2/BCL-XL53 and IAPs.54 In these cases, a molecule binds at the 
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surface and directly prevents the most important “hotspot” side chains from interacting 
(Figure 1.3). In addition, the search for orthosteric inhibitors has revealed important 
features of the dynamics of PPI surfaces. For example, Tilley and coworkers reported the 
discovery of a small molecule that inhibits binding between the cytokine IL-2 and the IL-
2 α receptor (IL-2Rα).55 Subsequent structural analysis suggested that this compound 
binds to IL-2 in a region that is critical for productive binding to IL-2Rα. Importantly, the 
unliganded IL-2Rα binding interface on IL-2 is dynamic and samples many distinct 
conformations. Binding of the small molecule restricts the total number of conformations 
sampled by IL-2, effectively “trapping” the protein in a conformation distinct from either 
the apo or IL-2Rα bound structures. Furthermore, the adaptive protein interface was more 
amenable to inhibitor discovery via disulfide tethering than an IL-2 subsite that is more 
conformationally restricted.56 Many protein–protein interfaces are similarly adaptive, and 
while thought to be relatively flat and featureless, such binding interfaces can nonetheless 
sample conformations that allow for the formation of a small molecule binding pocket 
(Figure 1.3).57,58 Why is it worth considering classic and adaptive orthosteric inhibitors as 
different classes? While both types ultimately inhibit the PPI by occluding the site of 
interaction, medicinal chemistry efforts to optimize them will depend on their 
mechanism. For example, classic orthosteric inhibitors do not induce substantial 
conformational rearrangement of the binding site, and therefore the ligand free structure 
of the protein can be used to guide the synthesis of new analogs. On the other hand, 
adaptive inhibitors require a conformation of their protein target that is distinct from the 
apo structure. Thus, structure-guided medicinal chemistry campaigns must be undertaken 
with this in mind. 
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Figure 1.3 Mechanisms of small molecule inhibition of protein-protein interactions. Several different 
binding modes for small molecule inhibitors of PPIs are shown. Orthosteric inhibitor directly competes 
with one partner for binding. Orthosteric inhibitor taking advantage of an adaptive protein interface 
stabilizes a protein conformer such that the interaction surface is no longer amenable to binding. An 
allosteric inhibitor binds a site distal from the PPI interface, resulting in structural rearrangement in the 
target protein. 
 
1.3.2.2 Allosteric PPI inhibition 
Binding of small molecules at allosteric sites can also produce robust inhibition of PPIs 
(Figure 1.3). The interaction between Runx1 and CBFβ mediates formation of the 
heterodimeric transcription factor CBF.59 In some cases of acute myeloid leukemia, 
CBFβ is fused to the smooth muscle myosin protein, favoring formation of the CBFβ-
Runx1 complex and resulting in dysfunction in CBF transcription.60–62 Thus, inhibition of 
CBF heterodimer formation represents an attractive therapeutic strategy. Unfortunately, 
this interface is relatively large and featureless, characteristic of the difficult PPIs 
described previously. While attempts to discover orthosteric inhibitors of CBFβ-Runx1 
binding have been unsuccessful, a combination of computational and NMR screens 
identified a class of 2-aminothiazoles that bind to an allosteric site on CBFβ distinct from 
the Runx1 binding interface and block CBFβ-Runx1 complex formation in vitro and in 
HEK293 cells.63 Importantly, NMR chemical shift perturbations revealed that compound 
binding at the allosteric site produces changes in CBFβ conformation and/or dynamics at 
the heterodimerization site. Similarly, irreversible binding of a small molecule at an 
allosteric site on the regulator of G-protein signaling protein 4 (RGS4) produces more 
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robust inhibition of binding to Gαo than covalent modification within the binding 
interface.64 Temperature-accelerated molecular dynamics and NMR spectroscopy 
revealed how small molecule binding at an allosteric site on RGS4 is transmitted to the 
G-protein binding site in order to destabilize the PPI and block its GTPase accelerating 
activity.65 
 
Together, these studies suggest that allostery is a powerful approach for PPI inhibition 
and that it is particularly advantageous in circumventing the difficulties associated with 
challenging PPI interfaces, namely those with weak affinity and/or large SAs. This idea is 
illustrated in Table 1.1, in which the chemical structure of a subset of PPI inhibitors is 
listed next to the method used for their discovery, their mechanism of inhibition, and the 
class of the targeted PPI. This summary emphasizes the idea that allostery is a common 
property exploited by inhibitors of difficult targets and that certain discovery methods 
appear to be geared toward finding such molecules (as discussed below). 
 
Table 1.1 Summary of protein-protein interaction inhibitors.  
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Table 1.1 Continued 
 
High affinity, small SA (gray); low affinity, small SA (green); high affinity, large SA (blue); low affinity, 
large SA (purple). 
 
1.3.3 Promoting protein complex assembly 
Small molecules can also be used to stabilize (rather than inhibit) PPIs, as described for 
the HDAC3–SMRT complex.36 In some cases, such potentiation can be therapeutically 
beneficial. Natural PPI stabilizers have been identified that nicely illustrate this idea.66 
The immunosuppressant cyclosporin A acts as a “molecular glue” between the peptidyl-
prolyl cis-trans isomerase cyclophilin A and the protein phosphatase calcineurin.67 
Similarly, FK506 stabilizes the interaction between the peptidyl-prolyl isomerase FKBP 
and calcineurin.68 Another immunosuppressant, rapamycin, uses a similar approach to 
inhibit mTOR kinase.69 An example critical in plant development is the hormone auxin, 
which binds to TIR1 F-box proteins and stabilizes their interactions with Aux/IAA 
transcriptional repressor proteins.70 Finally, acyl-homoserine lactone (AHL) molecules 
are used by photobacteria in quorum sensing-mediated bioluminescence. AHL binding 
facilitates dimerization of LuxR-type transcription factors, increasing their DNA binding 
capacity and expression of target genes.71,72 Importantly, in all cases, ternary complex 
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formation is essential for function; that is, in the absence of small molecule, protein 
complex formation is negligible. 
 
A number of synthetic stabilizers of PPIs have also been identified in recent years. For 
example, the murine double minute proteins MDM2 and MDMX are often overexpressed 
in cancer and negatively regulate p53-dependent gene expression.73,74 The tumor 
suppressor p53 controls pro-apoptotic and growth suppressing genes, and thus activation 
of p53-dependent transcription could have utility in cancer therapy.75 However, inhibition 
of either the p53–MDM2 or p53–MDMX interaction alone was not sufficient to fully 
restore p53 signaling, and simultaneous inhibition of both PPIs is necessary for full 
activity.76,77 Unfortunately, structural differences in the p53 binding sites of MDM2 and 
MDMX have hindered development of dual antagonists.78 Graves and coworkers at 
Roche Research Center instead identified a class of small molecules that inhibit both 
p53–MDM2 and p53–MDMX binding by inducing MDM2–MDMX protein 
dimerization, occluding the p53 binding site.79 While most reported examples of PPI 
stabilizers bind directly to the protein–protein interface, establishing contacts with both 
binding partners (those discussed in this chapter are summarized in Table 1.2),66 it is 
reasonable to speculate that small molecules might also be identified to stabilize specific 
PPIs through allosteric regulation, in which compound binding at a distal site would 
modulate the protein interface such that binding affinity is increased. 
Table 1.2 Summary of protein-protein interaction stabilizers 
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Table 1.2 Continued 
 
1.4 Methods for finding modulators of protein-protein interactions 
Recent reviews have discussed the specific need for new methods in finding modulators 
of PPIs.19,80 One identified challenge is that many traditional HTS methods rely on the 
measurement of direct binding between two protein partners. Such methods may not be 
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suitable for finding potent inhibitors of some categories of PPIs, such as weaker ones. 
Another challenge is that very few methods are available that provide insight into the 
effects of a small molecule on broader PPI networks. This is particularly important for 
PPI inhibitor campaigns because screens must be specifically geared toward the 
discovery of molecules with the most suitable features, such as disrupting a subset of 
PPIs or favoring others.81 In other words, you get what you screen for. 
 
Figure 1.4 Considerations for choosing the best approach for protein-protein interaction inhibitor 
discovery. Central questions to consider include if the multi-protein complex can be reconstituted in vitro 
with recombinant proteins, how strong the interactions between individual components, and if there is any 
precedent for sites to perturb. It is important to note that some approaches might be best used in tandem and 
that more than one platform might be best for different systems.  
 
Due to the inherent complexity of multi-protein systems, it is difficult to provide a “one-
size fits all” approach for future work, as a given HTS campaign must necessarily be 
geared for the complex of interest (Figure 1.4). For instance, many biophysical methods 
demand little advance knowledge of the complexities of a given system and require only 
purified recombinant protein. In addition, these approaches can quickly provide valuable 
information on protein and ligand-binding sites, allosteric networks, and druggable 
interfaces. On the other hand, cellular screening methods are well suited for multi-protein 
complexes composed of transient interactions that cannot be reconstituted in vitro. In this 
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section, I highlight several successful approaches to discovering PPI modulators and 
comment on needs for the future. This overview is not meant to be an exhaustive list of 
all HTS methods, but is rather meant to provide a general roadmap for the design of 
screening campaigns. 
 
1.4.1 Biophysical methods 
Some PPIs are difficult to directly measure, although assays based on fluorescence 
polarization (FP), surface plasmon resonance (SPR), fluorescence energy transfer 
(FRET), bioluminescence energy transfer (BRET), differential scanning fluorimetry 
(DSF), hydrogen-deuterium exchange, AlphaLisa, and NMR spectroscopy have been 
developed and each has its strengths.82,83  
 
1.4.1.1 Flow cytometry protein interaction assay 
FP is typically effective when the PPI involves a small SA;84 however, many PPIs occur 
over large, flat surfaces that lack such a discrete binding site. In these instances, a flow 
cytometry-based protein interaction assay (FCPIA) has proven to be a powerful, versatile 
alternative for PPI inhibitor discovery. In this method, one partner is biotinylated and 
attached to avidin beads, while the other partner is labeled with a fluorophore. A flow 
cytometer is used to measure bead-associated fluorescence, providing a quantitative 
measurement of protein binding.85–87 FCPIA was used to discover inhibitors of the high-
affinity interaction between a regulator of G-protein signaling protein RGS4 and Gαo (KD 
~ 4 nM).88 Importantly, RGS4 accelerates GTPase activity of Gαo, and inhibitors of the 
PPI also block GTPase stimulation. FCPIA has also been used to identify inhibitors of 
weaker PPIs, including that between Hsp70 and the BAG family of nucleotide exchange 
factors (KD ~ 1 μM).89,90  
 
1.4.1.2 Capillary electrophoresis 
Another technique used to study protein complexes is capillary electrophoresis (CE). This 
method allows for separation of complexes from their individual components based on 
their size and charge. Labeling one or more of the individual protein partners enables 
sensitive detection of bound:free ratios.91,92 CE has been used to identify inhibitors of a 
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number of macromolecular complexes, including those between SH2 domains and short 
phosphorylated peptides93 and Hsp70–BAG.89 One advantage of CE is that it allows for 
easy detection of aggregators, a common problem in PPI inhibitor screens. Finally, both 
CE and FCPIA are compatible with multi-color fluorescent labeling, which facilitates the 
ready detection of ternary and higher order complexes in 384-well plate format. 
 
1.4.1.3 NMR spectroscopy 
NMR spectroscopy-based strategies are particularly useful for the detection of ligand 
binding to protein interfaces, even that those that involve modest affinity (e.g., high 
micromolar or millimolar dissociation constants).94 Furthermore, these experiments often 
illuminate the ligand-binding modes by chemical shift perturbations. This approach has 
been particularly powerful for fragment-based screens. Protein-observed NMR screening 
requires homogenous 15N or 13C isotopically labeled protein that has high solubility and 
stability even at high concentrations.95 Isotopic labeling can be costly, and data 
acquisition for NMR spectra is often time-consuming. One alternative is ligand-based 
NMR screening and another is protein-observed fluorine NMR spectroscopy (PrOF 
NMR), an attractive approach with high sensitivity and rapid data collection. The 19F 
nucleus is highly responsive in NMR experiments and accounts for 100% of naturally 
occurring fluorine, eliminating the need for isotopic labeling.96 Native tyrosine residues 
are replaced with singly labeled fluorinated tyrosine, allowing for sensitive detection of 
protein conformation in simplified 1D-NMR spectra. This approach is particularly useful 
in the discovery of inhibitors of PPIs due to the enrichment of aromatic amino acids at 
PPI interfaces and has been used to characterize ligand binding to the transcriptional co-
activation domain CBP/p300 GACKIX97 and bromodomains in BRD4, BrdT, and 
BPTF.98 In addition, genetic incorporation of trifluoromethyl-phenylalanine was used to 
probe protein–ligand interactions within the thioesterase domain of fatty acid synthase.99 
Recently, a full PrOF NMR fragment screen was used to discover several new small 
molecule ligands for distinct binding sites on CBP/p300 GACKIX, confirming the 
druggability of this dynamic protein interface.100 
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Another emerging approach to get around the typical size limits of NMR spectroscopy is 
to label methyl groups on amino acid side chains. Methyl groups frequently reside in the 
hydrophobic interior of proteins and are sensitive reporters of protein structure and 
dynamics.101 NOEs can be used to determine spatial proximity of methyl groups, 
reporting on tertiary and quaternary protein structure.102,103 Furthermore, methyl groups 
located at the end of side chains undergo slower relaxation kinetics, facilitating the 
acquisition of NMR spectra for large proteins with high sensitivity and resolution.104,105 
Researchers at Abbott Laboratories adapted this approach to screen a series of protein 
targets using selective 13C labeling of methyl groups in valine, leucine, and isoleucine 
side chains, demonstrating the utility of this strategy in HTS for target proteins up to 110 
kDa in size.106 
1.4.2 Site-directed fragment-based screening 
Covalent disulfide trapping, or Tethering, can be used in HTS to facilitate discovery of 
PPI inhibitors. In this method, fragment molecules containing disulfide moieties 
covalently modify a natural or engineered cysteine. The relative strength of the 
interaction is typically measured by competition with DTT or similar thiol modification 
reagent, permitting the selection of fragments that have the best affinity for the site.107,108 
Binding is typically explored by crystallography, SPR or mass spectrometry. Tethering is 
a particularly powerful technique because it is site-directed. Indeed, Tethering screens 
have demonstrated that adaptive, conformationally flexible regions of protein–protein 
interfaces are often more amenable to inhibitors.109–111 Tethering was recently used to 
successfully define the role of an allosteric site in activation of the PDK1 kinase. 
Engineered cysteines lining the rim of the PDK1-interacting fragment (PIF) pocket on 
PDK1 were screened for disulfide capture against a library of fragment molecules.112 
Interestingly, tethered fragments at a single site resulted in both activation and inhibition 
of PDK1, and the allosteric effect was unrelated to binding potency. Rather, fragment 
binding at a single allosteric site elicited subtle changes in the active conformation of 
PDK1, leading to potentiation or inhibition of kinase activity. Another recent example 
identified inhibitors of a specific cysteine mutant of Ras.113 
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Fragments identified from Tethering screens can be powerful chemical probes for 
dissecting allosteric networks in flexible proteins. For example, the GACKIX domain of 
the transcriptional co-activator protein CBP/p300 displays considerable structural 
plasticity.114 A recent Tethering screen yielded a small molecule (1-10) that has a 
remarkable effect on the overall thermal stability of GACKIX and was used as an aid in 
crystallization in order to obtain the first X-ray crystal structure of GACKIX at 2 Å 
resolution.115 More recently, 1-10 was used in conjunction with kinetic and computational 
analyses to reveal the mechanism of allostery between two activator-binding sites in 
GACKIX. Binding of one ligand does not affect the association kinetics for the second 
partner, but rather decreases the rate of dissociation of the complex.116 These results 
suggest that cooperativity between the two activator-binding sites is achieved by 
increasing the energy barrier for dissociation, effectively stabilizing the GACKIX ternary 
complex.117 In other words, inhibition of activator binding is mediated by favoring the 
unbound binary complex. 
1.4.3 Adaptive protein interfaces 
One screening approach is to take advantage of the conformational plasticity of PPIs. 
Protein surfaces that mediate contacts with a variety of other proteins are typically 
flexible, allowing them to adapt to each partner. For example, the GACKIX domain of 
the transcriptional co-activator CBP/p300 is an important regulatory node of gene 
expression and mediates binding to diverse transcriptional activators via two 
allosterically coupled binding sites.50,114,118 Majmudar and coworkers reasoned that small 
molecules could take advantage of this intrinsic motion to trap specific states.119 
GACKIX was screened with the activator MLL bound in the deeper and more 
conformationally flexible binding site, and this approach identified two natural products, 
sekikaic acid and lobaric acid. These compounds bind to a dynamic site on CBP/p300 
GACKIX and allosterically inhibit interactions at the distal binding site with good 
specificity. In this case, knowledge of the adaptive, local PPI network was used to 
establish a screening paradigm that favored discovery of the desired probe. 
 
Another recent example focused on nuclear receptors and their co-activator proteins. The 
retinoid X receptor (RXR) contains a dynamic protein interface, termed activation 
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function 2 (AF2) that mediates interactions with co-activator proteins.120,121 Sheepstra and 
coworkers used a combination of NMR spectroscopy and molecular docking to identify a 
natural product honokiol that targets both sides of the adaptive AF2 domain.122 They used 
rational design to “split” the two functions of honokiol, generating a potent RXR agonist 
with one and an antagonist with the other. The first ligand inhibits the RXR-coactivator 
PPI by binding at an allosteric site, while the second ligand binds directly to the ligand-
binding site on RXR to favor interactions with the co-activator. Like the example of the 
CBP/p300, this approach exploits the inherent conformational flexibility of the AF2 
domain and demonstrates how binding of small molecules at the same protein interface 
can differentially modulate specific PPIs. 
 
Another interesting example involves the adaptor protein 14-3-3 introduced earlier. 
Binding between 14-3-3 and the plant proton pump PMA2 was monitored by SPR, and a 
small compound library was screened for stabilizers of the interaction.123 This campaign 
identified small molecules that promote the PPI between 14-3-3 and PMA2 by binding to 
a flexible groove on 14-3-3 and making contacts with both partners. Synthetic 
optimization of the pyrrolinone scaffold in one of these molecules resulted in the 
development of a derivative that further stabilized the 14-3-3−PMA2 interaction.124 This 
example is interesting because the screening method was designed such that the two 
partners were near their half-maximal concentrations, which likely facilitated the 
discovery of the “hits”. Most screening campaigns involve saturating concentrations of 
the two interacting partners; not surprisingly, inhibitors are more commonly observed 
under these conditions. 
 
These successful HTS campaigns demonstrate how a conformationally dynamic protein 
can be targeted with small molecules to specifically modulate the assembly and 
disassembly of multi-protein complexes. A key design feature of these screens is that 
structural knowledge of the system was used to guide the screen and favor identification 
of compounds with the desired mechanism. 
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1.4.4 “Gray-box” screening 
In many cases, weak binding affinity between a protein and its binding partner can 
complicate the design of an effective screening assay. In these cases, it can be useful to 
screen the functional output of the interaction, rather than the physical interaction itself. 
A method referred to as “gray-box” screening125 was developed specifically for this 
purpose. The name of this method comes from the term “black box” screens, which is 
applied to phenotypic assays. While screens in whole cells or organisms are powerful, it 
is often difficult to find the target. Likewise, biochemical screens against purified 
proteins, such as kinases or proteases, are clean, but they often ignore the impact of PPIs 
and non-enzyme partners. Gray-box screens are designed to include not just the enzyme, 
but also its binding partners, and the physical target of an inhibitor is therefore not 
obvious until follow-up mechanistic studies have been performed. In the first example of 
this approach, the ATPase, Hsp70, was mixed with its co-chaperones, including Hsp40. 
These co-chaperones act as catalysts of Hsp70’s ATPase activity,126–128 so the readout of 
the screen was largely a result of the PPIs and not the enzyme activity per se. Thus, the 
functional consequence of the interactions, measured as elevated turnover, can be used as 
a surrogate for binding.129,130 This type of approach has identified many specific chemical 
modulators of PPIs between Hsp70 and co-chaperones, ATPase activity, and chaperone 
function.48,131,132 Indeed, I discuss in Chapter 2 a screen against all possible binary and 
ternary complexes in the prokaryotic Hsp70 system which identified inhibitors that were 
specific for given co-chaperones, each taking advantage of previously unexplored 
allosteric networks to inhibit Hsp70 activity.133 Such diverse inhibitors are likely to be 
powerful tools and could enable the definition of Hsp70 PPI networks in a cellular 
environment. Gray-box screening has also been used to identify inhibitors of the 
interactions between Gα proteins and regulators of G-protein signaling (RGS) proteins, 
which act as GTPase activating proteins (GAPs). In this case, GTPase activity was used 
as a surrogate for RGS-Gα binding, and this screen identified several molecules capable 
of targeting the specific interactions between different RGS proteins and Gαi.134 In 
another example, the progesterone receptor (PR) was reconstituted with Hsp90 chaperone 
complexes, and compounds were screened for their ability to inhibit refolding of PR, a 
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physiological substrate of Hsp90.135 Overall, gray-box screening is particularly well 
suited to finding inhibitors of challenging PPIs. 
1.4.5 Screening in cells 
Some PPI networks cannot be readily replicated in vitro, demanding the use of cell-based 
screening platforms. However, even for a well-defined PPI, cell-based screens of the 
native network will likely yield modulators of up- and downstream interactions, required 
substantial deconvolution. To circumvent these challenges, enzyme fragment 
complementation can be used, allowing for a specific PPI to be screened in the cellular 
environment such that the functional output of the assay is dependent solely on the PPI of 
interest.136 In this approach, protein fragments derived from enzymes such as luciferase, 
β-galactosidase, or dihydrofolate reductase are fused to putative interacting partners. The 
inactive fragments can reassemble into a functional complex upon interaction of the 
protein partners. Reconstituted enzymatic activity is used to quantify protein binding, 
even between transiently interacting partners. 
 
The split luciferase assay can be used to detect PPIs in cells137 and can be expanded to 
include a Cre-recombinase-mediated cassette exchange138 allowing for inducible gene 
expression. The recombinase-enhanced bimolecular luciferase complementation platform 
(ReBiL) allows for the detection and analysis of even weak PPIs in living cells in real 
time. This platform enabled the detection of the transient PPI between the E2 ubiquitin-
conjugating enzyme UBE2T and its partner E3 ubiquitin ligase FANCL.139 This complex 
has a low micromolar dissociation constant and cocrystallization required the creation of 
a fusion protein between UBE2T and FANCL.140,141 This complex has previously eluded 
detection in living mammalian cells, although the ReBiL platform was able to readily 
detect the interaction. Furthermore, this assay was used to evaluate several reported small 
molecule and peptide antagonists of p53–MDM2 and p53–MDM4 interactions.139 In 
particular, SAH peptides did not disrupt complex formation between p53 and either 
MDM2 or MDM4; rather, their previously reported cellular activity could be contributed 
to p53-independent cell membrane disruption. Importantly, ReBiL was readily adapted to 
1536-well format, making it a powerful, high-throughput technique for the detection of 
even weak or transient protein complex formation in real time in living cells. 
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1.5 Dissecting protein networks in vitro and in cells 
While the previous sections focused on methods for discovering modulators of PPIs, it is 
also critical to understand the impact of the molecules on broader PPI networks. A key 
tool here continues to be mass spectrometry. Many groups have developed methods for 
measuring and quantifying PPI networks in cells.142 What has been less well explored is 
how small molecules affect these systems. This is somewhat surprising, and a more 
concerted effort to study how compounds change PPI networks will provide significant 
insight. Inhibiting a single protein target with a small molecule affects not only the direct 
interactions between the target and its partners, but also propagates changes throughput 
the entire protein network (Figure 1.5). In addition, the shape of the ligand and the 
accompanying conformer of the bound protein target dictate how changes are transmitted 
throughout the overall protein network, both in the extent of modulation and which 
“arms” of the network are affected. One might envision that some inhibitors might act on 
the same target, but produce different outcomes because of their unique pattern of 
affected PPIs (Figure 1.5). 
 
Figure 1.5 Schematic representation of how small molecules might propagate changes in protein-
protein interaction networks. (A) A theoretical drug target interacts with multiple proteins, which connect 
it to the broader PPI network. (B) Treatment with an inhibitor might weaken some PPIs (dotted lines) and 
strengthen others (dark lines). The ultimate response to the inhibitor is manifested by both the direct effect 
on its target and the new state of the perturbed PPI network. (C) A different inhibitor, even acting on the 
same target, might generate a non-overlapping phenotype by trapping the target in a state that perturbs the 
network in distinct ways. 
 
1.5.1 Mass spectrometry can detect changes in protein structure 
Proteins and other macromolecules exist in an ensemble of conformational states, and 
binding to other macromolecules or ligands can have profound effects on their 
 23 
dynamics.143,144 Each member of the structural ensemble has the potential to bind different 
partners or perform specific tasks.145 As discussed, many small molecules trap particular 
protein conformations and these states can propagate important downstream effects.146 
Thus, one powerful method is to explore time-dependent perturbations in protein 
structure using mass spectrometry (MS).147,148 Pioneering efforts in native MS and 
nanoflow electrospray ionization (nESI) have revolutionized the study of large protein 
complexes with its increased sensitivity and preservation of weak non-covalent 
interactions.149 Because detection occurs in the gas phase, this technique effectively 
captures a “snapshot” of a binding equilibrium that exists in solution. Furthermore, 
multiple protein partners can be detected simultaneously within the context of the larger 
assembly without the need to isolate specific complexes.150 nESI is therefore particularly 
suited to the study of multi-protein complexes in real time. Recently, it has been used to 
quantify the assembly of complexes between the molecular chaperones Hsp90, Hsp70 
and the co-chaperones FKBP52 and HOP,151 as well as polydispersed oligomers of small 
heat shock proteins.152 
 
Ion mobility-mass spectrometry (IM-MS) is a technique that separates macromolecules in 
the gas phase, analogous to electrophoresis in solution. Measurement of ion migration, or 
drift time, can be used to generate information on the collisional cross section of a protein 
of interest, which can in turn be used to infer changes in the folded conformation of a 
protein upon ligand or macromolecule binding.153 The introduction of collision-induced 
unfolding measurements enable IM-MS to report on more subtle changes in protein 
tertiary structure induced by ligand binding.154,155 This development has been useful for 
evaluating different binding modes of similar ligands, in particular the subtle differences 
in kinase structure upon binding to type I and type II inhibitors.156 This approach was 
sensitive enough to cluster several well-characterized type I and type II Abl kinase 
inhibitors based on their preferred protein structure and has the potential to be adapted to 
a larger screen of a chemical library for evaluation of ligand-induced changes in protein 
conformation. 
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1.5.2 Small molecules produce diverse cellular outcomes through the same target 
It is important to consider that small molecule modulators of PPIs are often not simple, 
functional “on-off switches”. Rather, compounds can have sundry effects on function 
because the immediate PPIs are linked to the broader network. To illustrate this 
complexity, it is worth considering the example of Hsp70 inhibitors. Hsp70 is a 
molecular chaperone that regulates protein quality control through a conserved 
mechanism of ATP hydrolysis and substrate binding. Many classes of Hsp70 inhibitors 
have been identified and each of these inhibits nucleotide turnover in vitro.157,158 Thus, 
one might assume that each of these compounds have similar downstream effects on 
Hsp70’s functions in cells. However, this assumption turns out to be incorrect because 
each category of inhibitor has a unique impact on Hsp70 PPIs. Efforts by multiple groups 
have provided Hsp70 “inhibitors” that either compete with ATP or inhibit interactions 
with specific classes of co-chaperones.159 In each case, the compound blocks steady-state 
ATPase activity in vitro, yet the cellular effects are not equivalent. For example, 
rhodacyanines that inhibit PPIs between Hsp70 and its nucleotide exchange factors160 
lead to dramatic degradation of the polyglutamine expanded androgen receptor (polyQ-
AR),161 a well-established Hsp70 client, while molecules that inhibit ATP binding162 lead 
to substantial increases in accumulation of polyQ-AR.163 Therefore, two classes of 
molecules with equivalent ability to inhibit ATPase activity have opposing effects on 
polyQ-AR levels, although the exact mechanisms that link these events to cellular 
outcome are not yet clear. Nonetheless, molecules targeting the same protein can produce 
distinct outcomes, likely due to differences in the way that the target, in this case Hsp70, 
engages with downstream partners. An increased understanding of how protein networks 
are linked to disease may eventually allow for a more rational approach to drug discovery 
and improved screening paradigms that more correctly predict outcomes. In many ways, 
these observations mirror what is observed in GPCR agonists/antagonists. 
 
1.5.3 Methods for detecting small molecule-induced changes in local and global 
protein networks 
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1.5.3.1 Affinity purification and quantitative mass spectrometry 
Emerging large-scale PPI maps have been instrumental in defining the protein 
interactome in mammalian cells.164,165 Advances in quantitative mass spectrometry, 
including its combination with affinity purification (AP-MS), have allowed for dynamic 
profiling of PPIs at near physiological conditions.166 In this technique, a protein of 
interest (bait) is expressed with an epitope tag, which is used to purify the bait protein 
from cell lysate along with its interacting protein partners (prey).167 Commonly used tags 
include the short FLAG tag or the tandem affinity purification (TAP) tag. The TAP 
approach requires two affinity tags separated by a protease cleavage site.168 Purification 
of the bait and prey proteins from cell lysate occurs over two steps, and this strategy can 
decrease the identification of false positive proteins in subsequent analysis. Tandem mass 
spectrometry is then used for identification and quantitation of the isolated proteins. This 
powerful approach allows for rapid sequencing and identification of thousands of 
individual peptides, including characterization of post-translational modifications.169,170 
Furthermore, mass spectrometry is readily adapted to quantify protein abundance in the 
original sample, which can provide insight into the dynamics of protein complex 
assembly (and disassembly) in response to pharmacological manipulation.171 It is 
important to note that the lack of detection in an AP-MS experiment does not imply a 
lack of interaction between the bait protein and a prey protein of interest. The stringency 
of washing conditions can disrupt transient PPIs, which can complicate analysis.166 
 
Despite these limitations, many groups have nonetheless successfully used AP-MS to 
identify and characterize protein complexes in living cells in response to pharmacological 
manipulation. In Saccharomyces cerevisiae, polyglutamine (polyQ) fragments form 
cytosolic aggregates, and this process is regulated by molecular chaperones.172 The 
dihydropyrimidine 115-7c promotes binding of Hsp70 to Hsp40 and polyQ, increasing 
polyQ solubility. AP-MS revealed changes in proteins bound to polyQ fragments as a 
function of polyQ length, aggregation time, and 115-7c treatment.173 In a similar study, 
Thompson and coworkers used AP-MS to study acute changes in the interaction network 
associated with turnover of microtubule-associated protein tau.174 Several proteins, 
including Hsp70 and Hsp90 had differential association with tau following treatment with 
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an inducer of tau degradation. In both examples, MS was a powerful tool for dissecting 
the dynamic changes in multi-protein complexes in response to pharmacological 
disruption of PPIs. 
 
1.5.3.2 Covalent chemical crosslinking  
A major hurdle to AP-MS is the difficulty in identifying partners with low affinity and/or 
low abundance. Several groups have developed creative solutions to this challenging 
problem, including crosslinking. Examples of synthetic crosslinkers include activated 
diesters linked by a cyclic quaternary diamine. The diamine is cleavable by collision-
induced dissociation and facilitates identification of crosslinked peptides.175 Another 
crosslinking method is the use of genetically encoded photoactivatable amino acids, such 
as p-benzoyl-L-phenylalanine (Bpa), which are used to covalently and site-specifically 
capture PPIs in their native environment.176,177 This approach has been successfully 
adapted to both stable, high-affinity PPIs as well as more transient, moderate- to low-
affinity PPIs within the transcriptional machinery. Photoactivation of Bpa encoded in the 
transcriptional activator Gal4 captured its stable interaction with the suppressor protein 
Gal80.178 Interactions of transcriptional activators with co-activator proteins are typically 
much more transient.179 For example, the Swi/Snf chromatin-modifying complex is a 
proposed binding target for the viral activator VP16, although the specific interactions 
had evaded detection with traditional methods.180 Photo-crosslinking of Bpa confirmed 
that VP16 makes direct contacts with both Snf2 and Snf5 during transcription 
initiation.181 Because this approach is site-directed, it can be combined with mass 
spectrometry to localize interaction “hot spots” for specific PPIs and to identify and 
characterize novel binding partners for a protein of interest.182 
 
1.5.3.3 Proximity biotinylation 
A recently reported proximity biotinylation approach, BioID is a complementary method 
for mapping specific PPIs within large multi-protein complexes. This strategy is 
particularly advantageous because it does not require that complexes be maintained 
across numerous purification steps and therefore has the potential to identify more 
transient PPIs compared to traditional AP-MS techniques.183 In this method, the bait 
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protein is fused to a mutated prokaryotic biotin ligase BirA. This enzyme covalently links 
acceptor proteins with biotin via an activated intermediate (biotinoyl-5′-AMP). However, 
the mutant enzyme dissociates rapidly from the activated biotinoyl-5′-AMP, creating a 
“cloud” of activated biotin surrounding the bait protein.184 The activated biotin can then 
covalently modify exposed lysine residues on the prey proteins, which can include direct 
partners as well as neighboring proteins. Alternatively, specific prey proteins can be 
fused with an acceptor peptide for the biotin ligase.185 Rather than subsequent affinity 
purification with the tagged bait protein, prey proteins are enriched with streptavidin 
purification and identified by mass spectrometry. This approach has been successfully 
adapted to the in vivo characterization of a number of diverse, dynamic protein 
complexes, including the chromatin-associated mediator complex,186 members of the 
nuclear lamina183 and nuclear pore complexes,187 and components of the inner membrane 
complex in Toxoplasma gondii, among others.188 These complementary approaches, 
including AP-MS, protein crosslinking, and proximity biotinylation can be used in 
tandem to create a full picture of a protein complex in living cells, as each approach has 
the potential to identify novel interactions. 
 
1.6 Conclusions and Outlook 
Multi-protein complexes are the “hubs” of the cellular PPI networks and attractive drug 
targets for a variety of diseases. I have illustrated in this chapter several “success stories” 
of small molecules that target PPIs. Often, the development of new methodology was 
required to identify these PPI modulators. Indeed, creative HTS strategies are beginning 
to expand the toolbox of available approaches, although there is no algorithm or “road 
map” for a successful screen. Rather, each campaign must be designed individually, 
taking into account the affinity of the interactions, the topology of the interaction 
surfaces, and the interplay between different components of the system. For instance, a 
phenotypic or gray-box screen has the best chance of success for finding small molecules 
that can perturb protein networks. However, these strategies require significant 
knowledge of the structure and function of individual PPIs within a greater protein 
complex, highlighting the importance of basic research in order to be able to ask the right 
questions. 
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1.7 Thesis outline 
Although great strides have been made in targeting PPIs with small molecules, several 
fundamental questions remain; namely, can we selectively modulate some PPIs and not 
others within a larger protein network? Can we use such inhibitors to reveal biological 
functions of a given protein complex? Finally, can small molecules be used to “tune” 
protein networks in a predictable way? In this dissertation, I address several of these key 
questions. In Chapter 2, I outline a novel, robust HTS strategy for finding inhibitors of 
specific PPIs within the Hsp70 chaperone complex. In Chapter 3, I use an inhibitor of the 
Hsp70−BAG interaction to elucidate the role of this complex in pro-survival signaling. 
This probe allowed me to discover that the inhibitor of apoptosis proteins (IAPs) are a 
previously unexplored class of Hsp70 client proteins. In Chapter 4, I describe initial 
efforts to study the effect of inhibitors on more global protein networks, using protein 
kinases and the Hsp70 system as illustrative examples. Finally in Chapter 5, I discuss the 
implications of this work and describe future strategies for targeting PPIs, both for the 
development of tool compounds as well as potential therapeutics. 
 
Notes 
This chapter is adapted from Cesa, L. C. et al. “Direct and Propagated Effects of Small 
Molecules on Protein-Protein Interaction Networks” 2015 Frontiers in Bioengineering 
and Biotechnology 3: 119. Laura C. Cesa, Anna K. Mapp, and Jason E. Gestwicki 
contributed to these ideas. 
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Chapter 2 
Inhibitors of Difficult Protein-Protein Interactions Identified by High-Throughput 
Screening of Multi-protein Complexes 
 
2.1 Abstract 
Multi-protein complexes are important in all aspects of cellular function, and there is 
interest in finding inhibitors of individual protein−protein interactions (PPIs) within these 
complexes. As discussed in Chapter 1, PPIs with weak affinities and/or large interfaces 
have traditionally been more resistant to the discovery of inhibitors, partly because it is 
more challenging to develop high-throughput screening (HTS) methods that permit direct 
measurements of these physical interactions. In this chapter, we explore whether the 
functional consequences of altering a weak PPI might be used to assess binding of a 
small molecule modulator. As a model, we used the bacterial ATPase DnaK and its 
partners DnaJ and GrpE. Both DnaJ and GrpE bind DnaK and catalytically accelerate its 
ATP cycling, so we used stimulated nucleotide turnover to indirectly report on the status 
of these PPIs. In pilot screens, we identified compounds that blocked activation of DnaK 
by either DnaJ or GrpE. Interestingly, at least one of these molecules selectively blocked 
binding of DnaK to DnaJ, while another compound disrupted allostery between DnaK 
and GrpE without altering the physical interaction. These findings suggest that the 
activity of a reconstituted multi-protein complex might be used in some cases to identify 
allosteric inhibitors of specific, challenging PPIs within a larger protein network. 
 
2.2 Introduction 
Multi-protein complexes are critical to cellular functions.7,8,189,190 These complexes are 
typically assembled from a combination of enzymes and non-enzymes: the enzymes, such 
as demethylases, proteases, or ATPases, often conduct the work associated with the 
system, while the non-enzymes regulate this activity, either by dictating subcellular 
location, guiding the selection of binding partners, or controlling enzyme turnover rates. 
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Thus, the protein–protein interactions (PPIs) between enzymes and non-enzymes are 
critical for the overall function of the complexes and inhibitors of these PPIs are 
important chemical probes.13,24 More recently, there has also been renewed interest in 
targeting PPIs in the treatment of disease.12,14,19,20 
 
2.2.1 PPIs are challenging drug targets 
As discussed in Chapter I, while there has been tremendous progress in the general area 
of PPI inhibitors, it has become clear that some types of PPIs are more challenging to 
target than others.21,191 In particular, PPIs involving weak (KD > 200 nM) interactions that 
occur over large contact surfaces (> 2,500 Å2) tend to be more difficult to inhibit.21 One 
challenge in finding inhibitors of weak interactions is that it is difficult to develop robust, 
high-throughput screening (HTS) methodology to directly measure the physical 
interactions between transient partners. Accordingly, many research groups have been 
interested in exploring new HTS platforms that are specifically designed for use against 
these types of challenging PPIs.129,130 These methods, such as fragment-based screens and 
high content screening (HCS), are promising to open the number of “druggable” PPIs to 
include even the challenging targets.21,191 
 
2.2.2 The prokaryotic Hsp70 multi-protein complex as a model system 
Despite the advances advances described in Chapter 1, major challenges remain, 
particularly in targeting those PPIs involving weak interactions. These observations have 
driven us to use the Escherichia coli chaperone complex, which is composed of an 
enzyme (DnaK) and multiple non-enzymes (DnaJ, GrpE, and peptide substrate), as a 
model system.192 DnaK is a member of the highly conserved heat shock protein 70 kDa 
(Hsp70) family of molecular chaperones, which are important in protein quality 
control.193,194 Like other Hsp70s, DnaK is an ATP-driven enzyme that has a nucleotide-
binding domain (NBD) and a substrate-binding domain (SBD) (Figure 2.1). ATP is 
hydrolyzed in the NBD, while the SBD binds to hydrophobic segments of polypeptides, 
such as those exposed in misfolded proteins.195,196 Allosteric communication between the 
two domains modulates the affinity of DnaK for peptides; DnaK binds peptide substrates 
loosely in the ATP-bound state, while it binds tightly in the ADP-bound form.197,198 A 
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major role of DnaK’s non-enzyme partners, DnaJ and GrpE, is to regulate this ATP 
cycling. Specifically, DnaJ and peptide substrates stimulate the rate of nucleotide 
hydrolysis in DnaK,127,199 while GrpE accelerates release of ADP and peptide.126 Together, 
the components of the DnaK-DnaJ-GrpE-peptide complex work together to coordinate 
ATP hydrolysis and regulate dynamic binding to misfolded proteins. 
 
Figure 2.1 Schematic of the DnaK-DnaJ-GrpE-substrate system. Nucleotide hydrolysis by DnaK is 
stimulated by DnaJ and peptide substrate, while GrpE stimulates ADP and peptide substrate release. ATP-
bound DnaK has low affinity for substrates, and ATP hydrolysis triggers the ADP-bound, high affinity 
conformation. 
 
Each of the components of the DnaK-DnaJ-GrpE-peptide complex is thought to play an 
important role in chaperone functions in vivo, and this system is highly conserved in 
mammals.192 Thus, inhibitors of the individual PPIs are expected to be powerful chemical 
probes, and these molecules may even find use in the treatment of bacterial infections, 
cancer, and neurodegenerative diseases.157 However, DnaJ and peptides each bind DnaK 
with weak, micromolar affinities,128,200 while GrpE binds DnaK over a large and 
topologically complex surface (~ 2800 Å2).126 These partners interact with DnaK 
transiently (e.g., fast on-fast off), acting as catalysts rather than stable binding partners. 
As evidence of this mechanism, sub-stoichiometric amounts of DnaJ are sufficient to 
convert DnaK from its ATP- to ADP-bound state under single turnover conditions.201 
Further, structural studies on DnaK-DnaJ have provided insight into the possible 
mechanism of this transient interaction, as the protein–protein contact surface is shallow 
and almost entirely electrostatic,128 suggesting that the two proteins form dynamic 
complexes that are able to form and dissociate rapidly. In E. coli, the levels of DnaK are 
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approximately 10-fold greater than the concentration of DnaJ or GrpE, suggesting that 
this weak interaction is physiologically relevant. 
 
2.2.3 Enzymatic activity of reconstituted protein complexes can be used as a 
surrogate for binding in HTS 
As discussed above, it has proven especially challenging to find inhibitors of weak, 
transient PPIs, such as those between DnaK-DnaJ, not only because of these interactions 
are difficult to detect, but also for practical concerns including the high concentration of 
sample required for stringent binding screens.24,202 In this chapter, we hypothesized that 
we could use the enzymatic activities of the reconstituted DnaK-DnaJ, DnaK-GrpE, and 
DnaK-peptide complexes as a surrogate for the physical, bimolecular interactions. We 
considered this approach potentially feasible because, despite their moderate to weak 
affinities for DnaK, each of the non-enzyme partners (DnaJ, GrpE, and peptide 
substrates) produce dramatic effects on ATP cycling, enhancing steady-state hydrolysis 
by approximately 10-fold, 2-fold and 3-fold, respectively.127,203 Thus, even though they 
bind transiently, these non-enzyme “catalysts” produce potent effects on nucleotide 
turnover. 
 
We measured phosphate release from eight distinct, reconstituted E. coli DnaK 
complexes and screened a pilot chemical library for possible inhibitors. Strikingly, we 
found that both the identity of the non-enzyme (e.g., DnaJ or GrpE) and its stoichiometry 
relative to DnaK (e.g., maximal or half-maximal) affected the number and types of 
inhibitors that were identified. At least one of these molecules had the characteristics of a 
direct inhibitor of the DnaK interaction with DnaJ, while another molecule operated at an 
allosteric site in DnaK to block stimulation by GrpE. These results suggest that PPI 
inhibitors with distinct mechanisms-of-action can be identified via screening 
reconstituted multi-protein complexes in vitro. This approach should contribute to a 
growing arsenal of HTS methods for finding inhibitors of challenging PPIs. 
 
 33 
2.3 Results 
We reasoned that one way to screen for inhibitors of weak PPIs might be to monitor the 
functional consequences of the interactions (e.g., ATP hydrolysis), rather than measuring 
the physical binding events themselves. This approach, termed “gray-box screening” is 
particularly well suited for weak contacts, such as the one between DnaK and DnaJ, 
because these interactions are technically challenging to directly measure using typical, 
HTS-compatible formats, such as flow cytometry, FP, AlphaLisa, or surface plasmon 
resonance (SPR).83,204 Yet, the transient PPIs between DnaK and DnaJ provide robust and 
readily measured changes in enzymatic turnover.127,199 
 
Figure 2.2 Characterization of the stimulatory effects of DnaJ, GrpE, and NRLLLTG peptide on 
ATP turnover. Stimulation of DnaK’s ATPase activity by (A) DnaJ, (B) GrpE, and (C) NRLLLTG 
peptide was measured by malachite green. Results are the representative averages of triplicates of three 
independent experiments, and error is SEM. Data were fit to the Michaelis-Menten equation. The saturation 
(sat) and half-maximal (M) values are shown. DnaK = 0.4 μM. 
 
2.3.1 Design of HTS campaigns to identify inhibitors of the DnaK-DnaJ-GrpE-
peptide system 
A series of small-scale pilot screens was performed to better understand the potential 
feasibility of the PPI surrogate approach. We first expressed and purified E. coli DnaK, 
DnaJ and GrpE and synthesized a model peptide substrate with the sequence 
NRLLLTG.205 Using an adaptation of a malachite green assay for detecting release of 
inorganic phosphate,206 we confirmed that DnaJ, GrpE and the NRLLLTG peptide all 
stimulated the steady state ATPase activity of DnaK. During these experiments, we also 
determined the levels of each partner that was required to maximally and half-maximally 
promote hydrolysis (Figure 2.2). For example, DnaJ stimulated the ATPase activity of 
DnaK (0.4 μM) with a half-maximal concentration of 0.05 μM and reached full 
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stimulation at ∼6 μM, values consistent with published values.127,203 We then reconstituted 
DnaK with each of these partners to establish a series of 8 different screening targets 
(screens A-H) (Figure 2.3A). All of the screens used the same amount of DnaK (0.4 μM) 
and varied only in the identity and relative stoichiometry of the non-enzyme binding 
partner. In selecting this series of targets, we focused on exploring the effects of molar 
ratio by either saturating the levels of the partners (screens A, C, and E) or using half-
maximal amounts (screens B, D, and F) (Figure 2.3A). We hypothesized that high levels 
of non-enzyme partner might yield better signal:noise and Z′ values, while half-maximal 
levels might facilitate discovery of PPI inhibitors by decreasing competition between the 
test molecules and the partner proteins. In addition to the binary complexes, we also 
assembled ternary complexes of DnaK-DnaJ-peptide (screen G) and DnaK-GrpE-peptide 
(screen H). Screen G was included because DnaJ and peptide are known to use 
synergistic allosteric pathways to stimulate ATP hydrolysis,207 while screen H was 
included because GrpE alone has a relatively modest effect on ATPase activity, and we 
suspected that the signal:noise in the DnaK-GrpE screens (screens C and D) may not be 
sufficient to achieve good screening parameters. 
 
2.3.2 Parallel chemical screens yield inhibitors of distinct DnaK complexes 
The series of reconstituted targets was screened against a pilot library of ∼ 300 
molecules.129 This library was composed of commercially available compounds and was 
assembled at the University of Michigan’s Center for Chemical Genomics. Guided by 
previous observations,132 we specifically selected a library enriched in plant natural 
products because these molecules are expected to yield relatively high “hit rates” (up to 
3% or 4% in some DnaK screens),132 allowing us to rapidly and cost effectively test the 
performance of this HTS approach on a relatively small number of compounds. On each 
plate, 12 wells were assigned to a positive control (e.g., lacking only the enzyme, DnaK) 
and 12 wells served as negative controls (1% DMSO). Active molecules were defined as 
those that reduced the signal by at least three standard deviations from the negative 
controls with intrinsic fluorescence values less than 500 AFUs. Compounds that met 
these criteria were then subjected to dose–response in triplicate and were considered 
“confirmed actives” if they had IC50 values less than 75 μM (Figure 2.3A). Of the eight 
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screens, only the DnaK-GrpE screen with low GrpE levels (screen D) failed to give a Z′ 
factor greater than the 0.5 cutoff due to a poor signal:noise; thus, it was removed from 
subsequent analyses. 
 
Figure 2.3 High-throughput screens identify selective inhibitors of individual multi-protein 
complexes. (A) Results of eight parallel, pilot HTS campaigns. The indicated non-enzyme partner was 
added at an amount that either saturated steady-state ATP hydrolysis or at the half-maximal amount 
(KM,app). Confirmed actives = repeated in triplicate, dose response < 75 μM. Unique actives = compounds 
found with a specific non-enzyme but not others. (B) Comparison of the actives from screening 3,880 
molecules against the DnaK-DnaJ and DnaK-GrpE combinations in 384-well plates. In these screens, DnaJ 
was used at KM,app and GrpE at saturation. The chemical structures of representative unique actives are 
shown. 
 
 36 
 
Figure 2.4 Additional results from the parallel HTS campaigns. (A) Representative examples of the 
primary, raw screening results, highlighting the effects of saturating non-enzyme partner. (B) Chemical 
structures of the molecules re-purchasesd and confirmed as inhibitors of DnaK-DnaJ or DnaK-GrpE. 
 
2.3.2.1 Varying the identity and stoichiometry of the non-enzyme enables the 
discovery of unique inhibitors 
From the pilot screening results, a number of observations were made. First, seven 
compounds were inhibitors of all reconstituted complexes, regardless of their 
composition. The broad activity of these molecules suggests that they may be competitive 
inhibitors of ATP binding in DnaK or that they interfere with the assay (e.g., strong 
aggregators). More interesting were the compounds that acted on only specific multi-
protein complexes, but not others (“unique actives”) (Figure 2.3A and B). For example, 
10 compounds were identified as active in only the DnaK-DnaJ screen (screen B), but not 
the screens involving GrpE or peptide (screens C, E, and F). Likewise, 4 compounds 
were inhibitors in the DnaK-GrpE screen (screen C), but not in the screens involving any 
of the other non-enzymes. These results suggest that the combination of components 
chosen for the screen may favor discovery of molecules exclusive for that pair. This is an 
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interesting result because the same enzyme, DnaK, is used in all of the parallel pilot 
screens. We speculate that conformational changes, which occur as a consequence of the 
individual PPIs, might create new opportunities for inhibitor binding. For example, the 
ADP-bound form of DnaK is not heavily populated in the absence of DnaJ, because the 
rate-limiting step, ATP hydrolysis, is slow.208 Thus, molecules that bind the ADP-bound 
state of DnaK might only become potent when this state becomes significantly populated 
by the DnaJ-DnaK interaction. Another observation was that screens of ternary 
combinations did not reveal new compounds that were not already found in the relevant 
binary complexes (Figure 2.3B), although this result may be influenced by the small size 
of the pilot library. 
 
We also found that “saturating” the amount of non-enzyme (especially DnaJ or peptide) 
tended to suppress the identification of inhibitors, consistent with the idea that half-
maximal levels are more permissive to inhibitor discovery (Figure 2.3A and Figure 
2.4A). For example, dropping the level of DnaJ to its half-maximal concentration (0.05 
μM) increased the number of confirmed actives from 11 to 23 (Figure 2.3A). This 
observation is interesting because HTS campaigns, at least in our experience, typically 
start with the goal of optimizing the signal:noise in order to obtain the best possible 
screening statistics (e.g., Z′ factor, etc.). Thus, maximizing the signal in a PPI assay may, 
in some cases, create a disadvantage for the discovery of inhibitors. Together, these 
studies provided insights into the design principles and implementation strategies for 
screens against reconstituted multi-protein complexes. 
 
2.3.2.2 HTS hits are selective inhibitors of specific PPIs 
Next, we wanted to explore this HTS concept in studies of larger and more diverse 
chemical collections. In these studies, we focused on the DnaK-DnaJ (screen B) and 
DnaK-GrpE (screen C) combinations for rescreening against an expanded collection of ∼ 
3880 known bioactive molecules, including the MS2000 and NCC libraries. These 
compounds were screened at ∼ 50 μM in 384-well plate format using a quinaldine red-
based modification of the malachite green assay.209 The Z′ factors from these screens 
were between 0.6 and 0.7, and CV values were between 6% and 9% (Figure 2.3A). The 
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primary actives were subject to the same triage criteria as in the pilot screens, yielding 31 
confirmed hits against DnaK-DnaJ and 18 against DnaK-GrpE. Of these compounds, 10 
were common to both DnaJ and GrpE, leaving 21 unique hits for DnaK-DnaJ and 8 for 
DnaK-GrpE (Figure 2.3B). The unique inhibitors of DnaK-DnaJ included myricetin 
(Myr) and zafirlukast (Zaf), which were previously identified as inhibitors of DnaK-
DnaJ.130,132 In addition, these screens revealed a number of additional molecules, 
including pancuronium bromide (PaBr) and telmisartan (Tel), which appeared as actives 
in the DnaK-GrpE screen but not the DnaK-DnaJ screen (Figure 2.3B). 
 
Using repurchased compounds, we confirmed that Myr and Zaf are only inhibitors of the 
DnaK-DnaJ combination (Figure 2.5A), while Tel and PaBr were only inhibitors of the 
DnaK-GrpE combination (Figure 2.5B). For example, Zaf inhibited DnaJ-stimulated 
ATPase activity (IC50 = 37 ± 1 μM) but did not have a measurable effect on GrpE-
stimulation (IC50 > 200 μM). Because PaBr is weakly soluble and the activity of Myr has 
already been reported,132 we selected Zaf and Tel as test molecules for further 
characterization. Specifically, we measured the activity of these molecules against each 
of the possible binary combinations (DnaK-DnaJ, DnaK-GrpE, and DnaK-peptide) and 
against DnaK’s intrinsic ATPase activity. In these studies, we varied the levels of each 
non-enzyme and tested if compounds could interfere with the individual stimulatory 
activities. These results showed that Zaf is able to suppress the activity of DnaK-DnaJ, 
but that it had weak or no activity against DnaK-GrpE or DnaK alone (Figure 2.5C). In 
contrast, Tel had little activity against DnaK alone or the complexes containing DnaJ or 
peptide but it significantly inhibited the DnaK-GrpE combination (Figure 2.5D). 
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Figure 2.5 Active compounds identified in the binary HTS experiments are selective for either DnaJ- 
or GrpE-stimulated ATPase activity. (A) Zaf and Myr inhibit ATPase activity of the DnaK-DnaJ 
complex. Results are the representative averages of triplicates of three independent experiments. Error bars 
represent SEM. (B) Tel and PaBr inhibit the DnaK-GrpE complex. (C, D) The ATPase activity of either 
DnaK alone or DnaK stimulated by DnaJ, GrpE, or peptide substrate (NRLLLTG) was measured at three 
concentrations of Zaf (C) or Tel (D). Zaf has activity against the DnaK-DnaJ and DnaK-substrate 
combinations, with weak activity against the DnaK alone or DnaK-GrpE combinations. Conversely, Tel 
inhibited the DnaK-GrpE pair but had weak activity against the others. All experiments are representative 
averages of triplicate of three independent experiments, and the error bars represent SEM. Curves were fit 
to the Michaelis-Menten equation. 
 
We next wanted to explore the mechanisms-of-action of Zaf and Tel to begin defining the 
general ways that the compounds might interfere with the functions of the DnaK multi-
protein systems. Specifically, we were interested in whether these molecules might 
directly compete with non-enzyme partners for binding to DnaK (“orthosteric” inhibitors) 
or whether they might impact the communication between DnaK and the non-enzymes 
without disrupting the PPI itself (e.g., by binding to an important allosteric site). 
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Figure 2.6 Zaf binds the ADP-bound form of DnaK and enhances the apparent affinity of DnaK for 
substrates. (A) Intrinsic Trp fluorescence of DnaK in the presence of ADP (1 mM) and Zaf. Zaf had no 
effect on Trp fluorescence in the ATP-bound states (p = 0.06) (Figure 2.5). Results are the representative 
averages of triplicates of three independent experiments, and the error bars represent SEM. (B) Zaf 
enhances the apparent affinity of DnaK for a model peptide substrate (FITC-HLA), as measured by 
fluorescence polarization (FP). (C) Zaf partially inhibits binding of DnaJ to DnaK. DnaK and DnaJ were 
labeled with a fluorescence quench pair, as described in Section 2.6. Zaf weakened the interaction by ~2-
fold (p = 0.07). Binding curves were fit to the Langmuir binding equation; does-response curves were fit to 
the Hill equation. 
 
2.3.3 Zafirlukast preferentially binds ADP-DnaK and enhances DnaK’s affinity 
for substrate 
To explore the mechanism by which Zaf inhibits the DnaK-DnaJ combination, we first 
tested whether it interacted with DnaK using intrinsic tryptophan fluorescence. DnaK has 
a single tryptophan located at the NBD-SBD interface (Figure 2.6A), and this residue is 
commonly used to probe structural changes in DnaK.210 When DnaK (5 μM) was 
incubated with 25 or 100 μM concentration of Zaf, the fluorescence intensity at 342 nm 
decreased by ∼ 25% and the peak shifted by ∼ 2 nm (Figure 2.7A), suggesting that Zaf 
binds to DnaK. Using this approach, dose-dependent changes in tryptophan fluorescence 
were measured, and we found that the apparent affinity (KD) was dependent on 
nucleotide: Zaf bound DnaK with a KD of 52 ± 12 μM in the presence of ADP (Figure 
2.6A), but its KD was greater than 100 μM for apo- or ATP-bound DnaK (Figure 2.7B). 
The ADP-bound form of DnaK is known to have a better affinity for peptide substrates.196 
Thus, to test whether Zaf could stabilize the “tight binding” form of DnaK, we measured 
the affinity of DnaK for a fluorescent 10-mer peptide derived from the MHC class I 
antigen HLA-B2702 (FITC-HLA). We first confirmed that FITC-HLA binds to DnaK 
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with low micromolar affinity using a fluorescence polarization (FP) assay (Figure 2.7D). 
This affinity is similar to what had been previously found for binding of FITC-HLA to 
human Hsp70.211 Addition of Zaf enhanced the apparent affinity of DnaK for FITC-HLA 
(Figure 2.6B), suggesting that it stabilizes the tight-binding form of DnaK. 
 
Figure 2.7 Controls and characterization of Zaf activity in the DnaK-DnaJ-GrpE systems. (A) Raw 
tryptophan fluorescence spectra of Zaf binding to DnaK in the apo, ADP-, and ATP-bound forms. 
Nucleotide was added at 1 mM. Signal for Zaf alone was subtracted. (B) Zaf binds very weakly to the ATP-
bound form of DnaK, as measured by tryptophan fluorescence (see Figure 2.4A for the ADP results). (C) 
Zaf does not compete with a fluorescent nucleotide for binding to DnaK. ATP is shown as a positive 
control. (D) DnaK binds to the FITC-HLA peptide, similar to what was previously reported for human 
Hsp72. (E) As positive controls, both NRLLLTG peptide and human tau compete for binding with the 
FITC-HLA peptide, showing that binding occurs in the SBD. Results are the representative averages of 
triplicates of three independent experiments, and error bars represent SEM. Binding data were fit to the 
Langmuir binding equation; inhibition data were fit to the Hill equation. 
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To better understand the relationship between Zaf and nucleotide binding, we performed 
additional FP studies with a fluorescent nucleotide analogue (FAM-ATP). In this assay, 
Zaf was unable to compete with FAM-ATP for binding to DnaK (Figure 2.7C), 
suggesting that it binds outside the ATP-binding cleft to stabilize the ADP-bound state. 
Finally, we tested whether Zaf might block binding of labeled DnaJ to DnaK, using a 
fluorescence-quenching assay.132 In this platform, Zaf slightly weakened binding of DnaJ 
to DnaK by ~1.8-fold (Figure 2.6C). Although this effect did not reach statistical 
significance, it was nonetheless reproducible, suggesting that Zaf might partially block 
this PPI. Together, these studies suggest that Zaf binds the ADP-bound form of DnaK, 
stabilizes binding to peptides, and partially inhibits physical interactions with DnaJ. 
 
2.3.4 Telmisartan interacts with the IB subdomain of DnaK and allosterically 
inhibits nucleotide affinity 
To elucidate the mechanism of Tel inhibition, we first tested whether the molecule might 
bind to DnaK using the tryptophan fluorescence assay described above. Unfortunately, 
Tel interfered with the Trp fluorescence signature, preventing interpretation of the data 
(not shown). However, a recent mutagenesis study suggested a pocket in DnaK that 
might be involved in Tel-mediated inhibition of GrpE function.212 Specifically, it was 
recently found that mutations in the IB and IIB subdomains of DnaK, including Phe67, 
Arg71, Phe91 and Lys263, suppresses the ability of GrpE to stimulate DnaK’s ATPase 
activity. Because the behavior of these mutants was similar to what was seen with Tel 
addition, we hypothesized that the compound might also bind in this region. To test this 
model, we used induced fit docking to generate a model of Tel bound to the putative 
binding pocket in the NBD of DnaK (see Section 2.6). This simulation suggested that Tel 
might bind between the IB and IIB subdomains, and in the two best, low energy 
orientations, Tel was predicted to make hydrophobic contacts with a series of residues 
(Figure 2.8A). To test this prediction, we titrated Tel into a sample of 15N DnaKNBD 
(residues 1–388) and performed the TROSY-HSQC NMR experiment (Figure 2.8B). 
Analysis of the results suggested a number of strong (two standard deviations, 2σ) and 
intermediate (at least one standard deviation, 1σ) chemical shift perturbations. Mapping 
these chemical shifts onto the DnaKNBD crystal structure (PDB id 1DKG) supported the 
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idea that Tel binds to the 1B subdomain of the chaperone (Figure 2.8B and C). Residues 
with the largest change in chemical shift were found in the site predicted by 
computational docking to bind Tel. Additional residues were clustered in surface-exposed 
regions of the NBD, which could arise from allosteric interactions. We did not observe 
any binding of Tel to either DnaJ or GrpE by isothermal calorimetry (ITC) (KD > 100 
μM) (Figure 2.10D). Together with the NMR data, the results suggest that Tel binds to 
DnaK in the NBD, but not to either of the co-chaperones. 
 
Figure 2.8 Tel binds DnaKNBD by NMR. (A) Results of docking Tel to the IB subdomain, showing the 
two lowest energy conformations (see Section 2.6 for details). GrpE is removed from the structure (PDB id 
1DKG) for clarity. (B) Titration of Tel into the nucleotide-binding domain of DnaK (15N DnaKNBD) 
provided NMR chemical shifts that support the binding of Tel to DnaK. Red = > 2σ shift; yellow = > 1σ 
shift; green = < 1σ shift; gray = unassigned or overlapped. (C) Quantification of the changes in the proton 
NMR chemical shifts after Tel treatment. The dotted line represents the standard deviation of all the 
changes (σ); the dashed line represents 2σ. 
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Figure 2.9 Tel binds subdomain IB in DnaK to allosterically block GrpE activity. (A) Mutation of 
residues in the predicted docking site supports the proposed Tel-binding site. Tel inhibits GrpE stimulation 
of wild type and a control mutant (D233A), but mutations near the proposed binding site (R56A and 
M89A) were resistant. Results of the ATPase assays are the average of triplicates, and error bars represent 
SEM. (B) Overlay of Tel-sensitive residues on the co-crystal structure of DnaK’s NBD in complex with 
GrpE. Red = mutations that block GrpE stimulation. Blue = mutations that block Tel activity. Yellow = 
residues predicted to bind Tel by docking. 
 
To further explore the binding site suggested by the docking and NMR studies, we 
mutated some of the nearby residues (Arg56 and Met89) in the pocket and an unrelated 
residue, Asp233,212 and measured the ability of Tel to block GrpE-stimulation of these 
mutants using ATPase assays. These studies showed that both R56A and M89A were 
resistant to Tel, while the control mutant (D233A) was identical to wild type (∼ 1.5-fold 
increase in KM) (Figure 2.9A). Together, these results suggest that Tel might bind in a 
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pocket between the IB and IIB subdomains of DnaK. Interestingly, this predicted binding 
site does not overlap with the surface of DnaK that is normally bound to GrpE126 (Figure 
2.9B), suggesting that Tel acts through an allosteric mechanism. In fact, Tel had no effect 
on the physical interaction between DnaK and GrpE, as measured by the fluorescence-
quenching assay (Figure 2.10A). Together, these data suggest that Tel may interrupt 
allosteric conformational changes that occur in DnaK upon binding of GrpE, without 
blocking their physical interaction. 
 
Figure 2.10 Characterization of Tel effects on binding of DnaK to GrpE and peptide substrate. (A) 
Labeled DnaK binding to GrpE was measured as in Figure 2.6B. Tel did not have any effect on the 
apparent affinity (p = 0.33). (B) Tel inhibits binding of fluorescent nucleotide (FAM-ATP) to DnaK, as 
measured by FP. (C) Tel did not inhibit binding of DnaK to FITC-HLA peptide. All results are 
representative averages of three independent experiments, and error bars represent SEM. Binding data were 
fit to the Langmuir binding equation; inhibition data were fit to the Hill equation. (D) Tel did not bind to 
either DnaJ or GrpE, as measured by ITC. 
 
2.4 Discussion 
There is growing interest in targeting PPIs and an emerging realization that not all PPIs 
are equally amenable to HTS-based methods. We performed pilot screens using eight 
different combinations of DnaK with its various non-enzyme partners to explore whether 
stimulated enzymatic activity might be used as a surrogate for transient or challenging 
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PPIs. An interesting observation from the pilot screens was that changing the identity of 
the non-enzyme component (e.g., switching DnaJ for GrpE) allowed discovery of 
“unique actives” (e.g., those some compounds that inhibit one combination and not 
others). On first glance, this finding is counterintuitive, because the same enzyme, DnaK, 
was used in all of the screens. Why might changing the identity of the non-enzyme favor 
discovery of unique actives? It would seem unlikely that these compounds could be 
competitive with nucleotide, because such molecules would be expected to be inhibitors 
of all the combinations. Rather, our follow-up studies on Zaf and Tel (see Figures 2.6 
through 2.10) suggest that the molecules identified using this HTS approach may be more 
likely to disrupt specific PPIs or PPI-induced conformational changes. Another 
theoretical way that unique actives might emerge from these types of screens is through 
the action of the compounds on the non-enzyme (e.g., DnaJ or GrpE) itself. It is 
important to note that we cannot fully discount the possibility that Tel or Zaf might 
weakly bind to GrpE or DnaJ, although we were unable to measure such an interaction. 
However, it seems logical that such mechanisms will be identified in screens of larger 
chemical collections. 
 
2.4.1 Chemical screens yield molecules with distinct inhibitory mechanisms 
Following the pilot screens, we examined ∼ 3,800 compounds for their ability to inhibit 
ATPase activity of either the DnaK-DnaJ or DnaK-GrpE complexes. These studies 
confirmed the results of the pilot screens and led to the identification of a number of 
molecules that targeted one complex without influencing the other. To understand what 
types of mechanisms these molecules might have, we explored the activity of Zaf and Tel 
in a series of secondary assays. These assays were designed to reveal effects on PPIs and 
the biochemical activities of the DnaK systems.  
 
Interestingly, we found that Zaf only inhibited the ATPase activity of the DnaK-DnaJ 
combination and that it weakened the physical interaction between DnaK and DnaJ (see 
Figure 2.6). Also, this molecule bound the ADP-bound form of DnaK and stabilized 
substrate-DnaK complexes. Based on these findings, a likely mechanism is that DnaJ first 
promotes ATP hydrolysis in DnaK, followed by binding of Zaf to ADP-DnaK, which 
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traps this nucleotide state. This “dead-end” complex appears to have a weak ability to 
rebind to DnaJ, but a strong ability to remain bound to peptide substrates. It is known that 
DnaJ binds poorly to DnaK in the ADP-bound form.196 Thus, the effects of Zaf on the 
DnaK-DnaJ interaction are likely due to trapping of the “dead-end” ADP-bound complex. 
Interestingly, stabilization of the ADP-bound form of Hsp70s reduces accumulation of 
proteotoxic proteins in cellular and animal models of neurodegenerative disease,161,213 so 
this step in the ATPase cycle appears to be especially important in protein quality control. 
Molecules with a mechanism-of-action (MoA) similar to Zaf might be useful in those 
settings and, more importantly, this HTS approach might be a good platform for 
identifying compounds with this MoA. 
 
In contrast to Zaf, Tel was identified as an inhibitor of the DnaK-GrpE combination, with 
little effect on the DnaJ-DnaK or other combinations. Interestingly, Tel appeared to block 
GrpE activity without impacting the physical interaction between these partners. Rather, 
NMR, mutagenesis, and modeling results suggest that Tel might bind between the IB and 
IIB subdomains, on the opposite face of DnaK than the one involved in GrpE binding 
(see Figure 2.9). How might binding in this region impact GrpE function without 
impacting its affinity for DnaK? GrpE normally rotates the IIB subdomain relative to IB 
and opens the nucleotide-binding cleft.214 Thus, one possibility is that Tel might interfere 
with the conformational transitions needed to couple GrpE binding with its effects on 
ADP release, perhaps by limiting mobility of the IIB subdomain. Tel also had a mild (2-
fold) effect on FAM-ATP binding (see Figure 2.10B), but it is not yet clear how this 
reduced nucleotide affinity might relate to its inhibition of GrpE stimulation. 
 
2.4.2 Inhibitory mechanisms provide insight into allosteric networks in DnaK 
Although both Tel and Zaf were identified as inhibitors of DnaK’s ATPase activity in the 
primary HTS experiments, the subsequent mechanistic studies showed that they had very 
different mechanisms. For example, while Zaf dramatically enhanced binding of DnaK to 
FITC-HLA in the FP assay and had no effect on nucleotide affinity, Tel had no effect on 
FITC-HLA binding (Figure 2.10C) and interfered with binding to FAM-ATP (Figure 
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2.10B). Thus, although both Tel and Zaf might be considered “inhibitors” of DnaK, they 
have distinct mechanisms and target different co-chaperone activities (Figure 2.11). 
 
 
Figure 2.11 Zaf and Tel inhibit DnaK with distinct mechanisms are target different co-chaperone 
activities. Zaf partially inhibits the interaction between DnaK and DnaJ by binding to the ADP-bound state 
of DnaK. Tel interferes with conformational changes that couple GrpE binding with nucleotide release. 
 
It is worth noting that these HTS “hits” are unlikely to be selective for the DnaK system 
in cells. In fact, both Zaf and Tel are already FDA-approved drugs with previously 
known targets: Zaf is a leukotriene receptor antagonist used in the treatment of asthma,215 
while Tel is an angiotensin II receptor antagonist and selective modulator of peroxisome 
proliferator-activated receptor gamma (PPAR-γ).216 Although we did not consider Zaf or 
Tel to be particularly strong leads for further development, they are nonetheless useful 
probes of previously unexplored allosteric networks in DnaK and may provide a blueprint 
for the rational design of future inhibitors.  
 
2.5 Conclusions 
A growing number of studies have reported potent inhibitors of PPIs, including both 
small molecules and protein mimics that either directly12 or allosterically217 inhibit the 
formation of protein complexes. These molecules have great promise as chemical probes 
for better understanding the biology and “druggability” of multi-protein complexes. 
Against this backdrop, the studies described in this chapter provide an HTS approach that 
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appears to be particularly well suited for finding orthosteric and/or allosteric inhibitors of 
challenging PPIs, especially those in which the interaction produces a measurable change 
in enzyme turnover rates. Moreover, this modular approach allows for the discovery of 
inhibitors of specific PPIs within the context of a larger multi-protein system. 
 
2.6 Experimental procedures 
 
2.6.1 Reagents and general methods 
Myricetin (Myr) was purchased from Sigma (St. Louis, MO), zafirlukast (Zaf) from 
Cayman Chemical (Ann Arbor, MI), pancuronium bromide (PaBr) from Santa Cruz 
Biotechnology (Santa Cruz, CA), and telmisartan (Tel) from AK Scientific (Union City, 
CA). The identities and purities (> 90%) of all compounds were confirmed by NMR and 
mass spectrometry. Alexa Fluor 488 was purchased from Invitrogen, and BHQ-10 
carboxylic acid was obtained from Biosearch Technologies. All other biological reagents 
were obtained from Sigma (St. Louis, MO) unless otherwise noted. All spectroscopic 
measurements were obtained using a SpectraMax M5 microplate reader (Molecular 
Devices). 
 
2.6.2 Peptide synthesis 
The peptide FITC-HLA (RENLRIARLY) was synthesized on Wang resin using 
microwave-assisted DIC/HOBt solid-phase peptide synthesis. It was capped with two β-
alanine residues and labeled on resin via the N-terminus with fluorescein-5-
isothiocyanate (Anaspec). Crude TFA-cleaved peptide (> 90% purity) was extracted with 
ether and stored in DMSO as a concentrated stock at −20 °C until use. The NR peptide 
(NRLLLTG) was synthesized on Wang resin, cleaved with TFA, precipitated with ether, 
and purified with reverse-phase HPLC using 0.1% TFA/CH3CN solvent system (> 95% 
purity). The masses of the peptides were verified using electrospray ionization mass 
spectrometry. 
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2.6.3 Protein expression and purification 
DnaK, DnaJ, and GrpE were expressed and purified as previously described,130 using a 
His column and subsequent cleavage of the His tag by TEV protease. DnaK was further 
purified using an ATP column, while both DnaJ and GrpE were subjected to final 
purification on a Superdex 200 gel filtration column (GE Healthcare). All proteins were 
concentrated and stored in 25 mM HEPES buffer containing 10 mM KCl and 5 mM 
MgCl2 (pH 7.5) until use. Protein purities were estimated at greater than 90% by SDS-
PAGE. The BCA (bicinchoninic acid) assay kit (Thermo Fisher Scientific Inc.) was used 
to measure total protein concentration and the activity of the purified proteins was 
verified with the described ATPase assays. 
 
2.6.4 High-throughput screening 
The high-throughput screening methodology was developed following previously 
published protocols.129,130 The libraries used were a natural product library,132 the NCC 
collection of ∼500 bioactive molecules and the MicroSource MS2000 library containing 
∼2000 bioactives. The quinaldine red (QR) reagent was prepared fresh for each 
experiment by mixing stock solutions of 0.05% QR, 2% polyvinyl alcohol, 6% 
ammonium heptamolybdate tetrahydrate in 6 M HCl, and water in a 2:1:1:2 ratio. DnaK 
at 0.4 μM and the indicated concentrations of co-chaperones (DnaJ, GrpE, or NRLLLTG) 
were diluted into assay buffer (100 mM Tris-HCl, 20 mM KCl, 6 mM MgCl2, 0.01% 
Triton-X, pH 7.4), and 5 μL of this solution was added to each well of a white, opaque, 
low-volume 384-well plate (Greiner Bio-One). To this solution was added 200 nL of 
compound stocks (2 μM) or DMSO to each well for a final screening concentration of 
∼55 μM. ATP (1 mM) was added to begin the reaction, followed by incubation for 3 hr at 
37 °C. QR reagent (15 μL) was added, and the reaction was quenched with 2 μL of 32% 
sodium citrate after 2 min. Following incubation at 37 °C for 15 min, the fluorescence 
intensity (excitation 430 nm, emission 530 nm) was measured on a PHERAstar plate 
reader. Standard curves were obtained using stock solutions of dibasic potassium 
phosphate. Z′ scores were calculated using no DnaK solutions as the positive control 
(100% “inhibited”) and DMSO-treated samples as the negative control (0% inhibited). 
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2.6.5 ATPase assays 
ATPase assays were performed as described.129,130 Stock solutions of DnaK, DnaJ, or 
GrpE were made in assay buffer (100 mM Tris-HCl, 20 mM KCl, 6 mM MgCl2, pH 7.4). 
Unless otherwise noted, the DnaK concentration was 0.6 μM, while DnaJ and GrpE 
concentrations are indicated. If applicable, stock solutions of compound were made in 
DMSO and then diluted into 15 μL of assay buffer and protein in clear, flat-bottom 96-
well plates (Thermo Fisher Scientific Inc.) to the final concentrations noted. Absorbance 
was measured at 620 nm. Data were fit to the Michaelis–Menten equation (Y = VmaxX/[Km 
+ X]) in GraphPad PRISM. 
 
2.6.6 Tryptophan fluorescence 
Tryptophan fluorescence was measured as previously described.129,130 DnaK was diluted 
to 5 μM in storage buffer containing 1 mM of nucleotide and Zaf at the indicated 
concentrations, with a total volume of 25 μL in black, flat-bottom 96-well plates (Costar). 
The mixture was incubated for 30 min at 37 °C in the dark, and either the emission 
spectrum between 300 and 450 nm or emission at 340 nm (excitation 290 nm) was 
measured. Binding data were fit to a form of the Langmuir isotherm (Y = BmaxX/[KD + 
X]). 
 
2.6.7 Fluorescence quenching 
DnaK and DnaJ/GrpE were labeled with Alexa Fluor 488 and BHQ-10 carboxylic acid, 
respectively, and their binding affinity was measured by FRET as previously 
described.129,130 Briefly, compound was diluted to the final indicated assay concentration 
from a concentrated DMSO stock into 20 μL of assay buffer (50 mM HEPES, 75 mM 
NaCl, pH 7.2) containing 50 nM labeled DnaK, labeled DnaJ at the noted concentrations, 
and 1 mM ATP. Following incubation for 1 hr at 37 °C, fluorescence at 525 nm 
(excitation 480 nm, cutoff 515 nm) was measured. The compounds did not affect either 
the fluorescence of Alexa-labeled DnaK or the absorbance spectra of BHQ-10 labeled 
partner. Binding data were fit to the Langmuir isotherm, as described above. Statistical 
significance was determined using an unpaired t test. 
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2.6.8 Fluorescence polarization 
Binding of fluorescent peptide (FITC-HLA) to DnaK was carried out using the method of 
Ricci and Williams,211 with minor modifications. In a black, round-bottom, low-volume 
384-well plate (Corning), 5 μM DnaK, and 1 mM ATP in 10 μL of assay buffer (25 mM 
HEPES, 150 mM KCl, pH 7.2) were incubated with the indicated compound 
concentrations or a solvent control for 30 min at RT. A stock of FITC-HLA was diluted 
to 25 nM into each well, for a total volume of 20 μL. The plate was incubated in the dark 
for 10 min at RT before the fluorescence polarization (excitation 494 nm, emission 519 
nm) was read. The dose–response data was fit to the Hill equation (Y = Emax/[1 + 
(EC50/X)nH]), providing EC50 values. 
 
We also measured binding of a fluorescent ATP analogue, N6-(6-Amino)hexyl-ATP-5-
FAM (FAM-ATP) (Axxora LLC), to DnaK using a fluorescence polarization binding 
assay. An aqueous stock of FAM-ATP was diluted to 20 nM in assay buffer (100 mM 
Tris-HCl, 20 mM KCl, 6 mM MgCl2, pH 7.4) and titrated with DnaK in a black, round-
bottom, low-volume, 384-well plate (Corning) in a total volume of 20 μL. The plate was 
incubated in the dark for 10 min at RT before the fluorescence polarization (excitation 
485 nm, emission 535 nm) was read. Binding data were fit to the Langmuir equation as 
described above. Competition data were fit to the Hill equation. 
 
2.6.9 Docking 
We used AutoDock 4 to simulate binding of Tel to DnaKNBD. First, GrpE was removed 
from the crystal structure (PDB id 1DKG). For the computations, we used published 
parameters.218 The grid box was located between the IB and IIB subdomains, near the top 
of the nucleotide-binding cleft, with 0.2 Å resolution. Docked conformations were 
evaluated using PyMOL. The calculations were performed on an Apple MacBook5.1 
running Mac OS X 10.6.8. 
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2.6.10 Isothermal titration calorimetry 
Isothermal calorimetric titrations were performed on a VP-ITC MicroCalorimeter 
(MicroCal, Inc.) at 25 °C. DnaJ or GrpE were diluted into buffer containing 25 mM 
HEPES (pH 7.5), 5 mM MgCl2, 10 mM KCl, 5 mM TCEP, and 0.5% DMSO to a final 
concentration of 10 μM. Protein samples were extensively dialyzed and added into the 
calorimetric cell (cell volume = 1.43 mL). DnaJ and GrpE were individually titrated with 
100 μM Tel in 30 × 10 μL increments. Injections were performed at 2 μL/s. Data were 
analyzed using Microcal Origin (v2.9). 
 
2.6.11 NMR 
Binding of Tel to DnaKNBD was measured by 2D HSQC-TROSY NMR on a 
Varian/Agilent 800 MHz NMR system, using methods that were previously described.218 
Briefly, small aliquots of compound solution (100 mM in DMSO) were added to 15N-
labeled DnaKNBD(1–388) (100 μM) in NMR buffer (25 mM Tris, 10 mM MgCl2, 5 mM 
KCl, 10% 2H2O, 0.01% sodium azide, pH 7.1, 5 mM ADP, 10 mM potassium phosphate). 
Identical aliquots of DMSO without compound were added to the protein sample in NMR 
control experiments. Residues were selected as significantly affected if the compound-
induced chemical shift, correcting for the shift with DMSO alone, were above one 
standard deviation (1σ; see Figure 2.6). 
 
Notes 
This chapter is adapted from Cesa, L. C.  et al. “Inhibitors of Difficult Protein-Protein 
Interactions Identified by High-Throughput Screening of Multi-protein Complexes” 2013 
ACS Chemical Biology 8(9): 1988-1997. Laura C. Cesa, Srikanth Patury, Tomoko 
Komiyama, and Jason E. Gestwicki designed the experiments. Laura C. Cesa, Srikanth 
Patury, and Tomoko Komiyama conducted the experiments. Atta Ahmad and Erik R. P. 
Zuiderweg performed the NMR. We acknowledge the expert assistance of Lyra Chang, 
Steven Vander Roest, and Thomas McQuade. 
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Chapter 3 
XIAP is a non-canonical client of the Hsp70 molecular chaperone 
 
3.1 Abstract 
Proteins must achieve a proper three-dimensional structure in order to function 
appropriately. In cancer, many proteins harbor mutations that render them susceptible to 
misfolding and/or high turnover. Overexpression of molecular chaperones allows the 
cancer cell to cope with the proteotoxic stress induced by these mutations, and as a result, 
molecular chaperones are key players in tumor growth and important drug targets for 
cancer therapy. In particular, there has been significant interest in the development of 
both Hsp70 and Hsp90 inhibitors for the treatment of a variety of cancers. The 
development of Hsp90 inhibitors has coincided with the discovery of Hsp90-specific 
client proteins that are degraded in response to Hsp90 inhibition. However, no specific 
Hsp70 client proteins have been identified in cancer cells. In this chapter, we use an 
allosteric inhibitor of the interaction between Hsp70 and nucleotide exchange factors to 
show that the inhibitor of apoptosis protein family (IAPs) is a previously unexplored 
class of Hsp70 substrates, and that IAPs are degraded by Hsp70 but not Hsp90 inhibition. 
Supporting this, we have characterized the interaction between one IAP family member, 
XIAP, and Hsp70. XIAP interacts with Hsp70 at a non-canonical binding site and is 
degraded independent of the proteasome. These results have important implications for 
Hsp70 drug discovery by establishing that IAPs can be used as biomarkers for Hsp70 
target engagement in cells and our understanding of Hsp70-client interactions at the 
molecular level. 
 
3.2 Introduction 
Molecular chaperones are key players in cancer cell survival; overexpression of Hsp70 
and Hsp90 in particular has been linked to poor prognosis and resistance to 
chemotherapeutics.219,220 Hsp70 and Hsp90 assist in protein folding and prevent 
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misfolding and aggregation. Inhibition of Hsp90 causes degradation of “client” proteins, 
a group of oncoproteins including kinases, transcription factors, and E3 ubiquitin 
ligases.221,222 Knowledge of specific proteins degraded by Hsp90 has provided a 
benchmark for the development of Hsp90 inhibitors for use in the clinic. While it is 
thought that Hsp70 inhibitors will have similar effects on its client proteins, to date, no 
specific Hsp70 clients have been identified.223 
 
3.2.1 The Hsp70 complex as a drug target for cancer therapy 
Hsp70 is regulated through an allosteric mechanism that couples ATP hydrolysis in 
nucleotide binding domain (NBD) with affinity for clients in the substrate binding 
domain (SBD). In its ATP-bound state, Hsp70 has a low affinity for substrates, but upon 
ATP hydrolysis, it adopts a high affinity conformation.197,198 Traditionally, Hsp70 
substrate peptides are defined as short stretches of 4-5 hydrophobic amino acids that bind 
to Hsp70 in an extended conformation.195,196,224 While Hsp70 binding sites are typically 
buried in the hydrophobic interior of the folded client protein, Hsp70 has been shown to 
interact with proteins that are in partially folded conformations and to induce global 
unfolding in select substrates.225–227 However, Hsp70 does not accomplish these diverse 
tasks alone, but rather works in concert with a team of co-chaperone proteins. J proteins 
increase the rate of nucleotide turnover, while nucleotide exchange factors (NEFs) 
promote release of ADP following ATP hydrolysis.128,228 In addition, other types of co-
chaperones, including the tetratricopeptide repeat (TPR) domain containing proteins link 
Hsp70 with the larger network of molecular chaperones and the protein quality control 
machinery.229  
 
Because Hsp70 is essential for survival in both healthy and stressed cells, it is important 
to understand how to inhibit Hsp70 to achieve cell death in cancer cells while not 
affecting healthy cells. Our group has recently identified and characterized analogs of the 
rhodacyanine dye MKT-077 as selective Hsp70 inhibitors. These compounds bind to an 
allosteric site on Hsp70 only in the ADP-bound conformation,218 similar to the inhibitor 
zafirlukast identified in Chapter 2. The BAG family of NEFs binds to Hsp70 in the apo 
conformation,90 and MKT-077 analogs therefore inhibit interactions between Hsp70 and 
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the BAGs.160 In addition, both Hsp70 and the BAG3 co-chaperone have been shown to 
play essential roles in tumor progression, as knockdown of either protein resulted in 
upregulation of senescence genes and downregulation of genes involved in tumor growth, 
invasion, and metastasis.230 Our group has shown that inhibition of the Hsp70-BAG3 
interaction with the MKT-077 analog JG-98 was anti-proliferative in a variety of cancer 
cell lines, while it was markedly less cytotoxic in healthy mouse fibroblasts, validating 
this PPI as a potential therapeutic target.160 Finally, treatment with JG-98 and other MKT-
077 analogs causes destabilization of a number of substrate proteins, including FoxM1, 
tau, and polyQ-AR.160,161,213 Therefore, we hypothesized that we could use JG-98 as a tool 
compound to uncover new roles for Hsp70, particularly in complex with BAG3, in cancer 
signaling. 
 
3.2.2 IAPs are involved in multiple pro-survival signaling pathways 
In this chapter, we demonstrate that the inhibitor of apoptosis proteins (IAPs) are 
destabilized in response to treatment with an allosteric inhibitor of Hsp70. IAPs are 
important mediators of cell survival signaling and are overexpressed in many cancers.231 
IAPs are defined to contain at least one baculoviral IAP repeat (BIR) domain.232–234 The 
cellular IAPs c-IAP1, c-IAP2, and XIAP each contain three BIR domains, which allow 
them to bind to caspases and prevent apoptotic signaling cascades.235 IAPs can also 
trigger pro-survival signaling pathways through activation of NF-kB and E3 ligase 
activity of their C-terminal RING finger motif.236–238 In this chapter, we show that the 
IAPs are a class of specific Hsp70 client proteins and that XIAP interacts with Hsp70 
through a non-canonical binding mechanism. These results suggest that IAPs could be 
used as biomarkers of Hsp70 target engagement for drug discovery. 
 
3.3 Results 
Cancer cells have evolved to rely on overexpression of molecular chaperones in order to 
cope with their extreme proteotoxic stress. In particular, Hsp70 has generally been 
thought to inhibit apoptosis by protecting “client” proteins, like the oncoproteins Raf-1 
and AKT1 from degradation.239–241 This model is largely based on the activity of Hsp90, 
however.242–244 Treatment with Hsp90 inhibitors causes client release and ultimately their 
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degradation.245,246 However, it is not clear if Hsp70 plays a strictly “Hsp90-like” role in 
cancer cells, or if it is involved in unique pathways. In this chapter, we use a recently 
reported allosteric inhibitor of Hsp70-NEF interactions to probe the role of Hsp70 in pro-
survival signaling.  
 
Figure 3.1 JG-98 is cytotoxic with only mild effects on oncogenic kinases. (A) JG-98 (5 μM) kills 
MDA-MB-231 cancer cells with relatively rapid kinetics compared to 17-DMAG (5 μM) or bortezomib (40 
nM), as monitored by MTT assays. Results are the average of two independent experiments performed in 
quintuplicates. The error bars represent SEM. (B) Chaperone clients are degraded relatively late after 
treatment with JG-98 (10 μM), after onset of cell loss. Results are representative of experiments performed 
in duplicate. 
 
3.3.1 Inhibition of Hsp70 causes rapid cell death and destabilization of pro-
survival kinases 
In order to understand the mechanistic role of Hsp70 in cancer cells, we first measured 
the kinetics of the anti-proliferative effects of an allosteric Hsp70 inhibitor JG-98 and 
compared it to the effects of other proteostasis modulators, including the Hsp90 inhibitor 
17-DMAG and the proteasome inhibitor bortezomib. Strikingly, we found that the first 
signs of cell death in MDA-MB-231 cells occurred within 10 hours of treatment with JG-
98, whereas 17-DMAG and bortezomib exhibited markedly slower kinetics, with 
induction of cell death occurring after around 24 hours of treatment (Figure 3.1A). To 
understand this effect in greater detail, we measured the stability of several oncogenic 
client proteins. Hsp90 inhibitors are known to destabilize ~200 oncogenic clients, leading 
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to apoptosis.247 We found that treatment with the Hsp70 inhibitor JG-98 resulted in 
modest degradation of a few of the most sensitive Hsp90 clients, including Raf-1, AKT1, 
and CDK4 (Figure 3.1B). 
 
Figure 3.2 Inhibition of both apoptosis and necroptosis is necessary to prevent JG-98 cytotoxicity. (A) 
Cells were pretreated with z-VAD.fmk (40 μM) for 1 hour prior to addition of JG-98 (10 μM) and 
visualized using an Olympus IX83 inverted microscope. Black arrows indicate apoptotic cells; black 
arrows indicate necroptotic cells. (B) Cells were treated as in panel A and MTT assays were performed 
after 24 hours. Results are the average of three independent experiments performed in triplicate, and error 
bars are SEM. *p < 0.05.  
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However, destabilization of client proteins occurred many hours after the onset of cell 
death, in contrast with treatment with Hsp90 inhibitors, in which cell death and client 
degradation occur in unison.248,249 In addition, JG-98 did not induce a stress response, as 
indicated by the constant levels of Hsp70 and Hsp90. These results indicate that the 
mechanism of cell death in response to Hsp70 inhibitors cannot be explained with simply 
“Hsp90-like” effects. 
 
3.3.2 JG-98 induces necrosis when apoptosis is blocked 
In order to understand the mechanism of JG-98 cytotoxicity, we first verified that MDA-
MB-231 cells underwent apoptosis is response to treatment, as judged by morphological 
assessment and cleavage of apoptotic executers (caspase-3 and PARP) (Figures 3.1B and 
3.2A). However, despite caspase-3 activation by JG-98, inhibition of caspases with z-
VAD.fmk was not sufficient to prevent cell death induced by the Hsp70 inhibitor (Figure 
3.2B). In fact, we observed that cells pre-treated with the pan-caspase inhibitor displayed 
morphological features consistent with necrotic cell death, including a swollen cytoplasm 
and the development of cytoplasmic granules (Figure 3.2A). Furthermore, we also found 
that pre-treatment with necrosulfonamide (NSA) alone, a necroptosis inhibitor did not 
prevent cell death induced by JG-98 (Sharan R. Srinivasan, Ph. D. thesis). However, the 
combination of both the caspase inhibitor and the necroptosis inhibitor was able to 
prevent JG-98-mediated cell death (Figure 3.2B). 
 
To explore this phenomenon more broadly, we tested the cytotoxicity of JG-98 in 
combination with z-VAD.fmk or z-VAD.fmk plus NSA in a small panel of cancer cell 
lines derived from a variety of tissues. The apoptosis inhibitor z-VAD.fmk was unable to 
protect against JG-98 cytotoxicity in cells derived from breast (MDA-MB-231, MCF-7, 
SK-BR-3, T-47D), peripheral blood (Jurkat), lung (A549), or colon (HT-29) (Table 3.1). 
However, cervical derived tumor cells (HeLa) were partially protected from JG-98 
cytotoxicity by z-VAD.fmk alone (EC50 increased 2-fold). These results suggest that not 
all cell types share the same reliance on cell death pathways. Furthermore, the 
combination of z-VAD.fmk and NSA was required to block cell death in MDA-MB-231, 
MCF-7, SK-BR-3, and Jurkat cells. Finally, this combination was unable to prevent JG-
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98-mediated cell death in T-47D, A549, and HT-29 cells, and in A549 and HT-29 cells, 
the effect of JG-98 may have been mildly exacerbated. Hsp70 is known to be involved in 
lysosomal cell death,250 so JG-98 may activate alternative cell death pathways in some 
cell types. 
Table 3.1 Effects of apoptosis and necroptosis inhibitors on JG-98 EC50 (μM; fold change) in cancer 
cell lines 
Tissue Cell line  DMSO z-VAD.fmk z-VAD.fmk+NSA 
Breast MDA-MB-231  1.8 ± 0.5 1.6 ± 0.2 (1.0)ns 4.3 ± 0.6 (2.3)** 
 
MCF-7  1.1 ± 0.2 1.3 ± 0.2 (1.0)ns 2.8 ± 0.6 (1.4)* 
 
SK-BR-3  2.0 ± 0.3 2.2 ± 0.3 (1.0)ns 2.9 ± 0.5 (1.3)* 
 
T-47D  9.7 ± 1.0 10 ± 1 (1.1)ns 8.6 ± 1.8 (1.1)ns 
Leukemia Jurkat  8.0 ± 0.4 8.8 ± 1.0 (1.1)ns 14 + 2 (1.8)* 
Cervix HeLa  5.0 ± 0.6 14 ± 5 (2.0)* 15 ± 3 (2.3)* 
Lung A549  34 ± 7 32 ± 8 (1.0)ns 13 ± 2 (0.7)* 
Colon HT-29  12 ± 2 11 ± 1 (1.0)ns 1.7 ± 0.3 (0.1)** 
*p < 0.05; **p < 0.01; ns = not significant 
 
3.3.3 JG-98 activity is dependent on RIP1 and causes destabilization of IAPs 
The kinase RIP1 is an important regulator of both apoptotic and necroptotic signaling 
cascades and is also involved in NF-κB pro-survival signaling.251–253 Because JG-98 
seemed to initiate both apoptotic and necroptotic cell death, we determined if its effect 
was dependent on RIP1 kinase activity. Indeed, pretreatment with the RIP1 inhibitor 
necrostatin-1 almost completely blocked cell death with the Hsp70 inhibitor JG-98 
(Figure 3.3A). Neither 17-DMAG nor bortezomib cytotoxicity was prevented by 
necrostatin-1. 
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Figure 3.3 JG-98 induces cell death through a novel RIP1-dependent process. (A) JG-98 cytotoxicity 
prior to addition of compounds. Viability was determined by three independent MTT assays performed in 
quintuplicate. Error bars represent SEM. ***p < 0.001, ns = not significant. (B) JG-98 induces degradation 
of RIP1 modulators, but does not affect RIP1 levels. MDA-MB-231 cells were treated for 24 hours. Results 
represent three independent experiments. (C) JG-98 causes RIP1 oligomerization. MDA-MB-231 cells 
were treated with JG-98 (10 μM), 17-DMAG (10 μM), or bortezomib (40 nM) for 24 hours. Results are 
representative of two independent experiments. 
 
RIP1 is constitutively ubiquitinated by the E3 ligases XIAP, c-IAP1, c-IAP2, and 
cFLIPS/L.254 RIP1 ubiquitination is linked not only to its turnover, but also to non-
degradation pathways that modulate its activity.255 In addition, RIP1 ubiquitination is 
believe to protect against necroptosis.256 In order to understand how Hsp70 might 
modulate RIP1 function, we treated MDA-MB-231 cells with JG-98 and examined levels 
of RIP1 and the IAPs. Treatment with JG-98 caused a striking loss in XIAP, c-IAP1/2, 
and cFLIPL/S levels (Figure 3.3B). Furthermore, although total RIP1 levels did not 
change, JG-98 did induce an apparent oligomerization in RIP1, which was not observed 
with either 17-DMAG or bortezomib (Figure 3.3C). In fact, 17-DMAG caused RIP1 
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degradation, consistent with literature precedent.257 RIP1 has been shown to interact with 
itself and with the related kinase RIP3 to form dimers, oligomers, and even amyloid-like 
fibrils. These fibrils are thought to form a functional signaling complex to trigger 
necroptosis.258 It is tempting to speculate that Hsp70 inhibition might trigger both 
degradation of the RIP1 E3 ligases and oligomerization of RIP1 itself to induce cell 
death, although the exact mechanism of Hsp70-mediate RIP1 oligomerization or fibril 
formation remains to be tested. 
 
3.3.4 Hsp70 inhibition results in rapid degradation of IAPs 
We have shown above that inhibition of Hsp70 triggers cell death in cancer cells through 
a mechanism dependent on RIP1 kinase. Specifically, Hsp70 inhibition resulted in 
striking destabilization of the E3 ubiquitin ligases of RIP1, the IAPs. Therefore, we 
hypothesized that IAPs are specific clients of Hsp70. While it is well known that classic 
Hsp90 client proteins like kinases and transcription factors are also Hsp70 clients,239,240 
we wanted to determine if the reverse was true. Are IAPs clients of Hsp90 as well, or are 
they specifically regulated by Hsp70? In order to answer this question, we examined the 
kinetics of degradation of the IAPs XIAP and c-IAP1 and compared them to degradation 
of the traditional Hsp90 clients Raf-1 and AKT1 after treatment with both Hsp70 and 
Hsp90 inhibitors. Hsp70 inhibitors included the ATP-competitive inhibitor VER-
155008241 and the allosteric inhibitor JG-98259, and Hsp90 inhibitors included the ATP-
competitive inhibitor NVP-AUY922260 and the geldanamycin analog 17-DMAG261,262 
(Figure 3.4A). 
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Figure 3.4 IAPs are selectively destabilized by Hsp70 inhibition. (A) Crystal structures of human Hsp70 
(left, PDBid 2KHO) and yeast Hsp90 (right, PDBid 2CG9). Specific amino acids comprising the binding 
sites of Hsp70 inhibitors (VER-155008, JG-98) and Hsp90 inhibitors (NVP-AUY922, 17-DMAG) are 
highlighted. Orthosteric (ATP) binding sites are shown in red; allosteric sites are shown in yellow. (B) 
Destabilization of IAPs occurs after treatment with Hsp70 inhibitors. MDA-MB-231 cells were treated with 
10 μM JG-98, VER-155008, NVP-AUY922, or 17-DMAG for the indicated time points. Degradation of 
Hsp90 clients after Hsp90 inhibition is shown as a control. The blots shown are representative of at least 
two independent experiments. (C) Quantification of protein levels of the blots shown in (B). Degradation of 
IAPs occurs after 6 hour treatment with Hsp70 inhibitors, while Hsp90 clients are degraded after 6 hour 
treatment with Hsp90 inhibitors (red arrows). Results shown are averages of at least two independent 
experiments, and error bars represent SEM. 
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From these initial experiments, several interesting observations were made. Consistent 
with our previous results, inhibition of Hsp70 resulted in rapid destabilization of the 
IAPs, although degradation was more pronounced with the allosteric inhibitor JG-98 
versus the ATP-competitive VER-155008 (Figure 3.4B, panels 1 and 2). This indicates 
that the mode of inhibition may play a role in the kinetics of destabilization of Hsp70 
clients or that these effects may be client-specific. Furthermore, loss of the IAPs 
coincided with the kinetics of JG-98-mediated cell death, with degradation occurring 
between 3 and 6 hours. This result sharply contrasts with the delay in Hsp90 client 
destabilization. There is also a marked difference in the destabilization profile of Hsp90 
clients Raf-1 and AKT in response to Hsp70 inhibition (Figure 3.4B, panel 1). This effect 
is particularly strong in the first 6 hours of treatment with JG-98, after which time nearly 
75% degradation of c-IAP1 and 50% degradation of XIAP is observed, while Raf-1 and 
AKT1 levels remained constant (Figure 3.4C, panel 1, red arrows). This effect is reversed 
after treatment with Hsp90 inhibitors, particularly AUY922. In this case, Hsp90 clients 
are destabilized very rapidly upon treatment with AUY922, while the IAPs are not 
rapidly degraded (Figure 3.4B, panel 3); again, after 6 hours of treatment, Raf-1 and 
AKT1 levels are down nearly 90% of the DMSO control, while XIAP and c-IAP1 levels 
remain constant (Figure 3.4C, panel 3, red arrows). Notably, this pattern of client 
destabilization is consistent across multiple cell lines, including MCF-7 and HeLa cells. 
However, this effect is specific to cancer cells, as we observed only mild degradation of 
IAPs in IMR90 fibroblast cells (Figure 3.5). 
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Figure 3.5 JG-98 causes destabilization of IAPs in multiple cancer cell lines. (A) HeLa, (B) MCF-7, 
and (C) IMR90 cells were treated with 10 μM JG-98 or 17-DMAG for the indicated time points. Results 
shown are representative of at least two independent experiments. 
 
It is important to note that while degradation of IAPs and Hsp90 clients at later time 
points of exposure with 17-DMAG was observed (Figure 3.4B and C, panel 4), this 
compound is markedly cytotoxic under these conditions (Table 3.2), and these effects are 
therefore likely nonspecific. Taken together, these data support a mechanism in which the 
IAPs are specifically regulated by Hsp70 and are thus rapidly and selectively destabilized 
upon Hsp70 inhibition. 
Table 3.2 Summary of Hsp70 and Hsp90 inhibitor cytotoxicity (EC50; μM) in cancer cells 
  JG-98  17-DMAG 
MDA-MB-231  1.8 ± 1.0  11 ± 4 
MCF-7  0.78 ± 0.28  0.37 ± 0.16 
HeLa  2.1 ± 0.8  11 ± 5 
Cells were treated with the indicated compounds for 24 hours, viability measured by MTT assay. 
 
Because JG-98 analogs have previously been shown to promote ubiquitination and 
proteasomal degradation of FoxM1, tau, and polyQ-AR,161,213 we hypothesized that 
degradation of IAPs triggered by JG-98 would also be proteasome-dependent. We 
therefore pre-treated MDA-MB-231 cells with the proteasome inhibitor lactacystin263 
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prior to exposure to JG-98; strikingly, degradation of XIAP both in the presence and 
absence of lactacystin was observed (Figure 3.6), suggesting that degradation occurs 
independent of the proteasome. 
 
Figure 3.6 JG-98-induced degradation of XIAP is not proteasome-dependent. MDA-MB-231 cells 
were pretreatedwith 0.5 μM lactacystin for 1 hour before addition of 10 μM JG-98 for 24 hours. Blots 
shown (left) are representative of three independent experiments, and protein quantification (right) is 
shown as averages of three biological replicates. Error bars are SEM.  
 
3.3.5 XIAP BIR2 and RING domains are essential for Hsp70-mediated 
degradation 
Hsp70 inhibition leads to proteasome-independent degradation of XIAP. In order to 
understand the mechanism of recognition and degradation of XIAP by Hsp70, series of 
XIAP deletion mutations were designed, corresponding to the deletion of each individual 
domain, as well as truncations containing two and three BIR domains, respectively 
(Figure 3.7A). After treatment with JG-98 for 24 hours, most XIAP deletion mutants 
were degraded. Strikingly, however, the ΔRING mutation accumulated in response to 
JG-98 treatment (Figure 3.7B). In addition, we did not observe degradation for a mutant 
lacking the BIR2 domain and attenuated degradation for the ΔBIR1 mutation (Figure 
3.7B). Together, these data suggest that both the RING and BIR domains are essential for 
Hsp70-mediated degradation of XIAP. 
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Figure 3.7 Hsp70-mediated degradation of XIAP is dependent on the BIR2 and RING domains. (A) 
Domain architecture of XIAP. Point and deletion mutations are shown. (B) XIAP ΔBIR2 is not degraded 
and ΔRING is accumulated in response to Hsp70 inhibition. HeLa cells overexpressing the indicated 
FLAG-tagged XIAP deletion mutations were treated with 10 μM JG-98 for 24 hours. Blots are 
representative of at least two independent experiments and quantification is the average of at least two 
biological replicates. Error bars represent SEM. (C) XIAP V461E is resistant to degradation by Hsp70 
inhibition. HeLa cells overexpressing the indicated FLAG-tagged XIAP point mutations were treated with 
10 μM JG-98 for 24 hours. Blots are representative of two independent experiments and quantification is 
the average of two biological replicates. Error bars represent SEM. 
 
3.3.5.1 RING dimerization is essential for Hsp70-mediated degradation 
The RING domain of XIAP is important in mediating homodimerization and 
heterodimerization with the c-IAPs, as well as in promoting autoubiquitination.236 In 
order to determine if these functions of the RING domain play a role in Hsp70-mediated 
degradation, we made point mutations in XIAP that have previously been shown to block 
degradation and ubiquitin transfer (V461E and F495A, respectively)264,265 (Figure 3.7A). 
XIAP F495A was degraded in response to JG-98 treatment, whereas XIAP V461E was 
completely resistant to degradation (Figure 3.7C), suggesting that dimerization of the 
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RING domain is essential for degradation of XIAP following Hsp70 inhibition, whereas 
ubiquitin transfer is not.  
 
3.3.5.2 Caspase binding is dispensible in XIAP destabilization 
We next determined if the function of the BIR domains are essential for Hsp70-mediated 
degradation of XIAP. Through its BIR2 and BIR3 domains, XIAP interacts with caspases 
3, 7, and 9.234 We overexpressed point mutations that have been previously shown to 
block caspase 3 and 7 and caspase 9 binding (D148A and W310A, respectively),266 and 
after treatment with JG-98 for 24 hours, we observed degradation of both the D148A and 
W310A mutants, although the effect was slightly attenuated for W310A (Figure 3.7C). 
These results suggest that functional caspase 9 binding may be important for Hsp70 
recognition of XIAP, while binding to caspases 3 and 7 is dispensable for XIAP’s Hsp70-
mediated degradation.  
 
3.3.6 Hsp70 and XIAP form a complex in cells 
Given that dimerization of the RING domain of XIAP was essential for Hsp70-mediated 
degradation, while caspase binding was not, we next determined if Hsp70 directly 
interacts with XIAP to regulate its stability. We hypothesized that Hsp70 and XIAP form 
a complex in cells. Indeed, endogenous Hsp70 was immunoprecipitated with XIAP from 
MCF-7 cell lysate (Figure 3.8A). However, we were unable to pull down XIAP with an 
Hsp70 immunoprecipitation. We speculate that this is due to the relatively greater 
number of interacting partners of Hsp70 than XIAP. 
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Figure 3.8 Hsp70 binds XIAP in vitro and in cells. (A) XIAP is co-immunoprecipitated with Hsp70. 
Endogenous protein from MCF-7 cell extracts was immunoprecipitated with Hsp70 and XIAP antibodies. 
Blots are representative of three independent biological replicates. (B) Predicted Hsp70 binding sites on 
XIAP BIR2 and BIR3 (PDBid 1C9Q, 1F9X) are shown in red. Individual point mutations are shown on the 
sequences of the predicted Hsp70 binding sites. (C) Schematic of ELISA protein interaction assay. (D) 
XIAP (120-356) has a slight preference for binding apo and ATP-bound Hsp70, as measured by ELISA. 
Results are representative averages of triplicate of three independent experiments, and error bars are SEM. 
Binding data were fit to the Langmuir binding isotherm. 
 
3.3.7 Hsp70 binds XIAP (120-356) in vitro 
Using a prediction algorithm for chaperone binding sites,224 we determined XIAP 
contains seven predicted binding sites for the prokaryotic Hsp70 chaperone, all located 
within the BIR2 and BIR3 domains, consistent with the cellular degradation and 
immunoprecipitation data (Figure 3.8B). The cellular data suggests that Hsp70 forms a 
complex with the BIR2 and BIR3 domains of XIAP to regulate its stability and mediate 
its degradation in response to Hsp70 inhibition with JG-98. To further characterize this 
interaction in vitro, the minimal region of XIAP (120-356) predicted to interact with 
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Hsp70 was expressed and purified. In order to measure binding to Hsp70, a modified 
ELISA protein-protein interaction assay was used in which XIAP (120-356) was 
nonspecifically immobilized in a 96-well plate and incubated with full-length Hsp70 
(Figure 3.8C). In this platform, we found that Hsp70 bound XIAP (120-356) with high 
nanomolar affinity (KD = 260 ± 20 nM) (Figure 3.8D). It is well-established that Hsp70 
binds to client proteins more tightly when in the ADP-bound state; however, we found 
that ADP-bound Hsp70 bound to XIAP (120-356) with ~ 2-fold weaker affinity (KD = 
410 ± 50 nM) than apo or ATP-bound Hsp70. Given that JG-98 prefers binding to Hsp70 
in the ADP-bound state,218 we expected that JG-98 would likewise inhibit binding of 
Hsp70 to XIAP (120-356); indeed the addition of 10 μM JG-98 weakened the affinity of 
Hsp70 for XIAP (120-356) by ~ 2-fold (Figure 3.9A). 
 
Our cell-based experiments demonstrate that XIAP is degraded more rapidly and 
effectively by treatment with Hsp70 inhibitors rather than Hsp90 inhibitors, suggesting 
that it may be an Hsp70-specific client protein. Therefore, we expected that XIAP would 
not bind to Hsp90. We measured the ability of Hsc70 and Hsp90α to compete with 
Hsp70 for binding to XIAP (120-356) in the ELISA platform. Surprisingly, we found that 
both Hsc70 and Hsp90α bound to XIAP with similar affinity (Figure 3.9B). This result 
suggests that binding to XIAP is not an exclusive predictor of a chaperone’s ability to 
regulate its homeostasis. Furthermore, addition of a Smac mimetic267 blocked binding of 
Hsp70 to XIAP (120-356) (Figure 3.9C), suggesting that Smac or caspase binding to 
XIAP and Hsp70 recognition are mutually exclusive.  
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Figure 3.9 Additional biochemical analysis of the interaction between Hsp70 and XIAP (120-356). (A) 
JG-98 moderately decreases the affinity of Hsp70 for XIAP (120-356) by ELISA. (B) Hsc70 and Hsp90α 
compete with Hsp70 for binding to XIAP (120-356) by ELISA. (C) Binding of SM164 to XIAP (120-356) 
decreases affinity of XIAP for Hsp70 by ELISA. All experiments are representative averages of triplicate 
of three independent experiments, and error bars represent SEM. Binding data were fit to the Langmuir 
equation and inhibition data were fit to the Hill equation. 
 
3.3.8 Hsp70 and XIAP (120-356) form a multimeric complex in vitro 
XIAP contains seven predicted chaperone binding sites in its BIR2 and BIR3 domains. 
We wanted to determine which, if any, of the predicted sites are necessary for Hsp70 
binding in vitro. We therefore purified XIAP (120-356) constructs bearing individual 
point mutations in each of the seven predicted binding sites (see Figure 3.8B). We 
verified that each of these mutants retained WT-like secondary structure, measured by 
circular dichroism (Figure 3.10A) and measured their affinity for Hsp70 by ELISA. Of 
these mutants, Y190E, L207S, L307S, and L331S all bound Hsp70 with reduced affinity, 
with dissociation constants ranging from 2-fold (Y190E and L331S) to greater than 10-
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fold (L207S) weaker than the wild type protein (Figure 3.10C). However, none of these 
mutations completely abrogated Hsp70 binding, suggesting that Hsp70 may bind to 
multiple sites on XIAP (120-356). Furthermore, the lack of important “hot spot” residues 
is consistent with protein-protein interactions occurring over a large surface area, which 
is to be expected for the interaction between Hsp70 and XIAP.21,202 Indeed, Hsp70 and 
XIAP (120-356) were found to form a higher-order multimeric complex by size exclusion 
chromatography and multi-angle light scattering (SEC-MALS), approximately 200 kDa 
in size (Figure 3.10B).  
 
XIAP (120-356) Y190E and L207S both bind to Hsp70 with weaker affinity than WT; 
these residues are proximally located along the central β sheet in BIR2 (Figure 3.8B). We 
hypothesized that these mutants would also be resistant to degradation in response to 
inhibition of Hsp70 with JG-98. We therefore transfected full-length XIAP Y190E, 
L207S, and the corresponding double mutant in HeLa cells and compared total FLAG-
XIAP protein levels with and without JG-98 treatment. As expected, the Y190E mutant 
was not degraded upon Hsp70 inhibition, supporting the idea that this site is important for 
Hsp70 binding to XIAP (Figure 3.10D). Surprisingly, XIAP L207S and the double 
mutant were degraded in response to Hsp70 inhibition, similar to WT (compare Figure 
3.7B and 3.10D), suggesting that Hsp70 recognition alone is not sufficient to induce 
XIAP degradation. Taken together, these results support a model in which Hsp70 may 
preferentially recognize specific binding sites on XIAP to form a multimeric complex and 
mediate its homeostasis in cells.  
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Figure 3.10 Structure and binding of XIAP (120-356) mutants to Hsp70. (A) CD spectra for XIAP 
(120-356) WT and mutant proteins. Each reported spectrum is the average of 6 scans, subtracting the signal 
acquired for buffer alone. (B) Size exclusion chromatography analysis of XIAP (120-356) – Hsp70 
complex (absorbance at 280 nm versus elution volume). Approximate molecular weights calculated by 
multi-angle light scattering. (C) Binding of XIAP (120-356) point mutations to Hsp70, as measured by 
ELISA. Results are representative averages of triplicate of three independent experiments, and error bars 
are SEM. Binding data were fit to the Langmuir binding isotherm. (E) XIAP Y190E is resistant to Hsp70-
mediated degradation. HeLa cells overexpressing the indicated XIAP point mutations were treated with JG-
98 (10 μM) for 24 hrs. Blots are representative of two independent experiments (left), and quantification is 
the averages of biological replicates (right). Error bars are SEM. 
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3.3.9 XIAP is a non-canonical client of Hsp70 
Because XIAP binds Hsp70 in vitro and relies on Hsp70 for its stability in cells, we 
hypothesized that it would behave as a typical client protein. Canonical client binding is 
typically defined as an interaction with the Hsp70 SBD.268,269 In order to determine if 
XIAP (120-356) binds at a similar site, we first determined if it was able to compete with 
a fluorescent peptide substrate for binding to Hsc70 using a previously described 
fluorescence polarization assay.133 In this platform, the tracer FAM-HLA binds to Hsc70 
with low micromolar affinity dependent on the nucleotide state (KD = 3.6 ± 0.5 μM for 
ADP-bound Hsp70) (Figure 3.11A). XIAP (120-356) competed with FAM-HLA for 
binding to Hsc70 (Ki = 790 ± 180 nM), similar to the canonical NRLLLTG substrate 
peptide (Ki = 3.0 ± 1.3 μM) (Figure 3.11B). These findings suggest that XIAP (120-356) 
likely binds to Hsp70 similarly to known client proteins. We next wanted to determine if 
the reverse was also true; do peptide substrates compete with XIAP for binding to 
Hsp70? In order to answer this question, we used our ELISA protein-protein interaction 
assay. Surprisingly, we found that although XIAP (120-356) was able to compete with 
itself for binding to Hsp70 (IC50 = 6.9 ± 1.4 μM), the NR peptide was not (Figure 3.11C). 
Even more strikingly, we observed a Hill slope (nH) > 1 for XIAP competition, which 
would be expected for the multimeric complex suggested by SEC-MALS. 
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Figure 3.11 Characterization of the non-canonical interaction between Hsp70 and XIAP (120-356). 
(A) Client tracer (FAM-HLA) binds preferentially to ADP-bound Hsc70, as measured by fluorescence 
polarization. (B) XIAP (120-356) and NRLLLTG peptide compete with FAM-HLA peptide for binding to 
Hsc70 by fluorescence polarization. (C) NRLLLTG peptide does not compete with XIAP (120-356) for 
binding to Hsp70, as measured by ELISA. (D) Both Hsc70NBD and Hsc70SBD compete with full-length 
Hsp70 for binding to XIAP (120-356), as measured by ELISA. Results shown are representative averages 
of triplicate of three independent experiments, and error bars are SEM. Binding data were fit to the 
Langmuir binding isotherm, and competition data were fit to the Hill equation. 
 
The above results suggest that XIAP is able to compete with some substrates, but not 
others for binding to Hsp70. It has previously been shown that the HLA peptide makes 
secondary binding contacts outside of the canonical substrate binding site on Hsp70,270 
whereas NRLLLTG binds exclusively to the β-sheet SBD.271 Because XIAP was able to 
compete with FAM-HLA, while the NR peptide was unable to compete with XIAP for 
binding to Hsp70, we hypothesized that XIAP also makes secondary contacts outside of 
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the SBD. We therefore determined if the isolated Hsc70 NBD or SBD were able to 
compete with FL Hsp70 for binding to XIAP (120-356) in the ELISA platform. We 
found that both Hsc70NBD and Hsc70SBD competed with FL Hsp70 for binding to XIAP 
(120-356), indicating that XIAP interacts with each domain, at least partially (Figure 
3.11D). We performed TROSY-HSQC NMR with 13C, 15N – labeled Hsp70SBD and 
observed chemical shift perturbations distinct from those induced by the canonical 
NRLLLTG peptide (Figure 3.12A and B), supporting our observations from the 
biochemical experiments that XIAP binds to Hsp70 in a manner distinct from that of a 
canonical client. Further evidence of the non-canonical interaction is given by the fact 
that XIAP (120-356) does not stimulate ATPase activity of the prokaryotic Hsp70, a 
well-known feature of peptide substrates like NRLLLTG (Figure 3.12D).196 
 
Figure 3.12 Structural analysis of the Hsp70-XIAP (120-356) interaction. TROSY-HSQC NMR spectra 
for 13C, 15N – labeled Hsc70SBD (395-507) in complex with substrates (A) XIAP (120-356), (B) NRLLLTG 
peptide, and (C) KFERQ peptide. Spectra shown are Hsc70 alone (blue) and in complex with substrates 
(red). (D) XIAP (120-356) and RNase A do not stimulate ATPase activity of DnaK, as measured by 
malachite green. Results are averages of three independent experiments. 
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3.4 Discussion 
There is growing interest in the development of Hsp70 inhibitors as a promising 
therapeutic strategy for the treatment of a variety of cancers.272,273 However, to date, no 
Hsp70-specific client proteins have been identified, and the field has suffered from a lack 
of biomarkers for Hsp70 engagement in cancer cells.274 In this chapter, we identified the 
IAPs as a potential new class of Hsp70 client proteins. We also explored if these proteins 
are chaperoned exclusively by Hsp70 and the mechanism of client recognition. 
 
3.4.1 Hsp70 regulates RIP1-dependent cell death 
The results presented in this chapter support a model in which inhibition of Hsp70-NEF 
interactions triggers cell death proceeding through RIP1 kinase (Figure 3.13). This 
pathway appears to involve both RIP1 oligomerization and the rapid destabilization of the 
E3 ligases of RIP1. In its normal function, Hsp70 is known to protect a number of client 
proteins from degradation, and it seems likely that Hsp70 may normally stabilize the 
IAPs and block RIP1 fibril formation to prevent RIP1-dependent cell death. While the 
mechanism of RIP1 oligomerization in response to Hsp70 inhibition remains to be tested, 
preliminary data suggests that Hsp70 is able to prevent against RIP1 aggregation in yeast 
(Greg Newby, Susan Lindquist laboratory, MIT, personal communication), supporting 
this hypothesis. When the interactions between Hsp70 and the BAG family of NEFs is 
inhibited, apoptosis is the predominant cell death pathway. However, necroptosis can be 
initiated when apoptosis is blocked. Only dual inhibition of both apoptotic and 
necroptotic signaling or inhibition of RIP1 kinase activity was sufficient to prevent cell 
death in response to JG-98 in most cell types tested, suggesting an unexpected role for 
Hsp70 as a hub of multiple cell survival systems. These results clearly differentiate 
Hsp70 from other proteostasis regulators, making it an attractive drug target in cancer. 
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Figure 3.13 Model for Hsp70’s role in RIP1-dependent cell death pathways. Hsp70 stabilizes the RIP1 
E3 ligases, IAPs and FLIP and prevents formation of RIP1 oligomers. Inhibition of Hsp70-BAG 
interactions causes destabilization of the IAPs and RIP1 oligomerization, resulting in cell death through 
both apoptotic and necroptotic pathways. 
 
3.4.2 IAPs are biomarkers for Hsp70 target engagement 
By examining the kinetics of IAP destabilization following treatment with both Hsp70 
inhibitors and Hsp90 inhibitors, we found that IAP degradation is both more rapid and 
more pronounced after treatment with Hsp70 inhibitors. This effect is particularly 
noticeable in the first 6 hours after treatment with the allosteric Hsp70 inhibitor JG-98, 
after which time we observed up to 75% loss of IAP protein levels, while levels of classic 
Hsp90 clients remained unchanged. In addition, treatment with Hsp90 inhibitors elicits 
only limited IAP degradation, while the classic Hsp90 biomarkers (Raf-1 and AKT1) are 
destabilized rapidly and dramatically. Our preliminary work has also suggested that IAP 
degradation occurs following treatment with a JG-98 analog causes degradation of the 
IAPs in a mouse xenograft model (Figure 3.14A). Therefore, we propose that the IAPs 
can be used as a biomarker for Hsp70 target engagement in cancer cells. Cellular potency 
and efficacy of newly developed Hsp70 inhibitors can be assessed by examining IAP 
levels in the first 6 hours of treatment, and along with cytotoxicity measurements, this 
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type of analysis should provide a good benchmark for success in Hsp70 inhibitor 
development. 
 
Figure 3.14 JG-98 causes loss of XIAP in MCF-7 xenograft model. (A) JG-98 treatment in mice with 
MCF-7 cells xenografted causes XIAP degradation. Protein levels were measured by Western blots for 
samples from two separate animals. (B) Degradation of XIAP coincides with high MW smearing pattern. 
HeLa cells transfected with either full length FLAG-tagged XIAP or empty vector were treated with 10 μM 
JG-98 for 24 hours. JG-98 causes degradation of both overexpressed (left) and endogenous (right) XIAP. 
Results shown are representative of at three independent experiments. 
 
Surprisingly, we did not observe proteasomal degradation of IAPs following treatment 
with JG-98, as co-treatment with a proteasome inhibitor did not block degradation. We 
did observe a high molecular weight smearing pattern along with degradation of both 
endogenous and overexpressed XIAP after the addition of JG-98 (Figure 3.14B). While 
such a smearing pattern would be consistent with poly-ubiquitination, we cannot rule out 
the formation of high molecular weight XIAP oligomers or protofibrils. However, given 
that the dimerization function of the RING domain was essential for Hsp70-mediated 
degradation of XIAP, we speculate that Hsp70 inhibition may induce heterodimerization 
with c-IAP and poly-ubiquitination of XIAP, which has been observed previously.275,276 
XIAP has been shown to undergo lysosomal degradation by timosaponin AIII, and 
ubiquitation of XIAP was essential for its autophagic degradation.277 Therefore, it is 
likely that JG-98 may induce IAP degradation via chaperone-mediated autophagy 
(CMA), although this mechanism remains to be tested. 
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3.4.3 XIAP interacts with Hsp70 at a non-canonical binding site 
Our cellular data suggested that the IAPs are specific substrates of Hsp70, and we 
explored the biochemical basis for the interaction between Hsp70 and XIAP in vitro. 
Strikingly we found that a minimal binding region of XIAP (120-356) bound Hsp70 in an 
atypical nucleotide-dependent manner, with XIAP (120-356) having weaker affinity for 
ADP-bound Hsp70 than ATP-bound Hsp70. Although we observed an interaction 
between XIAP (120-356) and both the NBD and SBD of Hsp70, the interaction with the 
SBD was distinct from that of a canonical peptide substrate by NMR. These data suggest 
that XIAP may interact with Hsp70 primarily through binding to the α-helical lid or 
unstructured C-terminal domain, with secondary contacts in the NBD and peptide binding 
groove of the SBD. The lid in particular has been shown to undergo significant structural 
rearrangement during nucleotide cycling, and can adopt intermediate conformations 
between the typical “open” and “closed” conformations when bound to a full-length 
client protein.278,279 Partial closing of the lid may explain the preference of XIAP to bind 
apo or ATP-bound Hsp70. Notably, the well-characterized CMA substrate peptide 
KFERQ does not bind the canonical binding groove (Figure 3.12C), and neither XIAP 
nor the CMA client RNase A stimulate ATP hydrolysis of DnaK (Figure 3.12D). 
Together, these data support our hypothesis that XIAP is a non-canonical Hsp70 CMA 
client. 
 
In addition to the apparent non-canonical interaction, we noted from our mutagenesis 
data that no single mutation was sufficient to completely abrogate binding of XIAP to 
Hsp70. While it is possible that another site is necessary for recognition of XIAP by 
Hsp70, we hypothesize that XIAP harbors multiple Hsp70 binding sites. The observation 
of a ~200 kDa complex between XIAP and Hsp70 by SEC-MALS is inconsistent with 
1:1 binding stoichiometry and rather suggests formation of a multimeric complex. 
Multiple DnaK molecules have been shown to bind denatured rhodanese to alter its 
conformational distribution, and binding of DnaK to hTRF1 resulted in global unfolding 
of the substrate.226,280 Given the emerging model that Hsp70 induces rapid expansion of 
client proteins, a multi-site binding model is expected. 
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3.5 Conclusions 
In summary, Hsp70 is an important emerging drug target, but development of new Hsp70 
inhibitors has been limited by the lack of a biomarker for Hsp70 target engagement.273 In 
this chapter, we used an allosteric inhibitor of Hsp70-BAG interactions to show that the 
IAPs are specific clients of Hsp70, and that their rapid destabilization can be used to 
report on the efficacy of Hsp70 inhibitors in cancer cells. Hsp70 inhibition leads to cell 
death dependent on RIP1 kinase. Furthermore, we have found that Hsp70 recognizes the 
client protein XIAP through a non-canonical, multi-site binding mechanism. These 
results have important implications not only for the future therapeutic development of 
Hsp70 inhibitors, but also offer important insights into our understanding of how Hsp70 
recognizes full-length, native client proteins.  
 
3.6 Experimental procedures 
 
3.6.1 Reagents and general methods 
Antibodies used are as follows: XIAP (Enzo Life Sciences ADI-AAM-050-E), c-IAP1 
(Enzo Life Sciences ALX-803-335-C100), c-IAP2 (Cell Signaling Technology 3130), β-
actin (AnaSpec AS-54591), FLAG (Sigma Aldrich F1804), Hsp70 (SantaCruz 
Biotechnology sc-137239 and sc-33575), Raf-1 (SantaCruz Biotechnology sc-133), 
AKT1 (Cell Signaling Technology 2967), GAPDH (SantaCruz Biotechnology sc-32233), 
Hsp90 (SantaCruz Biotechnology sc-7947), cleaved caspase 3 (Cell Signaling 
Technology 9664), RIP1 (BD Pharmingen 610459), CDK4 (BD Pharmingen 559693), 
FLIP (Alexis ALX-804-428), goat anti-mouse HRP (AnaSpec 28173), goat anti-rabbit 
HRP (AnaSpec 28177), and goat anti-rat HRP (SantaCruz Biotechnology sc-2006).  
 
Inhibitors used are as follows: Necrostatin-1, bortezomib, VER-155008 (Sigma Aldrich), 
z-VAD.fmk (Enzo Life Sciences), necrosulfonamide (Millipore), lactacystin (Cayman 
Chemical), 17-DMAG (LC Laboratories), and NVP-AUY922 (ApexBio). JG-98 was 
synthesized according to previously described methods.259 All compounds were 
suspended in DMSO and the final solvent concentration was held at 1% in all assays. 
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All other biological reagents were purchased from Sigma Aldrich unless otherwise noted. 
All spectroscopic measurements were obtained with a SpectraMax M5 microplate reader 
(Molecular Devices). ATPase and fluorescence polarization assays were performed 
according to previously published methods.133 
 
3.6.2 Plasmids and site-directed mutagenesis 
XIAP mutants were prepared using the QuikChange site-directed mutagenesis kit 
(Stratagene). The following mutants were engineered into the human XIAP (120-356) 
gene in pet28a vector: L141S, Y190E, L207S, L231S, I276T, L307S, and L331S. Wild 
type and mutant XIAP (120-356) constructs all contained additional C202A C213G 
mutations for stability. N-terminally FLAG-tagged, full length XIAP in pCMV6 was 
obtained from GeneArt (Invitrogen). The following point and deletion mutations were 
made in the full length XIAP gene: V80D, D148A, W310A, V461D, M382L F384L, 
F495A, Δ26-93 (ΔBIR1), Δ163-230 (ΔBIR2), Δ265-330 (ΔBIR3), Δ376-416 (ΔUBA), 
and Δ450-485 (ΔRING).  
 
3.6.3 Protein expression and purification 
All His-tagged Hsp70 proteins (HSPA1A, HSPA8, Hsc70NBD (1-383) and Hsc70SBD (395-
509)) were purified as previously described using batch purification with Ni-NTA resin 
(Novagen) and subsequent cleavage of the His tag with TEV protease.212 Hsp70, Hsc70, 
and Hsc70NBD were further purified using an ATP column while Hsc70SBD underwent gel 
filtration chromatography on a Superdex 75 16/60 column (GE Healthcare). His-tagged 
Hsp90α was batch purified with Ni-NTA resin and anion exchange chromatography on a 
Source Q column (GE Healthcare). Fractions containing Hsp90α were pooled and 
dialyzed overnight into 20 mM Tris buffer (pH 7.5) containing 50 mM KCl, 6 mM β-
mercaptoethanol, and 10% glycerol. WT His-tagged XIAP (120-356) and its mutants 
were batch purified with Ni-NTA resin and eluted with 400 mM imidazole. DTT was 
added to 10 mM, and XIAP (120-356) was further purified by gel filtration 
chromatography on a Superdex 75 16/60 column (GE Healthcare) in 20 mM Tris buffer 
containing 200 mM NaCl, 50 μM Zn acetate, and 1 mM DTT (pH 7.5). Fractions 
containing XIAP (120-356), as assessed by SDS-PAGE were pooled, concentrated, and 
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DTT was added to 10 mM before storing at -80oC. The BCA (bicinchoninic acid) assay 
kit (Thermo Fisher Scientific Inc.) was used to determined protein concentration, and 
protein purities were estimated at > 90% by SDS-PAGE and Q-TOF LC-MS (Agilent).  
 
3.6.4 Tissue culture, viability assays, and transfections 
MCF-7 and HeLa cells (ATCC) were maintained in DMEM (Invitrogen) supplemented 
with 10% fetal bovine serum and 1% penicillin-streptomycin. MDA-MB-231 cells 
(ATCC) were maintained in DMEM supplemented with 10% fetal bovine serum, 1% 
penicillin-streptomycin, and non-essential amino acids. If indicated, cell viability was 
determined using the MTT assay as previously described.259 XIAP pCMV6 plasmids 
were transfected using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instructions. If indicated, cells were visualized using an Olympus IX83 inverted 
microscope. For each experiment, at least 10 individual frames were examined, and 
representative panels were chosen for presentation. 
 
3.6.5 Western blotting 
Cell extracts were prepared in chilled RIPA buffer (50 mM Tris pH 8, 150 mM NaCl, 1% 
Triton X-100, 0.5% Na deoxycholate, 0.1% SDS) unless otherwise indicated. Protein 
concentration was determined by the BCA assay and 20 μg of total protein was separated 
by SDS-PAGE on 10% Mini-PROTEAN TGX gel (Bio-Rad) and transferred to PVDF 
membrane (Thermo Fisher Scientific Inc). Membranes were blocked with 5% milk in 
TBS, 0.05% Tween for 1 hr at room temperature, incubated with primary antibodies 
overnight at 4oC, washed with TBS, 0.05% Tween, and incubated with the appropriate 
horseradish peroxidase conjugated secondary antibody for 1 hr at room temperature. 
Membranes were developed using chemiluminescence (ECL Prime, GE Healthcare).  
 
3.6.6 Co-immunoprecipitation 
Cell extracts were prepared in chilled lysis buffer (50 mM Tris pH 8, 150 mM NaCl, 1 
mM ATP, 10 mM KCl, 5 mM Mg(OAc)2, 1% NP-40) supplemented with protease 
inhibitor cocktail (Roche Applied Science). The total protein concentration was adjusted 
to 5 mg of protein in 1 mL of cell extract. PureProteome Protein G magnetic beads 
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(Millipore) were incubated with 6 μg of the appropriate antibody or nonspecific mouse 
IgG (Santa Cruz Biotechnology) for 30 min at room temperature with mixing, followed 
by antibody crosslinking with bis(sulfosuccinimidyl) suberate (Thermo Scientific) for 1 
hr at room temperature with mixing. The crosslinking reaction was quenched with 1 M 
Tris (pH 7.5) for 1 hour at room temperature with mixing. Meanwhile, equal 100 μL 
samples of cell lysate were pre-cleared by incubation with 50 μL of protein G beads for 1 
hour at room temperature with mixing. Protein complexes were immunoprecipitated by 
incubation of the pre-cleared lysate (1 mg total protein per IP) with 50 μL of antibody-
crosslinked protein G beads for 1 hour at room temperature with mixing. The 
immunocomplexes were washed 3 times with 500 μL of wash buffer (PBS pH 7.4, 0.1% 
Tween-20) and eluted with 0.1 M glycine (pH 2.6). Proteins were visualized by Western 
blot. 
 
3.6.7 ELISA 
Binding of human Hsp70 to XIAP (120-356) was measured using a protocol adapted 
from a previous report.174 XIAP (120-356) was non-covalently immobilized in the wells 
of a clear, flat-bottom 96-well plate (Thermo Fisher Scientific Inc) by incubating 100 μL 
of 100 nM XIAP (120-356) in immobilization buffer (20 mM MES, pH 5.2) overnight at 
37oC. XIAP (120-356) was removed from the wells, and the wells were washed with 3 x 
150 μL of TBS supplemented with 0.05% Tween (TBS-T). Each wash was incubated, 
with gentle rocking, for 3 min at room temperature. Following washing, 30 μL of Hsp70 
was added at the indicated concentrations in binding buffer (25 mM HEPES pH 7.4, 40 
mM KCl, 8 mM MgCl2, 100 mM NaCl, 0.01% Tween), supplemented with 1 mM ATP 
and 1 mM DTT. The plates were incubated at room temperature for 24 hrs with gentle 
rocking. Solutions of Hsp70 were removed and each well was washed as before and 
blocked with 100 μL of 5% milk in TBS-T for 5 min at room temperature. The plates 
were developed using 50 μL each of Hsp70 primary antibody (1:5000 in TBS-T) and an 
HRP-conjugated secondary antibody (1:5000 in TBS-T), washing with TBS-T between 
each 1 hr incubation at room temperature. Binding was detected using the TMB substrate 
kit (Cell Signaling Technology), and absorbance was read at 450 nm. Data were analyzed 
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using GraphPad Prism software and fit to the Langmuir binding isotherm (Y = BmaxX/[KD 
+ X]). 
 
3.6.8 Size exclusion chromatography and multi-angle light scattering 
XIAP (120-356) and Hsp70 were separated by size exclusion chromatography on a 
Superose 6 column (GE Healthcare) in 20 mM Tris buffer (pH 7.5) containing 200 mM 
NaCl, 5 mM MgCl2, 10 mM KCl, 50 μM Zn acetate, 1 mM DTT. The average molecular 
weight of the complex was determined using a DAWN HELEOS II MALS detector and 
Optilab rEX differential refractive index detector with ASTRA VI software (Wyatt 
Technology Corporation). The molecular weight of a selected peak was calculated using 
the Raleigh ratio of the static light scattering and protein concentration.  
 
3.6.9 Circular dichroism 
CD spectra of XIAP (120-356) were acquired on a J-715 spectropolarimeter (Jasco Inc) 
using a 1 mM pathlength quartz cuvette, subtracting the CD signal acquired for buffer 
alone (10 mM sodium phosphate pH 7.6, 100 mM NaF, 50 μM Zn acetate, 0.5 mM 
DTT). Data were converted to mean residue ellipticity (deg cm-1 dmol-1) according to the 
equation Θ = Ψ / (1000nlc), where Ψ is the CD signal in degrees, n is the number of 
amides, l is the path length in centimeters, and c is the concentration in decimoles per 
cm3. Each spectrum reported is the average of 6 scans. 
 
3.6.10 NMR 
Binding of XIAP (120-356) to Hsc70SBD was measured by 2D HSQC-TROSY NMR on a 
Varian/Agilent 800 MHz NMR system, using methods that were previously described.218 
Briefly, small aliquots of XIAP (120-356) (380 μM in storage buffer) were added to 13C, 
15N – labeled Hsc70SBD (395-507) (11 μM) in NMR buffer (25 mM Tris, 10 mM MgCl2, 5 
mM KCl, 10% 2H2O, 0.01% sodium azide, pH 7.1, 5 mM ADP, 10 mM potassium 
phosphate). Identical aliquots of buffer without compound were added to the protein 
sample in NMR control experiments. 
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Portions of this chapter have been submitted or are in preparation for submission for 
publication as Srinivasan, S. R.; Cesa L.C. et al. “Hsp70 Regulates RIP1-Dependent Cell 
Death”, under review at Nature Chemical Biology, and Cesa, L. C. et al. “X-linked 
Inhibitor of Apoptosis Protein (XIAP) is a Non-Canonical Client of the Hsp70 Molecular 
Chaperone”, in preparation. Laura C. Cesa, Sharan R. Srinivasan, Hao Shao, Anna K. 
Mapp, and Jason E. Gestwicki designed the experiments. Laura C. Cesa, Sharan R. 
Srinivasan, Hao Shao, and Chetali Jain conducted the experiments. Erik R. P. Zuiderweg 
performed the NMR. The XIAP (120-356) pet28a vector and Hsp90α pet151 vector were 
kind gifts from Dr. Jeanne Stuckey and Dr. Daniel Southworth, respectively. SM-164 was 
provided by Dr. Shaomeng Wang.  
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Chapter 4 
Identification of the Sub-Network of Client Proteins that are Dependent on the 
Molecular Chaperone Hsp70 
 
4.1 Abstract 
Protein-protein interactions (PPIs) form the backbone of a larger protein network 
essential for nearly all cellular processes. Multi-protein complexes are hubs in this 
networks and connect diverse cellular processes through a physical web of individual 
protein interactions. Although targeting the enzymatic activity of the core components of 
these complexes has long been a major goal in drug discovery, inhibiting the individual 
PPIs may offer several therapeutic advantages. Chief among these is the idea that 
targeting PPIs may allow for greater specificity in the ability to target certain cellular 
pathways and not others. However, it is often not straightforward to understood how 
modulation of a single PPI within a larger multi-protein complex might affect binding 
(and/or activity) of other downstream partners. In other words, by trapping a specific 
conformation of a given protein target, can we “tune” the protein network such that 
interactions with certain binding partners are strengthened while others are inhibited? In 
this chapter, we use a small molecule inhibitor of the molecular chaperone Hsp70 to 
understand how stabilizing a particular Hsp70 nucleotide state affects binding to both co-
chaperone and substrate proteins. We also describe preliminary efforts to characterize 
effects of small molecules on PPIs in another system with Src kinase. Knowledge of how 
small molecules are able to modulate protein networks will inform how we can we use 
such inhibitors to achieve a desired therapeutic outcome.  
 
4.2 Introduction 
Multi-protein complexes are ubiquitous in biology and are essential for many cellular 
processes, including gene expression, protein homeostasis, cell signaling, and countless 
others.7,8 These large structures are assembled around a “core” enzyme, such as a kinase, 
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phosphatase, or GTPase. Interactions between the core enzyme and adaptor and 
scaffolding proteins or other non-enzymes modulate the function of the complex by 
dictating subcellular localization, regulating enzymatic activity, or controlling substrate 
binding.1–3 The specific arrangement of these interchangeable modules is mediated by a 
combination of strong and weak interactions, giving rise to specificity in overall function 
while maintaining the transience necessary for regulatory signaling, in which binding 
partners trap certain conformations of the “core” enzyme and favor a specific outcome.4 
 
4.2.1 Small molecules propagates changes in protein networks 
As discussed in Chapter 1, it is increasingly appreciated that targeting the specific PPIs 
that comprise these systems could offer several advantages.11–13 For instance, by targeting 
specific PPIs within a larger enzymatic complex, it is possible to “tune” the output of the 
system without completely blocking activity, and this idea is well-established for 
modulators of GPCRs and nuclear receptors.14 In addition, the potential for specificity 
exceeds that of targeting the enzymes themselves, which often feature conserved active 
sites and mechanisms of action.15  
 
Interactions with immediate binding partners regulate the function of an enzyme and can 
also link the enzyme to a broader PPI network. In this chapter, we explore the effect of 
inhibiting a single protein target or “node” with a small molecule on both its direct 
interactions with binding partners and the function of the larger protein network. 
 
4.2.2 The Hsp70 molecular chaperone complex as a model system 
As a model system, we used the Hsp70 molecular chaperone complex (see Chapter 2). 
This system consists of the core enzyme Hsp70, an ATPase containing a nucleotide 
binding domain and a substrate binding domain connected by a short linker, and several 
families of co-chaperone proteins.192 Hsp70 is regulated by an allosteric mechanism 
whereby its affinity for substrates is dependent on its nucleotide state; the ATP-bound 
state adopts an “open” conformation with a characteristically low affinity for substrates, 
and ATP hydrolysis triggers a “closed” conformation with a higher affinity for bound 
substrates.197,198 Enzymatic activity of Hsp70 is regulated by a number of non-enzyme 
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binding partners. For example, J proteins increase the rate of ATP hydrolysis,127,199 while 
nucleotide exchange factors (NEFs) facilitate the release of ADP and allow Hsp70 to 
proceed through many iterative cycles of ATP binding and hydrolysis.126 In addition, 
interactions with scaffolding proteins and other non-enzymes link Hsp70 with the larger 
network of molecular chaperones and protein quality control machinery; in particular, E3 
ligases bind to Hsp70 and promote substrate ubiquitination and proteasomal 
degradation.281–283 Importantly for this work, Hsp70 also makes PPIs with client proteins. 
As discussed in Chapter 3, Hsp70 binds to a wide number of both folded and unfolded 
proteins. This interaction can be stabilizing in some cases, such that interactions with 
Hsp70 are required for the lifetime of the client.  
 
In this chapter, we examined the effect of an allosteric inhibitor of Hsp70 on its network 
of substrate proteins using an unbiased proteomics approach. We found that treatment 
with an Hsp70 inhibitor resulted in destabilization of a number of “client” proteins in 
cells. Therefore, we used the pattern of protein degradation in response to Hsp70 
inhibition to infer how inhibition of Hsp70 propagates changes throughout the larger 
network of Hsp70 substrates. This approach allowed us to define a subset of the proteome 
that relies on Hsp70 for stability. 
 
4.3 Results 
JG-98 is an allosteric inhibitor of Hsp70 that stabilizes the ADP-bound state of Hsp70 by 
binding in the NBD at a site distal to the nucleotide binding site.218 The BAG family of 
NEFs prefer binding to apo-Hsp70,90 and therefore JG-98 acts as an inhibitor of the PPI 
between Hsp70 and the BAGs (Figure 4.1). Importantly, JG-98 has little effect on other 
PPIs with Hsp70, including J proteins or TPR (tetratricopeptide repeat) domain 
containing proteins.284 It had previously been shown that inhibition of the Hsp70-BAG3 
interaction led to destabilization and degradation of a number of known Hsp70 client 
proteins, including FoxM1, tau, and polyQ-AR.160,161,213 We hypothesized that we could 
use JG-98 to tune the Hsp70 PPI network such that interactions with BAGs were 
selectively disrupted while interactions with other co-chaperones were unaffected. We 
measured this pattern of PPI disruption, allowing us to identify a network of Hsp70-BAG 
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dependent client proteins using mass spectrometry and proteomics. In other words, we 
could disrupt a single PPI in the sub-network and then explore the functional implications 
on the Hsp70-client interactions.  
 
Figure 4.1 JG-98 allosterically inhibits the Hsp70-NEF interactions. Hsp70 hydrolyzes ATP to 
modulate its affinity for substrate proteins. J proteins stimulate ATP hydrolysis, while NEFs promote 
nucleotide release. JG-98 binds to Hsp70 at an allosteric site, stabilizing the ADP-bound conformation and 
inhibiting interactions with BAG NEFs. The ADP-bound state in turn has a higher affinity for substrate 
proteins, which we hypothesized would lead to degradation of bound substrates. 
 
4.3.1 JG-98 causes rapid degradation of classic Hsp90 client proteins 
In order to identify proteins sensitive to Hsp70 inhibition, we first wanted to determine 
the kinetics of degradation of known clients following treatment with JG-98. It is well 
known that Hsp90 clients like kinases, transcription factors, and E3 ubiquitin ligases are 
rapidly destabilized in cells following treatment with both Hsp90 and Hsp70 
inhibitors.239,240 Indeed, in Chapter 3, we demonstrate that some Hsp90 clients are also 
sensitive to inhibition of Hsp70 with JG-98 in a number of breast cancer cell lines. 
Therefore, we treated MCF-7 and MDA-MB-231 cells with 10 μM JG-98 over 24 hours  
and blotted for Hsp90 clients Raf-1 and AKT1. Degradation of these client proteins was 
more pronounced in MCF-7 cells, with Raf-1 degradation after 2 hours of JG-98 
treatment and AKT1 degradation after 6 hours (Figure 4.2A). In MDA-MB-231 cells, 
degradation occurred after 4 and 6 hours, respectively (Figure 4.2A). 
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Figure 4.2 JG-98 causes degradation of classic Hsp90 client proteins. (A) JG-98 induces rapid 
degradation of Hsp90 clients Raf-1 and AKT1 in MCF-7 (left) and MDA-MB-231 (right) cells. Cells were 
treated with 10 μM JG-98 for the indicated time points. (B) 5 hour JG-98 treatment is sufficient to induce 
degradation of Raf-1 and AKT1 in MCF-7 (left) and MDA-MB-231 (right) cells. Cells were treated with 
JG-98 at the indicated concentrations for 5 hrs. All blots shown are representative of two independent 
biological replicates, and protein levels were quantified across all biological replicates. Error bars are SEM. 
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Figure 4.3 JG-98 mediated cytotoxicity is dependent on binding to Hsp70. A) JG-98 is weakly 
cytotoxic in 5 hour treatment window in MCF-7 (left) and MDA-MB-231 (right) cell lines. Cells were 
treated with JG-98 at the indicated concentrations for 5, 24, and 72 hrs. Viability was measured with the 
WST-1 reagent. (B) JG98-biotin binds to Hsp70, but not Hsp90. Affinity of biotinylated JG-98 for DnaK, 
Hsp72, and Hsp90α in an ELISA assay (left schematic). Protein was immobilized in the wells of a 96-well 
plate and incubated with JG98-biotin. Binding was detected with streptavidin-HRP. All results shown are 
representative averages of triplicate of three independent experiments, and error bars are SEM. 
 
Given this window of JG-98 treatment after which Hsp90 clients became destabilized, we 
hypothesized that 5 hour treatment would be sufficient to induce degradation of both Raf-
1 and AKT1 in both MCF-7 and MDA-MB-231 cells. At the same time, we wanted to 
pick a relatively early time point to minimize the opportunity of finding secondary 
effects. After 5 hour treatment with 10 μM JG-98, we observed at least 50% degradation 
of both client proteins in both cell lines (Figure 4.2B). These results suggest that this 
 93 
treatment regime was indeed sufficient to cause measurable degradation of several known 
Hsp90 client proteins.  
 
4.3.2 JG-98 is mildly cytotoxic after 5 hours 
In order to simplify analysis of future proteomics data, we wanted to ensure that JG-98 is 
not inducing significant cell death under treatment conditions sufficient to induce 
degradation of classic Hsp90 clients. We therefore measured cell viability in both MCF-7 
and MDA-MB-231 at 5 hours, 24 hours, and 72 hours following treatment with JG-98. 
While JG-98 was strongly anti-proliferative in both cell lines at 72 hours (EC50 = 510 ± 
230 nM and 220 ± 220 nM, respectively), it was less potent at 24 hours (EC50 ~ 10 μM 
for both cell lines) (Figure 4.3A). At just 5 hours however, we did not observe significant 
loss of cell viability in either cell line at 10 μM JG-98 (EC50 > 40 μM) (Figure 4.3A). 
These results suggest a treatment and dosing regime in which the effects of JG-98 on 
client would primarily be due to its effect on the PPI between Hsp70 and BAG3, and not 
a secondary effect.  
 
4.3.3 JG-98 binds Hsp70, but not Hsp90 
While it is well established that inhibition of Hsp70 causes destabilization of canonical 
Hsp90 clients,239,240 we wanted to ensure that the effect of JG-98 on Raf-1 and AKT1 
stability was due to its affinity for Hsp70, not because of any interaction with Hsp90. JG-
98 has a very different chemical structure than known Hsp90 inhibitors, but this was still 
an important control. We therefore expressed and purified recombinant Hsp70 and Hsp90 
from bacteria and measured their affinity for a biotinylated analog of JG-98 using a 
modified ELISA assay.259 In this platform, JG-98 bound the human stress inducible 
Hsp72 and its prokaryotic paralog DnaK with comparable affinity (KD = 0.9 ± 0.4 μM 
and 3.5 ± 2.2 μM, respectively) (Figure 4.3B). As expected, we did not observe 
significant binding to Hsp90α (KD > 30 μM) (Figure 4.3B). These results that JG-98 
induces degradation of Hsp90 clients primarily by binding to Hsp70. 
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4.3.4 Hsp70 inhibition results in qualitative proteomic changes 
By examining changes in Raf-1 and AKT1 levels and measuring cell viability in response 
to JG-98 treatment, we identified a treatment regime in which Hsp90 clients were 
degraded but significant cell death had not yet occurred. We next wanted to determine the 
effect of this JG-98 treatment on global protein levels, using Western blotting of several 
known Hsp90 clients and silver staining of whole cell lysates as a qualitative assessment 
of the stability of the proteome after acute disruption of Hsp70 function. We grew large 
10 mL cultures of MCF-7 and MDA-MB-231 cells and treated parallel cultures of each 
cell line with either 10 μM JG-98 or 0.1% DMSO for 5 hours. Cell extracts were blotted 
for the Hsp90 client proteins Raf-1, AKT1, HER2, and CDK4. As expected, we observed 
degradation of all proteins under these treatment conditions, with more dramatic 
reductions in protein levels observed in MDA-MB-231 cell lysate (Figure 4.4A).  
 
Figure 4.4 JG-98 treatment results in qualitative proteome-wide changes in protein expression levels. 
(A) JG-98 treatment results in degradation of multiple Hsp90 client proteins. MCF-7 (left) and MDA-MB-
231 (right) cells were treated with 10 μM JG-98 for 5 hrs. Cell extracts were blotted for Raf-1, AKT1, 
HER2, CDK4, and actin as a loading control. (B) JG-98 causes qualitative changes in global protein levels. 
MCF-7 (left) and MDA-MB-231 (right) cells were treated with 10 μM JG-98 for 5 hrs. Cell extracts were 
separated by SDS-PAGE and silver stained. Black arrows indicate individual protein bands decreased in 
both cell lines; red arrows indicate protein bands decreased in only one cell line. All results shown are 
representative of two independent biological replicates. 
 
We then wanted to qualitatively assess protein levels across the proteome in both cell 
lines after JG-98 treatment. This type of experiment could be performed in a number of 
different ways. We chose separate equal amounts of total protein by SDS-PAGE to see if 
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there were obvious changes in a subset of the proteome. Indeed, we observed several 
changes in both cell lines under these treatment conditions (Figure 4.4B). Interestingly, 
while some bands were decreased in response to JG-98 treatment in both cell lines 
(Figure 4.4B, black arrows), we also observed distinct changes in MCF-7 cells that were 
not present in MDA-MB-231 cells and vice versa (Figure 4.4B, red arrows). These results 
suggest that Hsp70 may play cell-type specific roles in protein quality control. For 
example, MDA-MB-231 is a triple negative breast cancer cell line, indicating that cells 
do not overexpress the estrogen receptor (ER), progesterone receptor (PR), or HER2.285 
Conversely, MCF-7 cells are negative for only HER2 overexpression, but express both 
estrogen and progesterone receptors.286 Both ER and PR are members of the class of 
nuclear hormone receptors, a group of known Hsp90 clients.287,288 Hsp70 has been shown 
to collaborate with Hsp90 and a number of co-chaperones to stabilize the glucocorticoid 
receptor (GR),151,289,290 and differential effects of JG-98 on global protein levels in MCF-7 
versus MDA-MB-231 may be due to variation in expression of both known Hsp90 clients 
and unknown Hsp70 clients in these cells.  
 
4.3.5 Quantitative proteomics reveals a network of client proteins sensitive to 
Hsp70 inhibition 
Given the promising qualitative assessment of changes in protein levels in response to 
JG-98 treatment, we hypothesized that this inhibitor would allow us to define a network 
of proteins, the levels of which are sensitive to inhibition of the interaction between 
Hsp70 and BAG3. While it is well known that Hsp90 clients are degraded in response to 
treatment with Hsp70 inhibitors,239,240 it is not known if the pool of Hsp70 clients is 
redundant with Hsp90 clients. In other words, are all Hsp70 clients also Hsp90 clients? 
Our results described in Chapter 3 suggest that this is not the case, as the inhibitor of 
apoptosis proteins (IAPs) are sensitive to Hsp70 inhibition, but not Hsp90 inhibition. We 
therefore wanted to define the global network of Hsp70 client proteins in more detail. 
 
4.3.5.1 10% of identified proteins are differentially expressed in SILAC 
Stable isotope labeling with amino acids in cell culture (SILAC) is a powerful tool to 
quantify changes in global protein levels under different conditions.291,292 We therefore 
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used this approach to identify which proteins are differentially expressed after inhibition 
of Hsp70 with JG-98 in MCF-7 cells.  
 
Figure 4.5 Hsp70 inhibition results in differential expression of 10% of the identified proteome. (A) 
Schematic of SILAC experimental workflow. Parallel cultures of heavy and light labeled MCF-7 cells were 
treated with either 10 μM JG-98 or 0.1% DMSO for 5 hrs. Cell extracts were mixed in a 1:1 heavy:light 
ratio and subjected to in-gel tryptic digest. Proteins were identified by MS/MS and relative quantitation was 
obtained by comparing the intensity of light and heavy peaks of individual peptides. (B) Histogram of 
protein quantitation of ~1000 identified proteins with a probability cutoff of 0.9. With a FDR of 0.05% 
(dashed lines), ~100 proteins (10% of those identified) were differentially expressed. (C) Comparison of 
Hsp70-dependent proteome with Hsp90-dependent proteome identified in a similar analysis.293 Numbers 
represent individual peptides, not taking into account common peptides in protein groups. (D) Protein 
interaction map of proteins with decreased expression after JG-98 treatment, predicted by STRING.294 A 
total of 56 interactions were observed of 63 total proteins (p-value – 1.26e10-6). 
 
Parallel cultures were grown in media spiked with either 12C6 (“light”) or 13C6 (“heavy”) 
labeled arginine and lysine. The heavy culture was treated with 10 μM JG-98, while the 
light culture was treated with 0.1% DMSO (Figure 4.5A). Cell extracts were mixed in a 
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1:1 heavy:light ratio, resolved by SDS-PAGE and digested with trypsin. Following 
additional separation by reverse phase liquid chromatography, proteins were identified 
using tandem mass spectrometry (MS/MS). By comparing the abundance of individual 
peptide ions of a given protein in the light versus heavy state, the absolute quantitation of 
protein levels in both cultures was determined. With a probability cutoff of 0.9, we 
identified ~1000 total proteins. Comparing the heavy:light ratio of all identified proteins 
and setting a false discovery rate (FDR) of 0.05% allowed us to determine that the levels 
approximately 10% of all identified proteins were changed by Hsp70 inhibition (Figure 
4.5B). More specifically, ~60 proteins were found to have lower levels following JG-98 
treatment (Table 4.1), while 35 proteins had higher levels under the same conditions 
(Table 4.2).  
Table 4.1 Identified proteins with decreased expression after JG-98 treatment 
Expression 
ratio 
Unique 
peptides 
Gene name Expression 
ratio 
Unique 
peptides 
Gene name 
0.46 2 KPNA3 0.19 1 TCEB1 
0.37 3 HIST1H1C 0.19 1 IRF7 
0.10 3 RPS19 0.28 4 AHSG 
0.44 20 RPL30 0.21 2 H2AFY 
0.30 4 ARFGAP1 0.12 3 RPL36A 
0.46 6 ASNA1 0.37 1 SERBP1 
0.02 1 SNX2 0.42 2 CLTA 
0.27 14 CLIC3 0.13 3 SNAP25 
0.25 11 SERPINA1 0.33 2 RPS23 
0.46 2 JUP 0.29 1 VDAC2 
0.23 2 KRT1 0.22 2 ASPM 
0.41 3 KRT79 0.41 1 SMARCC1 
0.22 1 HSP90AB4P 0.34 1 HIST2HPS2 
0.23 14 PSMC3 0.23 1 PLA2G3 
0.46 2 CAST 0.42 1 DDX58 
0.46 4 VARS 0.08 2 ORM1 
0.40 27 RPL3 0.09 1 GC 
0.44 9 PSMD8 0.22 8 C4B1 
0.44 2 HNRNPA3 0.46 2 LAGE3 
0.21 3 PrLZ 0.36 1 MPHOSPH10 
0.45 27 RPS20 0.20 1 VPS28 
0.44 15 RPL15 0.20 2 GLOD4 
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Table 4.1 continued 
Expression 
ratio 
Unique 
peptides 
Gene name Expression 
ratio 
Unique 
peptides 
Gene name 
0.42 17 RPS15A 0.40 2 ITPK1 
0.29 2 YWHAH 0.11 1 SYMPK 
0.45 9 RPL32 0.13 2 ZFAT 
0.41 4 PEA15 0.03 3 PIN4 
0.44 18 PREX1 0.20 1 SNRNP40 
0.31 3 EIF3C 0.23 2 ATXN2L 
0.44 13 C14orf166 0.46 2 RBM3 
0.41 1 TUBB6 0.20 1 PTPRQ 
0.32 2 GOT2 0.39 1 CUL3 
0.19 1 TCEB1 0.51 2 DIABLO 
 
Table 4.2 Identified proteins with increased expression after JG-98 treatment 
Expression 
ratio 
Unique 
peptides 
Gene 
name 
Expression 
ratio 
Unique 
peptides 
Gene 
name 
7.90 4 KPNA4 2.64 1 DNPEP 
3.39 9 EDF1 2.85 2 SERPINB6 
2.59 10 S100P 2.28 2 NOMO2 
2.92 4 RPL22 2.86 1 MED4 
2.09 3 NPLOC4 52.88 2 STXBP3 
2.58 5 AIP 2.09 1 HIP1R 
2.19 4 LSM1 3.53 1 LRBA 
6.97 3 HDGFRP2 3.99 1 WDR77 
3.28 2 KPNA6 15.25 2 PSMB6 
2.98 3 POTEF 3.53 3 IRS1 
2.17 22 CTTN 3.07 2 CREBBP 
2.28 6 SAFB 2.10 2 H1FX 
3.34 4 SF1 3.80 2 PSMD5 
3.01 4 USP7 5.81 1 UNC5D 
2.18 6 ACIN1 15.22 1 PPP1R13B 
2.29 3 CBFA2T3 5.10 2 FAH 
2.12 3 SRP54 1.83 37 HSPA9 
 
It is important to note that this analysis did not identify either of the “control” proteins 
(Hsp90 clients Raf-1 and AKT1), likely because of the low expression levels of those 
proteins. Thus, this dataset it not intended to serve as a definitive list of Hsp70 clients. 
Moreover (as discussed in more detail below), this experiment requires additional 
biological and technical replicates. Despite these caveats, we were interested in 
understanding if any patterns would emerge. We therefore used gene ontology (GO) 
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enrichment analysis with the Database for Annotation, Visualization, and Integrated 
Discovery (DAVID) to identify specific categories of biological processes (GO terms) 
that are more prevalent in our dataset than others.295,296 From this analysis, the top GO 
terms enriched in our dataset included translation elongation, translation regulation, and 
RNA processing (Table 4.3). Importantly, the enriched processes also included apoptosis, 
macromolecular complex assembly, and protein ubiquitination, all of which are known to 
be broadly regulated by Hsp70.194  
Table 4.3 Top GO terms in identified proteins with differential expression after JG-98 treatment 
Cluster Enrichment score 
Translation elongation 9.33 
RNA processing 2.39 
Macromolecular complex assembly 1.98 
RNA splicing 1.79 
Glycolysis 1.69 
tRNA aminoacylation 1.48 
Chromatin assembly 1.47 
Ubiquitin-protein ligase acitivity 1.43 
Intracellular protein transport 1.31 
Translational initiation 1.08 
Response to insulin stimulus 1.04 
Insulin-like growth factor receptor binding 1.02 
Generation of precursor metabolites and 
energy 
0.88 
Transcription coactivator activity 0.82 
Apoptosis 0.66 
Phospholipid binding 0,64 
Actin filament organization 0.62 
Regulation of synaptic plasticity 0.56 
Endopeptidase inhibitor activity 0.50 
Regulation of neuron differentiation 0.43 
(negative) regulation of apoptosis 0.41 
Protein kinase binding 0.40 
Cell cycle process 0.36 
(positive) regulation of apoptosis 0.32 
Transcription 0.28 
Inflammatory response 0.27 
Vesicle-mediated transport 0.26 
Nucleotide binding 0.23 
Transcription activator activity 0.18 
Proteolysis 0.07 
Calcium ion binding 0.05 
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4.3.5.2 Hsp70 and Hsp90 regulated proteomes are partially overlapping 
A major goal of our proteomic analysis was to determine if the group of proteins that rely 
on Hsp70 for their stability overlaps with the group of proteins that is sensitive to Hsp90 
inhibition; are all Hsp70 clients also Hsp90 clients? Kuster and colleagues recently used 
geldanamycin, a well-characterized Hsp90 inhibitor, to identify the Hsp90 regulated 
proteome with SILAC.293 Their analysis revealed a network of approximately 1600 
Hsp90 client proteins, particularly enriched in protein kinases, across a panel of four 
different cell lines. We compared the proteins identified in this study with those proteins 
that were differentially expressed in our experiment. Notably, while a number of proteins 
were identified in both the Hsp70 and Hsp90 regulated proteome, we also identified 
many proteins that were only sensitive to Hsp70 inhibition (Figure 4.5C). Perhaps 
unexpectedly, the Hsp90 regulated proteome also contained proteins unique to that 
dataset, indicating that Hsp90 may be involved in protein quality control pathways that 
are not also regulated by Hsp70. It is important to note that the protein counts listed in 
this comparison are over-inflated, as they do not take into account protein groups, i.e. 
proteins that share common peptides and are thus indistinguishable in the MS/MS 
analysis. 
 
4.3.5.3 Inhibition of Hsp70-BAG3 PPI tunes the Hsp70 interactome 
JG-98 inhibits the interaction between Hsp70 and BAG3,160 and we hypothesized that 
blocking this PPI would tune the Hsp70 interactome such that some interactions were 
favored while others were disrupted. While we did not measure the “Hsp70-ome” 
directly, we instead used the relative expression of proteins identified in the MS/MS as a 
reporter of the pattern of Hsp70 PPIs that were strengthened or inhibited when the 
Hsp70-BAG3 interaction is blocked. We therefore determined if PPI networks were 
enriched in our SILAC dataset using the STRING database.294 From this analysis, we 
found that our dataset of proteins with decreased expression is enriched in PPIs (p-value 
= 1.26e10-6, 56 observed interactions of 63 total proteins) (Figure 4.5D). Notably, the list 
of proteins with decreased expression following JG-98 treatment contained several 
components of the ribosome and proteasome complexes, which was expected given the 
observed enrichment of translation regulation and protein ubiquitination GO terms in the 
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dataset. Together, this analysis suggests that inhibition of the Hsp70-BAG3 PPI might 
favor interactions between Hsp70 and components of the ribosome or proteasome to 
trigger their degradation.  
 
4.4 Discussion 
While it has been previously established that classic Hsp90 client proteins, including the 
kinases Raf-1 and AKT1 are sensitive to both Hsp70 and Hsp90 inhibition,239,240 it was 
less understood if the pool of Hsp70 and Hsp90 client proteins were completely 
overlapping, or if there existed a network of Hsp70-specific client proteins. In Chapter 3, 
we demonstrated that the IAP family represents a class of unique Hsp70 clients. This 
finding is important, both for fundamental knowledge of biology, but also for biomarker 
discovery. Thus, we considered it important to understand the role that Hsp70 plays in 
protein quality control in the context of the whole proteome. By treating breast cancer 
cells that had been grown in media containing “heavy” amino acids (13C6 – arginine and 
lysine) with JG-98, we were able to quantitatively assess the impact of Hsp70 inhibition 
on the whole proteome using SILAC.  
 
4.4.1 Hsp70 client proteins are involved in translation regulation, protein 
degradation, and apoptosis 
In this experiment, we found that approximately 10% of the identified proteome was 
sensitive to Hsp70 inhibition. Of these sensitive proteins, approximately 70% had lower 
levels of expression after JG-98 treatment, while the remaining 30% had higher levels of 
expression. This dataset was particularly enriched for proteins involved in regulation of 
protein translation and RNA processing, although we also observed a number of proteins 
responsible for protein ubiquitination and degradation as well as macromolecular 
complex assembly, processes in which Hsp70 is known to play a role.194 Furthermore, we 
observed enrichment in proteins essential for apoptotic signaling, such as 
Smac/DIABLO, which is released from the mitochondria during apoptosis and binds to 
the IAPs to block their ability to inhibit caspases.297,298 Given our observations in Chapter 
3 that Hsp70 plays a key role in IAP homeostasis, decreased Smac levels following 
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Hsp70 inhibition with JG-98 in our SILAC experiment provide further evidence for 
regulation of apoptotic signaling by Hsp70 in cancer cells. 
 
4.4.2 Only a fraction of the proteome is sensitive to Hsp70 inhibition 
Hsp70 is known to be a relatively promiscuous chaperone; nearly 100% of all cellular 
proteins are predicted to contain at least one Hsp70 binding site.224 These substrate 
peptides are defined as a stretch of 4-5 hydrophobic amino acids flanked by basic 
residues on either side.195,268,299 While such sequences would be expected to be buried in 
the interior of a protein in its native state, they would be exposed in a nascent, partially 
folded, or misfolded protein.300 Furthermore, given that Hsp70 has been shown to induce 
global unfolding in bound substrate proteins,226,280 it is unsurprising that Hsp70 has been 
linked to many protein quality control processes from folding of newly synthesized 
polypeptides to disaggregation of highly stable protein oligomers. Why then did we only 
observe sensitivity of 10% of the proteome to Hsp70 inhibition? It is possible that 
stabilization of the ADP-bound state of Hsp70 may strengthen its affinity for a number of 
co-chaperones that can specifically target some client proteins, but not others, for 
degradation. In addition, some proteins might fold faster than others, with the slow-
folding clients becoming more dependent on Hsp70. 
 
It has been hypothesized that with only 13 Hsp70 family members in eukaryotic cells but 
over 100 different co-chaperone proteins belonging to several diverse classes, that co-
chaperones would provide a selectivity “filter” for specific substrates.301,302 Indeed, the 
interaction of Hsp70 with one J protein family member is essential for uncoating of 
clathrin-coating vesicles.303,304 In addition, it has been shown that JG-98 potentiates 
binding between Hsp70 and HOP (Hsp70-Hsp90 organizing protein) to induce 
degradation of polyQ-AR,161,305 and this may also be the case for other co-chaperones and 
substrates. Finally, previous work from our research group suggests that JG-98 may 
preferentially target mortalin, the mitochondrial isoform of Hsp70.284 While it is unknown 
the extent to which mortalin binding sites are predicted to differ from those of cytosolic 
Hsp70, binding sites for the ER resident Hsp70 BiP occurred less frequently than 
cytosolic Hsp70 binding sites.224 It is therefore tempting to speculate that mortalin may be 
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responsible for maintaining protein homeostasis in a smaller subset of the proteome than 
cytosolic Hsp70.  
 
4.4.3 SILAC dataset lacks statistical power 
It is important to note that the SILAC mass spectrometry data presented in this chapter 
represents only one biological replicate, and it is therefore difficult to draw firm 
conclusions about statistical significance of proteins that were found to be differentially 
expressed. In addition, we did not independently verify either degradation or 
accumulation of proteins identified in the SILAC experiment with Western blots. It 
remains a possibility that any proteins with differential expression in SILAC could 
represent false positives or contamination. Finally, we identified ~1000 total proteins by 
MS/MS analysis, which itself represents only a fraction of the total proteome. Mass 
spectrometry is biased toward identification of high abundance proteins, although 
advances in instrumentation and analysis have improved the detection of proteins with 
low abundance.306 We are unable to draw conclusions about specific putative client 
proteins without additional biological replicates and independent experimental 
verification of differentially expressed proteins. 
 
4.4.4 Small molecules can be used to tune protein networks 
In summary, we have used an inhibitor of Hsp70 to demonstrate that binding of a small 
molecule to a single protein target can have profound effects on the global protein 
network. Hsp70 forms the core of a multi-protein complex made of interactions with a 
variety of different co-chaperone proteins. JG-98 binds at an allosteric site on Hsp70 to 
lock it in the ADP-bound conformation, inhibiting its interaction with the BAG family of 
nucleotide exchange factors, while strengthening interactions with substrates. Here we 
show that JG-98 treatment in breast cancer cells results in differential expression of about 
10% of the identified proteome, and this perturbation of the larger protein network 
suggests that certain proteins may rely preferentially on Hsp70 for their stability. Our 
work demonstrates that small molecules can effect changes in proteins distal from their 
primary target by modulating individual PPIs. 
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4.5 Future directions 
We have shown in this chapter that small molecules can be used to tune protein networks 
by stabilizing a unique set of PPIs while inhibiting others. By inhibiting a single protein 
target, Hsp70, the small molecule inhibitor JG-98 alters individual PPIs within the “hub” 
multi-protein complex to affect a subset of the proteome that is dependent on Hsp70 for 
stability. Kinases also form the core of multi-protein complexes that trigger signaling 
pathways through a defined set of downstream PPIs.307 Because kinase inhibitors are well 
known to recognize specific kinase conformations, we hypothesized that we could use 
these compounds to modulate the kinase-dependent proteome. Such a system might allow 
us to more closely examine acute changes in a PPI network in response to a series of 
small molecules. Unlike the Hsp70 system, there are many available inhibitors with 
different characteristics and many of the PPIs are well-validated. Thus, kinases seemed 
like a good model in which to extend the ideas of this chapter. 
 
4.5.1 Design of irreversible inhibitors of Src kinase 
Kinase inhibitors fall into four general categories, the two most important of which are 
type I and type II inhibitors. Type I inhibitors bind the orthosteric ATP-binding site, 
while type II inhibitors bind at an allosteric site to stabilize the closed or inactive 
conformation of the kinase.29 We expect that, while both classes of inhibitors inhibit the 
enzymatic activity of the kinase, they might produce distinct patterns of PPI disruption 
throughout the broader protein network. 
 105 
 
Figure 4.6 Conformation selective Src inhibitors may affect downstream PPIs. (A) Structure of the 
chicken c-Src kinase domain (PDB id = 3F6X). Catalytic Asp-Phe-Gly (DFG) motif is shown in blue, αC-
helix is shown in yellow, and non-catalytic, non-conserved Cys-277 targeted by irreversible inhibitors in 
shown in red. (B) Structures of conformation-selective, irreversible dasatinib analog c-Src kinase inhibitors. 
All inhibitors were designed, synthesized, and characterized by Frank Kwarcinski. (C) Co-
immunoprecipitation does not detect a complex between Src and FAK in MDA-MB-231 cell lysate. Flow-
through (FT), first wash (W), and elution (E) fractions of FAK, Src, and IgG IP conditions are shown. Blot 
is representative of two independent biological replicates. 
 
Dasatinib is an FDA-approved inhibitor of several tyrosine kinases,308 including Src 
family kinases, which are important tyrosine kinases involved in a number of oncogenic 
signaling cascades (Figure 4.6A).309,310 Understanding how small molecules disrupt the 
network of c-Src PPIs could provide a blueprint for the development of therapeutic c-Src 
inhibitors. Dr. Matthew Soellner’s research group at the University of Michigan recently 
developed a number of irreversible dasatinib analogs that target specific kinase 
conformations (Figure 4.6B).311 These compounds all target a non-catalytic, non-
conserved cysteine in the active site of c-Src; FEK-6-131 is a type I inhibitor that 
stabilizes the active conformation, while FEK-6-132 and FEK-6-139 stabilize the inactive 
conformation. FEK-6-132 causes a conserved Asp-Phe-Gly (DFG) motif required for 
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catalysis to flip outward, resulting in inactivation. FEK-6-139, on the other hand, causes 
displacement of the αC-helix. Each of these inhibitors stabilizes a specific kinase 
conformation. Furthermore, irreversible binding should facilitate labeling of c-Src kinase 
in living cells, which in turn will enable the study of the effect of these inhibitors on 
downstream PPIs. 
 
4.5.2 FAK may prefer binding to DFG-out conformation 
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase activated by c-Src to 
trigger multiple downstream signaling pathways essential for cell growth, adhesion, and 
migration.312 A recent screening campaign identified an inhibitor of c-Src that stabilizes 
the DFG-out conformation.313 Interestingly, this compound potentiated binding of FAK to 
c-Src, suggesting that FAK may prefer binding to c-Src in the DFG-out conformation. 
We therefore expected that the c-Src-FAK interaction would be a useful proof-of-concept 
that small molecules are able to effect distinct patterns of PPI disruption via binding to 
the same target. 
 
4.5.3 Co-immunoprecipitation does not detect the Src-FAK complex 
Previous work suggests that FAK may prefer binding to c-Src in the DFG-out, inactive 
conformation.313 We hypothesized that labeling endogenous c-Src with the Type II (DFG-
out) irreversible dasatinib analog would favor this interaction, while the interaction 
between FAK and Src labeled with either the Type I irreversible inhibitor or the analog 
that stabilizes the αC-helix-out inactive conformation would be disrupted. Therefore, we 
sought to capture the interaction between endogenous c-Src and FAK in living cells. 
MDA-MB-231 have high levels of endogenous c-Src expression (Matthew Soellner, 
unpublished data), and we thus prepared extracts from these cells and 
immunoprecipitated for both c-Src and FAK in order to detect the complex. 
Unfortunately, co-immunoprecipitation with either c-Src or FAK was not able to pull 
down the interacting partner in our hands (Figure 4.6C). Given that the interactions 
between many kinases and their substrates are transient (KD ~ 5 μM), it is not surprising 
that the c-Src-FAK complex was not identified by co-IP, as this technique typically 
favors detection of PPIs with higher affinity (KD < 1 μM).166  
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Although we were unable to detect an interaction between c-Src and its substrate FAK, 
conformation-selective, irreversible c-Src inhibitors could nonetheless be useful probes of 
c-Src function. For example, given that it is often difficult to detect weak PPIs, such as 
those between kinases and their substrates, by co-IP, phosphorylation of downstream 
substrates could be used a surrogate for binding to infer changes in the local PPI network 
in response to c-Src inhibition. This idea will be discussed more in Chapter 5.  
 
4.6 Experimental Procedures 
 
4.6.1 Reagents and general methods 
Antibodies used are as follows: Raf-1 (SantaCruz Biotechnology sc-133), Akt1 (Cell 
Signaling Technology 2967), HER2 (Cell Signaling Technology 4290), CDK4 (BD 
Pharmingen 559693), Src (Cell Signaling Technology 2123), FAK (Cell Signaling 
Technology 3285), β-actin (AnaSpec AS-54591), goat anti-mouse HRP (AnaSpec 
28173), and goat anti-rabbit HRP (AnaSpec 28177). JG-98 and JG98-biotin were 
synthesized according to previously described methods.259 All other biological reagents 
were purchased from Sigma Aldrich unless otherwise noted. All spectroscopic 
measurements were made on a SpectraMax M5 multimode plate reader (Molecular 
Devices). 
 
4.6.2 Tissue culture and viability assays 
MCF-7 cells (ATCC) were maintained in DMEM (Invitrogen) supplemented with 10% 
fetal bovine serum and 1% penicillin-streptomycin. MDA-MB-231 cells (ATCC) were 
grown in DMEM supplemented with 10% fetal bovine serum, 1% penicillin-
streptomycin, and non-essential amino acids. Cell viability assay was determined using 
the WST-1 reagent (Roche) according to the manufacturer’s instructions.  
 
4.6.3 Western blotting and silver stain 
Cell extracts were prepared in chilled RIPA buffer (50 mM Tris pH 8, 150 mM NaCl, 1% 
Triton X-100, 0.5% Na deoxycholate, 0.1% SDS) unless otherwise indicated. Protein 
concentration was determined by the BCA assay and 5 μg of total protein was separated 
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by SDS-PAGE on 10% Tris-glycine gel and transferred to PVDF membrane (Thermo 
Fisher Scientific Inc). Membranes were blocked with 5% milk in TBS, 0.05% Tween 
(TBS-T) for 1 hr at room temperature, incubated with primary antibodies overnight at 
4oC, washed with TBS-T, and incubated with the appropriate horseradish peroxidase 
conjugated secondary antibody for 1 hr at room temperature. After a final wash with 
TBS-T, membranes were developed using chemiluminescence (ECL Prime, GE 
Healthcare). The silver stain (Sigma Aldrich) was performed according to the 
manufacturer’s instructions.  
 
4.6.4 Protein expression and purification 
DnaK, Hsp72, and Hsp90α were expressed and purified as previously described, using a 
His column and subsequent cleavage of the His tag by TEV protease.212 DnaK and Hsp72 
were further purified on an ATP column. Both proteins were concentrated and stored in 
25 mM HEPES buffer (pH 7.5) containing 10 mM KCl and 5 mM MgCl2 until use. 
Hsp90α was further purified by anion exchange on a Source Q column (GE Healthcare) 
and dialyzed overnight into 20 mM Tris buffer (pH 7.5) containing 50 mM KCl, 6 mM β-
mercaptoethanol, and 10% glycerol. Protein purities were estimated at greater than 90% 
by SDS-PAGE. The BCA (bicinchoninic acid) assay kit (Thermo Fisher Scientific Inc) 
was used to determine protein concentration, and the activity of the purified proteins was 
verified with previously described ATPase assays (see Chapter 2 for details).133  
 
4.6.5 ELISA 
Binding of Hsp72, DnaK, and Hsp90α to JG98-biotin was determined using a modified 
ELISA assay as previously described.259 Hsp72, DnaK, or Hsp90α was non-covalently 
immobilized in the wells of a clear, flat-bottom 96-well plate (Thermo Fisher Scientific 
Inc) by incubating 50 µL of 0.06 mg/mL protein in immobilization buffer (20 mM MES, 
pH 5.2) overnight at 37oC. Non-immobilized protein was removed from the wells, and 
the wells were washed with 3 x 150 µL of TBS supplemented with 0.05% Tween (TBS-
T). Each wash was incubated, with gentle rocking, for 3 min at room temperature. 
Following washing, 25 µL of JG98-biotin was added at the indicated concentrations in 
binding buffer (25 mM HEPES pH 7.4, 40 mM KCl, 8 mM MgCl2, 100 mM NaCl, 
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0.01% Tween), supplemented with 1 mM ATP and 1 mM DTT. The plates were 
incubated at room temperature for 24 hrs with gentle rocking. Solutions of JG98-biotin 
were removed and each well was washed as before and blocked with 100 µL of 3% 
bovine serum albumin in TBS-T for 5 min at room temperature. The plates were 
developed using 50 µL of streptavidin-HRP, for 1 hr incubation at room temperature. 
After washing, binding was detected using the TMB substrate kit (Cell Signaling 
Technology), and absorbance was read at 450 nm. Data were analyzed using GraphPad 
Prism software and fit to the Langmuir binding isotherm (Y = BmaxX/[KD + X]). 
 
4.6.6 Proteomic analysis by SILAC MS/MS 
The base culture medium DMEM (deficient in L-arginine, L-lysine, L-glutamine, and 
sodium pyruvate) was supplemented with 10% fetal bovine serum, 1% penicillin-
streptomycin, L-glutamine, sodium pyruvate, and 100 μg/mL of either 12C6 (light) – or 
13C6 (heavy) – arginine and lysine. Parallel cultures of MCF-7 cells were propagated in 
either light or heavy media for at least eight cell divisions, and incorporation of the light 
and heavy amino acids was verified at > 97%. The heavy culture was treated with 10 μM 
JG-98 for 5 hours, while the light culture received vehicle (0.1% DMSO) alone. Cell 
extracts were prepared in chilled lysis buffer (50 mM Tris pH 8, 8 M urea, 0.1% SDS). 
Protein quantitation was performed with the BCA assay, and cell extracts were mixed in 
a protein concentration ratio of 1:1 heavy:light. Proteins were resolved by SDS-PAGE 
and stained with Coomassie. Individual bands were excised and subjected to in-gel 
reduction, cysteine alkylation, and digestion with trypsin. Tryptic peptides were resolved 
by reverse-phase liquid chromatography and introduced directly into an Orbitrap XL 
Tandem Mass Spectrometer. Proteins were identified by searching the MS/MS data 
against the human protein database with added decoy (reverse) sequences using 
X!Tandem/Trans-Proteomic Pipeline (TPP). Positive protein identifications were those 
with probability ≥ 0.9. SILAC ratios were calculated and differentially expressed proteins 
(0.05% FDR) were selected for further analysis. 
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4.6.7 Co-immunoprecipitation 
MDA-MB-231 cell extracts were prepared in chilled lysis buffer (50 mM Tris pH 8, 150 
mM NaCl, 1 mM ATP, 10 mM KCl, 5 mM Mg(OAc)2, 1% NP-40) supplemented with 
protease inhibitor cocktail (Roche Applied Science). The total protein concentration was 
adjusted to 5 mg of protein in 1 mL of cell extract. PureProteome Protein G magnetic 
beads (Millipore) were incubated with 6 µg of Src (Cell Signaling Technology 2123) or 
FAK (Cell Signaling Technology 3285) primary antibodies or nonspecific mouse IgG 
(Santa Cruz Biotechnology sc-2025) for 30 min at room temperature with mixing, 
followed by antibody crosslinking with bis(sulfosuccinimidyl) suberate (Thermo 
Scientific) for 1 hr at room temperature with mixing. The crosslinking reaction was 
quenched with 1 M Tris (pH 7.5) for 1 hour at room temperature with mixing. 
Meanwhile, equal 100 µL samples of cell lysate were pre-cleared by incubation with 50 
µL of protein G beads for 1 hour at room temperature with mixing. Protein complexes 
were immunoprecipitated by incubation of the pre-cleared lysate (1 mg total protein per 
IP) with 50 µL of antibody-crosslinked protein G beads for 1 hour at room temperature 
with mixing. The immunocomplexes were washed 3 times with 500 µL of wash buffer 
(PBS pH 7.4, 0.1% Tween-20) and eluted with 0.1 M glycine (pH 2.6). Proteins were 
visualized by Western blot. 
 
Notes 
This work is a collaboration of multiple research groups. JG-98 and JG98-biotin were 
synthesized by Xiaokai Li. The SILAC studies were performed at the Proteomic 
Resource Facility in the Department of Pathology at the University of Michigan by 
Venkatesha Basrur. Bioinformatic analysis of SILAC data was performed by Venkatesha 
Basrur and Damian Fermin. The irreversible Src kinase inhibitors were developed by 
Matthew Soellner’s research group and synthesized and characterized by Frank 
Kwarcinski. The Hsp90α pet151 plasmid was a kind gift from Daniel Southworth 
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Chapter 5 
Conclusions and Future Directions: Strategies for Targeting Protein Conformation 
and Dynamics 
 
5.1 Abstract 
Throughout this dissertation, I have described my efforts to target the Hsp70 molecular 
chaperone complex with small molecules in order to understand its biology in greater 
detail. Hsp70 regulates many diverse tasks in protein homeostasis by interacting with a 
variety of co-chaperone proteins that modulate its activites and shape its overall function. 
In Chapter 2, I developed a high-throughput screening (HTS) method to identify selective 
inhibitors of Hsp70’s interactions with two classes of co-chaperones, J proteins and 
NEFs, in parallel. In probing the mechanisms of action (MoA) of these inhibitors, I 
uncovered binding sites and allosteric networks that can be exploited by future inhibitors. 
I applied one such allosteric inhibitor, JG-98, to evaluate Hsp70’s role in pro-survival 
signaling, which led to the discovery of IAPs as a new class of Hsp70 client proteins in 
Chapter 3. These results suggest that Hsp70-NEF complexes are key regulators of cell 
survival and provide a novel biomarker. In addition to advancing our understanding of 
Hsp70 function, these results also provide a template for how multi-protein complexes 
might collaborate to carry out diverse cellular tasks. In this chapter, I expand on these 
broader possibilities. Specifically, I comment on possible future strategies for the 
discovery of new modulators of PPIs and describe how the assembly of multiple 
inhibitors targeting a single protein might be used to tune signaling in larger networks. I 
also speculate on how we might take advantageous of these probes to achieve a desired 
functional outcome, especially in designing new, safer therapeutics.  
 
5.2 Summary and conclusions 
In the cell, protein structure, function, and signaling are regulated by individual protein-
protein interactions. These interactions mediate the assembly of multi-protein complexes, 
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which are often constructed around a central “core” component, usually an enzyme. As 
discussed in Chapter 1, interactions of the core component with adaptor, scaffolding, and 
regulatory proteins then adjust the function of the enzyme by directing its subcellular 
localization or altering enzymatic activity.1–3 More broadly, these multi-protein 
complexes form hubs of the larger protein interaction network in the cell, connecting 
signaling cascades through a physical web of PPIs.5 Targeting individual PPIs with small 
molecules has recently gained favor in drug discovery because such inhibitors have 
greater potential for and are also able to “tune” protein function, rather than completely 
blocking activity.14 
 
While there have been great strides in PPI inhibitor discovery in recent years, there is still 
much work to be done. As discussed in Chapter 1, one of the biggest challenges has been 
targeting PPIs with large buried surface area and/or weak binding affinity. Therefore, a 
major goal of this dissertation was to understand how to tackle difficult PPIs. As a model, 
I focused on the heat shock protein 70 (Hsp70) system. Hsp70 forms the core of a multi-
protein complex with its co-chaperones. While many of these co-chaperones, including 
the J proteins and NEFs, regulate the ATPase activity of Hsp70, other co-chaperones, 
such TPR domain proteins, do not.194 Because the activity of Hsp70 is driven by its 
interactions with co-chaperones, there was great interest in developing selective 
inhibitors of the PPIs. However, many of these interactions are weak and others occur 
over large surface areas. 
 
5.2.1 Enzymatic activity can be used as a surrogate for binding in HTS 
When I first joined the Gestwicki laboratory in 2011, Lyra Chang and Yoshi Miyata had 
recently completed the first HTS campaign against bacterial Hsp70 (i.e. DnaK) in 
complex with co-chaperones.129,130,132 They made the important discovery that while the 
physical PPIs were difficult to measure, the binding of co-chaperones to Hsp70 could be 
estimated by effects on ATPase activity. Concurrently, Anne Gillies, Jennifer Rauch, and 
Victoria Assimon were making strides in biochemically characterizing Hsp70’s 
interactions with J proteins, NEFs, and TPR proteins, respectively.90,314,315 Together with 
Srikanth Patury and Tomoko Komiyama, I reasoned that because J proteins and NEFs 
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produce a diagnostic increase in Hsp70’s ATPase activity, enzymatic activity could be 
used as a surrogate for co-chaperone binding in HTS. In Chapter 2, I describe how we 
used this approach to discover small molecules that bind to DnaK and inhibit its 
interactions with specific co-chaperones.133 I found that zafirlukast binds specifically to 
ADP-bound Hsp70, blocking the physical interaction between the J protein and Hsp70 
and inhibiting J protein-stimulated ATP hydrolysis. On the other hand, telmisartan did 
not alter the PPI between Hsp70 and its NEF, but rather inhibited NEF-stimulated 
ATPase activity by interfering with the conformational change in Hsp70 that couples 
NEF binding with nucleotide release. This work demonstrates that individual PPIs within 
a multi-protein complex can be selectively inhibited with small molecules, and this HTS 
approach is particularly well-suited for finding both orthosteric and allosteric inhibitors 
of challenging PPIs. 
 
5.2.2 Hsp70 interacts with BAG co-chaperones to stabilize IAPs and regulate pro-
survival signaling 
To complement the screening approach, Yoshi Miyata and Xiaokai Li took advantage of 
an existing chemical scaffold, based on the rhodacyanine dye MKT-077, to build 
inhibitors of Hsp70.316 They showed that MKT-077 binds to Hsp70 at an allosteric site 
and stabilizes Hsp70 in the ADP-bound conformation.218 This compound had previously 
entered clinical trials due to its anti-proliferative activity in a number of cancer cell 
lines.317,318 Xiaokai and Hao Shao synthesized ~ 450 MKT-077 analogs and optimized 
this scaffold for Hsp70 binding, anti-proliferative activity, and various pharmacokinetic 
properties.259,319 Jennifer Rauch made the important discovery that one of the best analogs, 
JG-98, blocked the physical PPI between Hsp70 and the BAG family of NEFs.160 Sharan 
Srinivasan and I reasoned that we could use JG-98 to probe the role of the Hsp70-BAG 
complex in pro-survival signaling in cancer cells. In Chapter 3, I demonstrate that JG-98 
is strongly anti-proliferative in breast cancer cells and that the kinetics of degradation of 
classic Hsp90 clients does not correspond with the kinetics of cell death. Rather, JG-98’s 
anti-proliferative activity is dependent on the protein kinase RIP1, a master regulator of 
both cell death and survival signaling pathways, and blocking the Hsp70-BAG PPI 
results in rapid destabilization of several members of the IAP family. Importantly, the 
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kinetics of IAP degradation are closely aligned with the induction of cell death after 
Hsp70 inhibition. I go on to show that the IAPs are specific, non-canonical clients of 
Hsp70. This work has provided important insight into the mechanism by which Hsp70 
recognizes client proteins. Furthermore, because the IAPs are specific Hsp70 clients, their 
degradation can be used as a biomarker for Hsp70 target engagement in cells, which 
should aid in the future therapeutic development of Hsp70 inhibitors. 
 
5.2.3 A network of client proteins rely on Hsp70 for stability 
My findings in Chapter 3 provided a benchmark for how inhibition of the Hsp70-BAG 
PPI could be used to identify and characterize a specific class of Hsp70 client proteins. I 
then wanted to expand this approach to understand how inhibition of this PPI might 
propagate changes throughout the larger network of Hsp70-bound proteins, the Hsp70 
“interactome”. Andrea Thompson found that another Hsp70 inhibitor, methylene blue, 
accelerates the clearance of the microtubule-associated protein tau, and she used 
quantitative mass spectrometry to understand how the tau-associated proteome changes 
when degradation is induced with methylene blue.174 I was encouraged by Andrea’s 
findings and reasoned that I could use a similar approach to identify which proteins are 
destabilized by inhibition of the interaction between Hsp70 and BAG proteins. In Chapter 
4, I show that approximately 10% of the proteome relies on Hsp70 for stability and that 
this subset of the proteome is enriched with proteins involved in protein translation, 
degradation, and apoptosis. These results demonstrate that small molecules can modulate 
the assembly of multi-protein complexes, in that inhibition of one “node” of a larger 
protein network can have profound implications on individual PPIs downstream of the 
original target. 
 
5.3 Future directions 
The results in this dissertation highlight the importance of PPIs as drug targets. Future 
efforts in targeting PPIs with small molecules should increase our understanding of how 
to modulate Hsp70 and other protein complexes. 
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5.3.1 New HTS methodology for the discovery of PPI inhibitors 
In Chapter 2, I outline how the emergent properties of a PPI can be used in HTS instead 
of directly measuring the physical interaction with conventional biophysical methods.133 
In the case of Hsp70, binding of co-chaperone proteins results in stimulation of ATP 
turnover, and we used ATPase activity as the functional readout to identify inhibitors of 
specific PPIs. In the future, I propose that this method can easily be adapted to any 
system in which binding of one protein results in a measurable change in enzymatic 
activity of its partner. For example, many GTPases, phosphatases, and other enzymes 
have binding partners that might accelerate or inhibit turnover. One particularly 
interesting example might be the anticancer target Ras, a GTPase with well-validated 
binding partners.320 
 
Going forward, the “next stage” of PPI inhibitor discovery might involve targeting 
aspects of protein structure and function that do not involve enzymatic activity. 
Specifically, I propose that next generation screens should focus on two things: targeting 
protein conformations (rather than activities) and modulating ternary and higher order 
protein complexes (rather than just dimer interfaces). Importantly, the development of 
new methodologies to study these aspects of PPIs will lead to new discoveries. 
 
All proteins have dynamic motions and many will populate a number of discrete states. 
Thus, a single polypeptide sequence can adopt multiple conformations. For example, 
Hsp70 can be in the ATP- or ADP-bound conformation. Similarly, prion proteins are well 
known to have a healthy, normal conformer and a disease-associated conformer, typically 
with increased protease resistance.321 As chemical biologists, we might be able to take 
advantage of conformational dynamics to discover small molecules that “capture” a 
single protein conformation. Indeed, this approach has been used in targeting 
transcriptional co-activator proteins. Transcriptional co-activators allows need to adopt 
distinct conformers to recognize many different transcriptional activators, which initiates 
the first step in gene.50,114,118 By screening for inhibitors with one activator bound to the 
GACKIX domain of CBP/p300, my colleagues in the Mapp laboratory discovered 
allosteric inhibitors of specific PPIs between GACKIX and activators.119 This approach 
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might be adapted to any multi-protein system, provided there is sufficient structural 
information on how partners influence the conformation of the core protein. For example, 
in the Hsp70 system, BAG proteins bind tightly to apo- and ATP-bound Hsp70.90 One 
would expect that screening for inhibitors of Hsp70 in the presence of the BAGs would 
favor the discovery of small molecules that capture the ADP-bound conformation. 
 
It is also important to consider individual protein conformers and PPIs in the context of 
the larger protein network, as discussed in Chapter 4. When an inhibitor traps a specific 
conformer, this change likely has implications for PPIs within the multi-protein complex 
and beyond. However, we still need better analytical tools for studying such changes. To 
be useful for this purpose, the method should be capable of being used in HTS (e.g. low 
volume, high sensitivity), and it should report on multiple PPIs at the same time. In 
Chapter 1, I introduced how FCPIA and CE rely on multi-color fluorescent labeling to 
detect the effect of small molecules on ternary and higher order complex formation. 
Similarly, mass spectrometry has gained favor for capturing a “snapshot” of protein 
binding equilibrium in larger networks,150 and this method could also be readily adapted 
to study the effects of small molecules on the assembly of multi-protein complexes in real 
time.  
 
5.3.2 Small molecules propagate changes in global PPI networks 
When a molecule traps a conformer of a target protein, this change has effects throughout 
the web of cellular PPIs. In Chapter 4, I describe preliminary studies to characterize these 
effects in both the Hsp70 molecular chaperone and Src kinase PPI networks. These 
results illustrate how the PPI detection method must be adapted to the system of interest. 
For example, I identified a sub-network of Hsp70 client proteins by identifying which 
proteins were differentially expressed after Hsp70 inhibition. While I was able to use this 
information to infer which proteins might preferentially rely on Hsp70 for stability, it 
does not directly report on changes in the network of bound Hsp70 clients. In order to 
answer this question, I suggest a similar SILAC experiment with affinity purification for 
Hsp70, which would capture and identify Hsp70 interacting partners. This approach has 
 117 
the advantage that it could characterize how Hsp70’s interactions with both co-
chaperones and substrates are altered by inhibitors. 
 
On the other hand, I also outline initial efforts to define the effects of conformation 
selective Src kinase inhibitors on its PPIs with substrates proteins in Chapter 4. However, 
these interactions are typically weak and difficult to detect with co-immunoprecipitation 
techniques.166 In this case, it might be advantageous to examine how protein 
phosphorylation patterns change upon Src inhibition using SILAC phosphoproteomics. In 
this method, phosphopeptides are enriched in the MS analysis using specific antibodies or 
another affinity chromatography method.322,323 
 
In order to successfully define how protein networks change in response to chemical 
inhibitors, three considerations are important: 1) what are the PPIs that converge on the 
target protein?, 2) what conformation of the target is captured by the chemical tool?, and 
3) what robust detection method will be used to either measure changes in bound 
interacting partners (or functional outcomes)? I propose that protein systems that have 
clearly defined answers to these questions will be the most tractable. In other words, one 
should pick systems with clearly defined protein interactions (e.g. measured affinity, 
available structures, etc.), a panel of potent inhibitors with distinct MoAs (e.g. agonists, 
antagonists, etc.), and readily available analytical tools (e.g. good antibody for pull 
downs, high protein expression level, etc.). As illustrated in Figure 5.1, several different 
multi-protein complexes fulfill the first requirement, including Hsp70 (Figure 5.1A) and 
Src kinase (Figure 5.1B), as discussed earlier. In addition, co-activator proteins, such as 
CBP/p300 GACGIX, mediate transcription of a large array of target genes by binding to 
different activators (Figure 5.1C),50,114,118 and 14-3-3 adaptor proteins bind to hundreds of 
different partners to regulate their signaling cascades (Figure 5.1D).324,325 However, none 
of these systems have the combination of all three requirements that would seem to allow 
for full characterization of the global effects of PPI inhibitors. While there are many 
Hsp70 and Src ligands, interactions between these proteins and their binding partners can 
be difficult to detect. Conversely, there are successful methods to detect changes in target 
gene expression for specific transcriptional activators and to capture 14-3-3 interacting 
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partners, but discovery methods for conformation selective ligands of co-activators and 
14-3-3 proteins are still being developed.47,326,327 Nonetheless, advances in PPI inhibitor 
discovery and methods for in cell capture of protein networks will help make this 
ambitious goal a reality. 
 
Figure 5.1 Interactions of a central protein with diverse binding partners mediate the assembly of 
multi-protein complexes. (A) The Hsp70 molecular chaperone complex consists of a central ATPase 
(Hsp70, PDB id = 2KHO), which interacts with J proteins, NEFs, and TPR domain containing proteins at 
distinct binding sites. Each family of co-chaperones alters Hsp70 function in a unique way. (B) Src family 
kinases (PDB id = 1Y57) phosphorylate client proteins through interactions with the kinase domain. N-
terminal SH2 and SH3 domains mediate interactions with phospho-tyrosine residues and proline-rich 
binding partners, respectively. (C) The CBP/p300 GACKIX domain (PDB id = 2LXS) interacts with an 
array of transcriptional activation domains at two distinct, allosterically coupled binding sites. (D) 14-3-3 
proteins (PDB id = 1QJA) are a versatile class of adaptor proteins that bind to hundreds of different 
partners at two conserved binding sites in order to regulate their activity. 
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5.4 Broader implications 
It is now accepted that PPIs are important drug targets for the treatment of myriad human 
diseases; however, small molecules capable of modulating these interactions could also 
have utility beyond the clinic. Given the importance of PPIs in virtually all cellular 
processes from transcriptional regulation and protein folding to cell signaling and cell 
death, PPI inhibitors have already been shown, both in this work and by other research 
groups, to be powerful chemical probes in uncovering how interactions with specific 
binding partners translate to differences in the biology of a single protein target.202 
 
To this end, there is significant need to develop new methods for the discovery of PPI 
inhibitors, especially for more “challenging” interactions, as discussed in Chapter 1. In 
particular, the “gray-box” screening method described in Chapter 2 has the potential to be 
a powerful tool to identify selective inhibitors of individual PPIs within a larger multi-
protein complex. The strength of this assay is two-fold: 1) it measures changes in 
enzymatic activity resulting from individual PPIs, rather than the biophysical interaction 
between two protein partners itself, and 2) it is modular, meaning that many different 
binary and even ternary complexes can be screened in parallel. The use of enzymatic 
activity as a functional readout HTS means that some information on how small molecule 
“hits” modulate the biology of a system will be learned before any further biochemical 
characterization or analysis is undertaken. Furthermore, by screening multiple complexes 
in parallel, one can rapidly assemble a series of inhibitors of a single target, which is 
essential for future studies on how these inhibitors are able to alter binding across large 
protein networks, as discussed above. Finally, this technique is especially useful for 
multi-protein complexes assembled around a core enzyme and has already been applied 
by other research groups for the discovery of inhibitors of G protein signaling and Hsp90-
mediated protein folding.134,135 
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Figure 5.2 Comparison of GPCR ligands and PPI inhibitors. (A) An inverse agonist of a GPCR binds at 
the orthosteric site and blocks its activity in the presence or absence of native ligands. (B) Negative 
allosteric modulators (NAMs) only have an effect on activity in the presence of an agonist. NAMs prevent 
GPCR activation by reducing agonist efficacy. (C) An orthosteric enzyme inhibitor completely prevents 
activity in the presence or absence of binding partners. (D) An inhibitor of a specific PPI has no effect on 
enzymatic activity of its target alone, but abrogates binding of the regulatory partner, blocking the effect of 
the PPI on enzyme activity. 
 
PPI inhibitors identified from these types of screening campaigns can be utilized to 
uncover new biological roles of a given multi-protein complex and to inform future 
efforts in the development of PPI inhibitors as new therapeutics. The strength of these 
small molecules lies in their ability to provide nuance in inhibition; that is, they do not 
completely block all activity of their protein target, but rather “tune” the functional output 
of the whole multi-protein system.14 It is therefore useful to compare PPI modulators to 
ligands of G-protein coupled receptors (GPCRs) (Figure 5.2). For instance, inverse 
agonists interact with GPCRs and reduce activity, analogous to the effect of orthosteric 
enzyme inhibitors. By contrast, allosteric modulators alter the signaling output of the 
receptor only in the presence of the endogenous ligand or another agonist.27 Because 
interactions with regulatory proteins are essential for modulating the activity of a core 
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enzyme in a multi-protein complex, inhibitors of these PPIs would only block activity in 
the presence of a specific binding partner. Furthermore, just as allosteric modulators of 
GPCRs can either potentiate or inhibit downstream signaling, PPI modulators can also 
enhance or prevent binding interactions. This analogy also highlights how the field 
struggles with the lack of holistic terms to describe the effects of small molecules on 
enzymes, PPIs, and protein networks. Just as GPCR ligands have discrete effects on their 
targets, different “inhibitors” (even closely related ones) have unique effects on PPI 
networks. 
 
Figure 5.3 Inhibition of interactions between a single protein target and different binding partners 
can elicit different outcomes. A theoretical drug target (white) interacts with multiple binding partners, 
linking it to different “arms” of a larger PPI network that governs its biology. (A) Treatment with one 
inhibitor might inhibit interactions with a given binding partner A (green), directing it to a distinct 
outcome. The inhibitor not directly impacts the target and perturbs the global network. (B) Treatment with 
a different inhibitor blocks the interaction of the target with a binding partner B (blue). Even by acting on 
the same target, a different inhibitor generates a non-overlapping outcome by perturbing the network in a 
distinct way. Figure adapted from Cesa et al. (2015).202 
 
Finally, by understanding the specific roles of individual PPIs in affecting the overall 
biology of the multi-protein system, we can build a roadmap for the development of 
future inhibitors that alter downstream signaling events in a particular way. This concept 
was introduced in Chapter 1, that binding of protein A, for example, to an enzyme 
produces a given outcome A, while binding of protein B yields a different outcome B. If 
it is known that prevention of outcome A is therapeutically advantageous, then inhibitor 
discovery should focus on small molecules capable of inhibiting the interaction between 
protein A and the target enzyme (Figure 5.3). Therefore, preliminary studies, such as 
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those described in Chapters 3 and 4, of how tool compounds block specific PPIs to 
propagate changes in protein networks and elicit distinct functional outcomes are 
especially useful in guiding the development of future therapeutics. 
 
5.5 Concluding remarks 
In this chapter, I summarized my thoughts on a new way of thinking about PPI inhibitors. 
I outlined how they might best be identified and characterized, as well as how these small 
molecules can be used as tool compounds. The theme of this analysis is that inhibition of 
a single node of a protein network might have profound implications, even on binding 
events that are downstream from the target. However, we often lack the full set of tools 
for understanding this aspect of chemical biology. We need better methods to enable 
small molecule discovery, study protein conformation and dynamics, and measure PPIs 
with adaptor and regulatory proteins. Throughout the course of my thesis work, I have 
used a multidisciplinary approach, applying the tools of chemical screening and drug 
discovery to identify new inhibitors of Hsp70’s interactions with co-chaperones, 
biochemistry and cell biology to characterize how Hsp70 recognizes a previously 
unexplored class of client proteins to ensure their stability, and mass spectrometry and 
proteomics to explore how inhibition of Hsp70 leads to changes in global protein 
expression levels. In the future, the application of tools from diverse fields will be 
essential for understanding how best to exploit dynamic PPIs in order to achieve a desired 
functional outcome. 
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